feel better live longer glaxosmithkline annual report business review performance overview research development pipeline summary products competition intellectual property regulation manufacturing supply business review world market discusses financial nonfinancial activities gsk sales performance resources development performance segment reviews outlines factors including trends responsible business principal risks uncertainties likely financial review affect future development financial position resources financial review governance remuneration risk factors discusses management structures governance procedures also sets governance remuneration remuneration policies operated directors board corporate executive team members corporate executive team governance policy financial statements dialogue shareholders financial statements provide summary internal control framework groups financial performance throughout committee reports position st december consolidated remuneration policy financial statements prepared accordance director terms conditions ifrs adopted european union also ifrs director senior management remuneration issued international accounting standards board directors interests directors interests contracts shareholder information includes full product development pipeline discusses shareholder return form dividends share price movements financial statements directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap shareholder information quarterly trend five year record product development pipeline share price dividends nature trading market annual general meeting underlying sales growth excludes pandemic products investor relations registrar avandia valtrex see taxation information shareholders glossary terms cer represents growth constant exchange rates index sterling represents growth actual exchange rates see calculation results major restructuring described note financial statements presentation financial statements gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp contents exist improve quality human life enabling people feel better live longer work respecting people maintaining focus patient consumer whilst operating integrity transparency looking deliver shareholder value growth diversified global business delivering products value simplifying operating model running business responsibly follows report shareholders progress made year also seen visiting website wwwgskcomcorporatereporting notice regarding limitations director liability english law uk companies act safe harbour limits liability directors respect statements omissions report directors contained pages english law directors would liable company third party report directors contains errors result recklessness knowing misstatement dishonest concealment material fact would otherwise liable report directors pages inclusive comprise report directors drawn presented accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions provided law website glaxosmithklines website wwwgskcom gives additional information group notwithstanding references make annual report glaxosmithklines website none information made available website constitutes part annual report shall deemed incorporated reference herein cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual report gsk annual report gsk glance one worlds leading numbers researchbased pharmaceutical bn p healthcare companies committed improving quality turnover earnings per share human life enabling people feel better live longer p p earnings per share dividend per share major restructuring gsk focused business delivery three strategic priorities aim increase growth reduce risk group sales improve gsks longterm financial performance grow diversified global business us pharmaceuticals bn deliver products value europe pharmaceuticals bn simplify gsks operating model consumer healthcare bn emerging markets gsk global organisation offices countries pharmaceuticals bn major research centres uk usa belgium china shares listed london new york stock asia pacificjapan exchanges corporate head office brentford uk pharmaceuticals bn viiv healthcare bn bn research development consumer healthcare c bn peerleading spent bn growth horlicks sensodyne pipeline around rd major india worlds fastest growing latestage assets restructuring toothpaste brand total sales last years one worlds biggest investors rd biggest private sector funder rd uk c bn new compounds committed units lucozade new consumer healthcare vaccines starting phase iii improving returns rd ribena horlicks research innovation clinical trials since start aiming increase manufactured centres opened china estimated return uk every year india investment area vaccines emerging markets bn doses vaccines total gsk turnover supplied countries emerging markets around world broader definition pharmaceutical consumer healthcare turnover markets excluding usa western europe canada japan australia new zealand gsk annual report gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp gsk glance global company sites employees biologicals corporate consumer healthcare gms pharmaceuticals research development employees share world leading presence pharmaceutical market consumer healthcare source ims health global categories otc oral care nutritionals gsks business model responsible business balanced synergistic business multiple growth drivers malaria vaccine supporting core pharmaceutical rd operation potentially first malaria vaccine phase iii trials ongoing african countries million commitment supply doses synflorix reduced price developing countries next decade amc financing mechanism year commitment treat school age children africa risk intestinal worms leader gsk ranked first access medicine indexes core pharmaceutical rd target date value chain raw materials product disposal carbon neutral find visit us wwwgskcomcorporatereporting chairman ceo summary dear shareholder gsk also business built strong values deep commitment operating integrity taken last two half years implementing steps make company responsive flexible strategy transform business model address significant open societys expectations challenges industry faces payers search ever cost effective healthcare demand escalates new better increasing returns shareholders medicines done direct aim enhancing returns able fund returns shareholders bolton shareholders improving lives patients consumers acquisitions significant increase legal settlements whilst reducing net debt billion achieve substantially reengineered gsks business major restructuring rigorous approach adjusted net cash inflow legal matters capital allocation effects changes billion cash outflow legal settlements billion masked degree specific events reported sales gsk remains financially strong increased dividend example impacted generic competition valtrex p priority deliver growth reduced sales avandia pandemic related products dividend since dividends increased year meanwhile earnings impacted significant charge average growth fiveyear period took help resolve longstanding legal matters belies also started new longterm share buyback programme good progress made execute strategy enhance returns shareholders buybacks billion evident diversified underlying sales growth increasing expected potential pipeline believe gsk becoming balanced synergistic business lower risk profile option significant potential upside pipeline sir christopher gent andrew witty chairman chief executive officer gsk annual report chairman ceo summary continuing focus return investment operating valuesbased business integrity drive change improve returns investment continuing run business responsible way also central restructuring effective capital allocation continued changes made gsk make progress year continued progress significant commitment reinvestment costs saved restructuring programme work neglected tropical diseases candidate malaria vaccine enabled us diversify strengthen gsks sales base progressing phase iii trials africa goes well date billion cost extracted business first ever vaccine malaria potential track deliver billion annual savings save lives millions children infants africa also announced donate enough albendazole taken cost lower returning activities medicine protect schoolaged children africa reinvested key growth areas emerging markets intestinal worms intestinal worms cause ill health vaccines consumer healthcare reported sales schoolaged children infection businesses respectively major positive health impact helping reduce gsks dependency sales products improving environmental sustainability business also generated white pillswestern markets sales priority launched new set ambitious targets markets products decreased goal reduce environmental impact whole value time help reduce adverse impact chain raw materials product disposal carbon patent expirations group neutral delivering diversified underlying sales growth continuing work towards resolving number long reported sales fell impacted continued standing legal matters doubt scale legal effect generic competition valtrex rapid loss sales provisioning required significant however avandia following regulatory decisions autumn continue believe groups best interests resolve difficult comparison prior year included significant inherent unpredictability reduce gsks overall litigation sales pandemic products exposure legal cases underline important us led values everything however underlying sales growth sales excluding factors growth achieved despite changes board ongoing impacts us healthcare reform eu government september announced julian heslop retire cfo austerity measures testament strength rest end march replaced simon dingemans portfolio joined company cfodesignate january expect underlying sales momentum continue would like thank julian dedicated service gsk translate sustainable reported growth cfo member board last six years integrity increasing pipeline potential diligence outstanding technical ability ensured gsk remained financially strong period significant economic reforming rd improve returns investment key turmoil simons appointment cfo bring valuable new element strategy implementing saw experience capability support us implementing strategy evidence strategy making progress conclusion gsk peerleading portfolio around opportunities phase iii registration portfolio diverse doubt operating environment remains biopharmaceuticals vaccines addition nces also challenging pharmaceutical industry undergoing highly innovative assets currently available period intense change however believe gsk well indication one asset benlysta potentially placed succeed environment first new treatment lupus years currently journey create balanced synergistic business considered approval regulators usa europe increasing pipeline potential progressing well importantly delivering sustained progress nces accomplishing would like recognise significant new vaccines entering phase iii since start end contribution employees many partners remain expect phase iii data around assets including confident generate increased value shareholders potential new treatments type diabetes several rare well deliver better outcomes patients consumers diseases multiple cancer types made fundamental changes allocate rd expenditure directing late stage pipeline reducing cost risk externalising parts earlystage discovery dismantling infrastructure terminating development areas low financial scientific return target remains deliver rate return gsks rd around pharmaceutical company explicitly set sir christopher gent andrew witty challenging target chairman chief executive officer see gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp discover world gsk chosen ten case studies demonstrate progress made strategic priorities stories viewed online wwwgskcomcorporatereporting gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp strategy since focused business around delivery three strategic priorities aim increase growth reduce risk improve longterm financial performance grow diversified global business plans diversifying business create balanced product portfolio move away drive growth pharmaceutical reliance traditional white pillswestern markets sales generated business core markets markets products decreased time fulfil potential emerging help reduce adverse impact patent expirations group markets expect generate future sales growth strengthening core pharmaceuticals business expand business japan supplementing increased investment growth areas emerging markets vaccines japan dermatology consumer healthcare sales emerging markets build leadership dermatology vaccines japan dermatology proforma basis excluding grow vaccines consumer acquisitions consumer healthcare healthcare businesses deliver products value plans aim sustaining industryleading pipeline products deliver value focus best science healthcare providers focusing improving rates return delivering diversify externalisation best science rd organisation required multifaceted approach example increased level externalisation research taken difficult decisions around repersonalise rd pipeline progressions focused disease areas believe prospects focus return investment successful registration launch differentiated medicines greater one largest diverse development pipelines industry approximately latestage assets vast majority programmes address unmet medical need importantly nearly twothirds new chemical entities new vaccines simplifying operating model plans evolve commercial model business continues change shape essential transform operating model reduce complexities improve efficiencies reduce cost global reshape manufacturing restructuring programme removed billion cost since track deliver target billion annual savings savings streamline processes extracted developed country sales marketing support functions rd reduce working capital manufacturing infrastructure reinvested higher returning activities emerging markets vaccines consumer healthcare outlook whilst operating environment remains challenging made significant progress restructuring rigorous returnsbased approach capital allocation expect underlying sales momentum sales excluding valtrex avandia pandemic related products continue translate reported growth constant exchange rates despite anticipated pricing reductions usa europe us patent compositions containing combination active substances seretide advair expired various patents diskus delivery device exist usa number years outlook timing impact entry followon competition uncertain gsk notified acceptance us fda application followon product refers seretideadvair contains active ingredients would expected precede introduction product able predict may occur followon product may enter us market products may experience generic competition advance stated patent expiry result settlement patent proceedings see note legal proceedings pages gsk peerleading development pipeline assets currently market indication end expect phase iii data around additional assets improvements net debt position increasing returns shareholders increased gsks dividend priority deliver growth dividend also commenced new longterm share buyback programme remain confident generate increased value shareholders well deliver better outcomes patients consumers see performance overview pp weiver ssenisub strategies measures progress focused business use number measures made good progress year number around delivery three track progress notable successes strategic priorities strategic priorities medium long term include following grow diversified performance core excluding pandemic products avandia valtrex pharmaceuticals underlying pharmaceutical including vaccines sales global business vaccines businesses billion grew year broadening balancing diversification sales sales white pillswestern markets fell portfolio moving away turnover reliance white pillswestern markets contribution emerging sales emerging markets pharmaceutical business markets overall grew billion represent sales growth pharmaceutical turnover growth consumer sales consumer healthcare business grew healthcare business billion represent group turnover build leadership position dermatology sales grew proforma basis excluding dermatology acquisitions approximately nearly billion representing nearly group turnover expansion japanese business sales gsk japan grew nearly billion received approvals four new compounds build biopharmaceutical portfolio arzerra recorded sales million first full year us market launched europe benlysta filed approval usa europe deliver contribution sales new products launched since excluding flu new products pandemic vaccines grew contributed products value pharmaceutical sales transforming rd ensure number reimbursable product received six product approvals usa eu deliver current approvals filings since start pipeline also able seven assets currently filed regulators sustain flow products years come sustaining latestage pipeline maintained around assets phase iii registration ten new chemical entities new vaccines entering phase iii since start enhanced rd productivity objective increase estimated rate return increased externalisation rd around drug discovery signed eight new collaborations increase external nature discovery giving external discovery engines complement discovery performance units simplifying delivery major restructuring achieved annual cost savings billion programme remain track reach billion annualised savings operating model simplifying operating model reduce working capital working capital reduced billion including ensure fit purpose million cash lower pandemic receivables able support business cost efficient way calculation underlying sales growth described see performance overview gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp key performance indicators turnover bn cer growth reported sales underlying sales growth sales excluding pandemic products avandia valtrex earnings per share major restructuring pence cer growth earnings per share adversely impacted legal costs million million excluding legal costs eps major restructuring pence free cash flow reduced level free cash flow reflected higher legal settlements year free cash flow legal settlements million million total shareholder return glaxosmithkline total return index glaxosmithkline pharma peers return index ftse total return index index includes abbott labs amgen astrazeneca bristol myers squibb eli lilly johnson johnson merck novartis pfizer roche holdings sanofiaventis reflects bn legal charge calculation cer growth described calculation results major restructuring described note financial statements presentation financial statements calculation free cash flow described gsk annual report pp weiver ssenisub research development research development pharmaceuticals dpu develops business plan specific deliverables investment covering multiple years plans also include areas gsk rd built one strongest broadest pipelines opportunity collaborations external organisations potential new medicines industry believe pipeline could enhance dpus deliverables return include potential deliver value patients payers collaborations large small companies academia improve rates financial return rd investment internal rd expertise gives us strong basis identifying appropriately progressing pipeline products safely forming collaborations drug discovery typically efficiently deliver innovative new medicines patients inlicensing optionbased collaborations primary goal rd function discovery investment board dib reviews business plans development new products typically long expensive dpu dib responsible revising plans identifying uncertain process possible predict areas improvement monitoring dpu delivery agreed compounds development succeed fail risks inherent targets investment membership dib comprises senior rd process described fully risk factors rd commercial management external individuals section risk rd deliver commercially relevant expertise including life science investment experience successful new products understanding payer perspectives chaired svp gsk allocates rd investment reference potential medicines discovery development returns available target therapeutic markets individual dpu annual expenditure technical commercial risks associated products total annual rd expenditure pipeline factors reviewed phase development process central decision proceed delivering medicines patients next stage costs incurred stage carefully managed compound advances latestage development typically maximise likely future return consistent groups phase iia undergo much larger scale studies humans overall objective increasing irr rd activities investigate efficacy safety time current level estimated around work optimising compounds physical properties returns generated however primarily determined formulation produced delivered efficiently eventual commercial impact new products achieve sufficient quantities manufacturing process regulatory approval launched convert results activities regulatory file projected rate return includes products launched submission regulatory agencies st january compounds phases iib iii medicines development teams mdts small units six ten development process calculation based actual sales people responsibility compound later forecast sales relevant products stages development filing regulatory agencies adjusted reflect expected failure rates around assets latestage development comprising broadly line standard industry failure rates cost base individual projects used calculation comprises estimate attributable rd costs actual projected milestone payments gsk also actively seeks opportunities add products appropriate estimated profit margins capital investment latestage portfolio relationships companies working capital requirements factored calculation latestage assets typically take form inlicensing based historical performance copromotion arrangements likely aligned existing areas therapy expertise investment details full product development pipeline made pharmaceutical vaccine assets set pages product management board pmb assesses technical website performance marketed products commercial investment case project progress discussed detail financial review pages development pmb cochaired chairman rd president north america pharmaceuticals includes heads discovering potential medicines pharmaceutical region global manufacturing early stage rd drug discovery seeks identify biological projects reviewed pmb certain key decision points targets involved development diseases commit medicine development commit phase iii commit create small molecules biopharmaceuticals interact file launch funding generally allocated next key disease targets wealth scientific discoveries recent decision point typically two four years ahead pmb years made essential highly selective also carries annual latestage funding review investment invest drug discovery resources focusing resources projects reviewed adjusted necessary prioritised areas likely deliver significant medical advances returns investment individual latestage project incurred annual expenditure total annual rd expenditure conducted reevaluation advances discoveries global biomedical science led us exit areas research governance judged unlikely provide sufficient scientific therefore financial rd decisions overseen number boards oversight returns also tried create entrepreneurial environment strategic issues overall budget management across rd drug discovery pursuing best scientific opportunities whether owned rd executive team radex dib pmb control internal external created discovery performance units dpus investment decisions early late stage rd described groups scientists group focusing one particular disease pathway responsible scientific advisory board sab chaired svp medicines driving discovery development potential new medicines discovery development includes number external early stage clinical trials completion phase scientific experts sab reviews challenges science lla nearly dpus underlying development programmes provides advice related issues pmb key investment points gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp research development gsks chief medical officer chair global safety board biologicals scientific committee bsc defines overall rd ultimately accountable oversight major decisions regarding new product licensing strategy vaccines business patient safety global safety board responsible internally chaired biologicals president includes heads approving pivotal studies investigating issues related vaccines rd disease areas clinical epidemiology business patient safety arising development programme development departments members bsc postlaunch information gsk clinical trials widely easily assesses high potential vaccine inlicensing opportunities decides available clinical study register gsks website exploratory projects inlicensing opportunities also wwwclinicaltrialsgov endorses target product profiles start early vaccine projects addition bsc aligns rd clinical commercial diseases developing world plans early projects responsible prioritising exploratory continued investment research diseases developing research early vaccine projects world essential longterm improvement health people live regions part development review committee drc oversees late response challenge operate drug discovery unit development vaccine portfolio including strategy project prioritisation based tres cantos spain focuses malaria resource allocation drc chaired head global tuberculosis adapting business model pursue vaccine development membership includes heads open innovation strategy rd diseases developing clinical research global industrial operations global commercial world elements new approach include open centre excellence rd industrialisation medical intellectual property open resources launch post marketing studies set assess open data compounds additional vaccination programmes monitor vaccine safety rd sites usa uk focused development new medicines treat hivaids drug resistant bacteria two distinct rd groups formed vaccines vaccine research conducted rixensart belgium provide specific focus prophylactics antigen specific cancer immunotherapeutic asci portfolio new global vaccine rd efforts addressing prevention development organisation created pulling together clinical treatment three world health organizations late development rd organisations allowed us give priority infectious diseases clear focus projects vaccine development leaders overall responsibility development particular project vaccines rd active fields vaccine research development animals research production portfolio vaccines approved ethical regulatory scientific reasons research using animals marketing scientists devoted discovering remains small vital part research development new innovative vaccines contribute health wellbeing medicines vaccines use animals people generations around world discovery alternative constantly strive reduce numbers used development new vaccine complex process requiring long committed maintaining high standards humane term investment vaccines development care treatment laboratory animals undertake internal one strongest vaccine pipelines industry external review assure standards traditionally vaccines used ward illness vaccine division working develop immunotherapeutics vast majority experimental methods use animals aimed educating patients immune system identify actively engaged research develop validate attack cancer cells highly specific manner tests either avoid use animals reduce numbers needed animals used due measures taken vaccine discovery involves many collaborations academia prevent minimise pain distress biotech industry identify new vaccine antigens expressed yeast bacteria mammalian cells purified understand use animals research purposes high level followed formulation clinical commands high level public interest statement lots vaccine may involve mixing antigens selected care ethical use animals research views gsk novel proprietary adjuvant systems combinations use nonhuman primates details voluntary decision selected adjuvants designed elicit appropriate immune use great apes chimpanzees together response specific antigen right combination antigen information reports available website adjuvant system help body mobilise effective research development consumer healthcare immunological pathway designed provide maximum protection specific diseases targeted populations continuous creation development innovative products keeps brands relevant vibrant valuable portfolio formulated candidate vaccine evaluated safety spans three major categories otc medicines oral healthcare efficacy perspective different phases preclinical nutritional healthcare major brands dedicated rd testing clinical trials involving healthy individuals teams including regulatory partner work alongside range safety analysis small group volunteers commercial brand team colleagues officefree hub environments phase dose adjustment proof concept phase ii foster collaboration fast decisionmaking hubs largescale safety efficacy analysis phase iii results quickly become preferred way working innovation obtained clinical trials data regarding development centres weybridge uk parsippany usa quality largescale production process facilities expanded model china india combined regulatory file submitted authorities countries vaccine made available full diverse product development pipeline key late stage projects include novel technologies new combinations superior formulations gsk annual report pp weiver ssenisub pipeline summary full diverse product development key pipeline projects comprising new phase iii chemical entities biological entities vaccines large comparative study compound versus new combinations new indications placebo andor established existing compounds phase iii treatment patients filed approval recently establish clinical benefit safety approved highlighted advanced status shown includes filed following successful approvals usa eu phase iii trials file product approval regulatory authorities approval approval granted begin market medicine vaccine full pipeline pages website assets moved approvals assets terminated phase iii usa eu phase iii development ipx parkinsons tyverbtykerb avandamet xr disease first line therapy type diabetes hormone receptor positive mek avandia statin breast cancer usaeu inhibitor metastatic type diabetes melanoma arzerra refractory almorexant chronic lymphocytic braf inhibitor primary insomnia leukaemia eu metastatic melanoma new generation flu revoladepromacta vilanterol vaccine influenza idiopathic combination drug prophylaxis thrombocytopaenic copd purpura eu simplirix genital herpes prophylaxis duodartjalyn fixed crohns disease dose combination drug zoster vaccine benign prostatic prevention shingles hyperplasia usaeu duchenne votrient renal muscular dystrophy cell cancer eu migalastat hci prolia post fabry disease menopausal osteoporosis eu integrase inhibitor hiv fixed dose combination epzicomkivexa adenosine deaminase severe combined immune deficiency inlicence alliance relationship third party find visit us wwwgskcom gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp pipeline summary therapeutic area compound indication phase iii filed approved biopharmaceuticals albiglutide type diabetes arzerra chronic lymphocytic leukaemia first line therapy use relapsed patients arzerra diffuse large b cell lymphoma relapsed patients arzerra follicular lymphoma refractory relapsed patients otelixizumab type diabetes benlysta systemic lupus erythematosus denosumab bone metastatic disease arzerra chronic lymphocytic leukaemia refractory patients prolia hormone ablativechemotherapy bone loss prostate cancer patients prolia postmenopausal osteoporosis cardiovascular metabolic darapladib atherosclerosis infectious diseases relenza treatment influenza neurosciences ipx parkinsons disease horizant restless legs syndrome trobaltpotiga retigabineezogabine epilepsy partial seizures oncology metastatic melanoma metastatic melanoma votrient ovarian cancer maintenance therapy revoladepromacta chronic liver disease induced thrombocytopaenia revoladepromacta hepatitis c induced thrombocytopaenia tyverbtykerb breast cancer adjuvant therapy tyverbtykerb gastric cancer tyverbtykerb head neck squamous cell carcinoma resectable disease votrient renal cell cancer adjuvant therapy votrient sarcoma votrient tyverbtykerb inflammatory breast cancer avodart reduction risk prostate cancer duodartjalyn benign prostatic hyperplasia fixed dose combination revoladepromacta idiopathic thrombocytopaenic purpura tyverbtykerb breast cancer first line therapy votrient renal cell cancer respiratory copd immunoinflammation vilanterol copd vilanterol copd ccx crohns disease relovair vilanterol asthma relovair vilanterol copd paediatric vaccines mosquirix malaria prophylaxis plasmodium falciparum nimenrix menacwytt neisseria meningitis groups c w disease prophylaxis menhibrix hibmencytt neisseria meningitis groups c haemophilus influenzae type b disease prophylaxis vaccines flu vaccine seasonal influenza prophylaxis zoster herpes zoster prevention flu pre pandemic prepandemic pandemic influenza prophylaxis pumarix pandemic influenza prophylaxis antigen specific cancer magea treatment melanoma immunotherapeutic asci magea treatment nonsmall cell lung cancer rare diseases duchenne muscular dystrophy adenosine deaminase severe combined immune deficiency migalastat hcl fabry disease dermatology tazarotene foam acne vulgaris duac low dose acne vulgaris calcipotriene mild moderate plaque psoriasis itraconazole tablets onychomycosis veltin acne vulgaris hiv hiv infections abacavir sulphate lamivudine hiv infections inlicence alliance relationship third party gsk annual report pp weiver ssenisub products competition intellectual property pharmaceutical products intellectual property principal pharmaceutical products currently directed nine intellectual property key business asset company main therapeutic areas description products pages effective legal protection intellectual property analysis sales therapeutic area via patents trademarks registered designs copyrights domain name registrations critical ensuring reasonable competition return investment rd principal pharmaceutical competitors range small large trademarks pharmaceutical companies often substantial resources companies gsks commercial products protected registered trademarks major markets may local variations abbott laboratories example usa trademark advair covers amgen product sold eu seretide trademark protection may astrazeneca generally extended long trademark used renewing necessary gsks trademarks important bristolmyers squibb maintaining brand identity products gsk enforces eli lilly trademark rights prevent infringements johnson johnson patents merck novartis policy try obtain patents commercially important protectable inventions discovered developed rd pfizer activities patent protection new active ingredients available roche holdings major markets patents also obtained new drug sanofiaventis formulations manufacturing processes medical uses devices administering products although may obtain patents pharmaceuticals may subject competition products products prevent challenged period patent protection patent expire grant patent mean generic versions manufacturers generic products typically issued patent necessarily held valid enforceable incur significant research development education court court determines patent hold invalid marketing development costs consequently able non infringed unenforceable protect market offer products considerably lower prices branded third party entry prior patent expiry significant litigation competitors research development based company concerning challenges summarised note normally seek achieve sufficiently high profit margin financial statements legal proceedings sales volume period patent protection repay original investment generally substantial generate life patent countries years filing profits fund research future competition generic date however long development time pharmaceutical products generally occurs patents major markets expire products may result substantial amount patent life increasingly patent challenges made prior patent expiry used launch markets including usa claiming innovator patent valid andor europe possible lost time restored infringed generic product following loss patent leads variations amount patent life actually available protection generic products rapidly capture large share product market certain countries provide period market particularly usa data market exclusivity prevents third party company relying clinical trial data enter market believe remaining competitive dependent upon copy period exclusivity discovery development new products deliver value healthcare providers improved outcomes patients together patent expiry dates significant products effective marketing existing products following table dates provided expiry patents usa major european markets active ingredient within pharmaceutical industry introduction new unless otherwise indicated include extensions patent products processes competitors may affect pricing term including paediatric use usa available result changing patterns product use assurance patents vaccines relate vaccine compositions products become outmoded notwithstanding patent trademark protection addition increased government pressures physicians patients use generic pharmaceuticals rather brandname medicines may increase competition products gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp products competition intellectual property pharmaceutical products products compounds indications major patent expiry dates competitor brands usa eu respiratory veramyst fluticasone furoate rhinitis nasacort flixotideflovent fluticasone propionate asthmacopd qvar singulair expired expired compound compound expired diskus device diskus device hfadevice hfadevice formulation formulation seretideadvair salmeterol xinafoat asthmacopd singulair symbicort expired fluticasone propionate spiriva asmanex pulmicort combination combination foster expired diskus device diskus device hfadevice hfadevice formulation formulation serevent salmeterol xinafoate asthmacopd foradil spiriva expired expired compound compound expired diskus device diskus device na hfadevice formulation antivirals relenza zanamivir influenza tamiflu valtrex valaciclovir genital herpes coldsores famvir expired expired shingles zeffixepivirhbv lamivudine chronic hepatitis b hepsera use use central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired requip ropinirole parkinsons disease mirapex expired expired restless legs syndrome requip xl ropinirole parkinsons disease mirapex formulation use seroxatpaxil paroxetine depression various effexor cymbalta expired expired anxiety disorders lexapro treximet sumatriptan naproxen migraine zomig maxalt relpax na combination use wellbutrin sr bupropion depression effexor cymbalta expired expired lexapro cardiovascular urogenital arixtra fondaparinux deep vein thrombosis lovenox fragmin expired expired pulmonary embolism innohep avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular formulation dysfunction post mi fraxiparine nadroparin deep vein thrombosis lovenox fragmin expired expired pulmonary embolism innohep lovaza omega acid ethyl esters high triglycerides tricor na formulation see outlook details uncertainty timing followon competition generic competition possible gsk annual report pp weiver ssenisub products competition intellectual property pharmaceutical products products compounds indications major patent expiry dates competitor brands usa eu antibacterials augmentin amoxicillinclavulanate common bacterial generic products expired expired potassium infections oncology arzerra ofatumumab refractory chronic mabtherarituxan pending pending lymphocytic leukaemia hycamtin topotecan ovarian cancer small cell doxil gemzar expired lung cancer cervical cancer promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura tykerbtyverb lapatanib advanced metastatic herceptin breast cancer positive patients votrient pazopanib metastatic renal cell carcinoma sutent nexavar afinitor vaccines boostrix diphtheria tetanus acellular booster vaccination adacel pertussis infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentacel pediacel polio hepatitis b hepb polio hepatitis b hepb pentaxim pentavac inactivated antigens cervarix hpv virus like particles human papilloma virus gardasil silgard vlps adjuvant mpl type aluminium hydroxide fluarix split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone subtypes type b antigens influvac aggripal fluad flulaval split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone none none subtypes type b antigens influvac aggripal fluad pandemrix derived split inactivated ahnv influenza focetria celvapan emerflu influenza virus antigen prophylaxis adjuvant prepandrix derived split inactivated influenza prophylaxis aflunov influenza virus antigen adjuvant synflorix conjugated pneumococcal invasive pneumococcal prevenar prevnar na polysaccharide disease hiv combivir lamivudine zidovudine hivaids truvada atripla combination combination epivir lamivudine hivaids truvada atripla expired expired epzicomkivexa lamivudine abacavir hivaids truvada atripla combination combination lexiva fosamprenavir hivaids prezista kaletra reyataz selzentry maraviroc hivaids isentress intelence prezista trizivir lamivudine zidovudine hivaids truvada atripla abacavir combination combination see note financial statements legal proceedings gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp products competition intellectual property consumer healthcare products brand products application markets competition oral healthcare aquafresh toothpastes toothbrushes prevention caries gum global colgatepalmolives colgate mouthwashes disease bad breath procter gambles crest sensodyne toothpastes toothbrushes prevention dental global colgatepalmolive sensitivity sensitivity toothpastes biotene mouthwash gel treat dry mouth many markets none polident denture adhesive improve comfort global fixodent poligrip denture cleanser fitted dentures corega clean dentures otc medicines panadol tablets capulets infant drops paracetamolbased treatment global except usa nurofen headache joint pain fever cold symptoms nicoderm gum patch mini lozenge treatment nicotine global novartis nicotinell niquitin cq original lozenge withdrawal aid retailers brands nicabate quitting smoking also nicorette usa nutritional healthcare lucozade energy sports drinks energy hydration uk ireland various sports drinks markets horlicks malted milkbased drinks nutrition uk ireland india ovaltine milo foods ribena blackcurrant juicebased vitamin cdelivering uk ireland robinsons drink health drink markets consumer healthcare competition gsk holds leading positions key consumer product areas worldwide second largest otc medicines third largest oral healthcare nutritional healthcare holds leading position uk ireland india environment consumer healthcare business operates become ever challenging consumers demanding better quality better value improved performance retailers consolidated globalised strengthened negotiation power cycle times innovation reduced main competitors include major international companies colgatepalmolive johnson johnson procter gamble unilever pfizer addition many smaller companies compete gsk certain markets major competitor products otc medicines usa metamucil laxative pepcid indigestion private label smoking control products uk lemsip cold remedy nurofen anadin analgesics nicorette nicotinell smoking control treatments oral healthcare major competitors colgatepalmolives colgate procter gambles crest nutritional healthcare major competitors horlicks ovaltine milo malted food chocolate drinks competitors ribena primarily local fruit juice products lucozade competes energy drinks gsk annual report pp weiver ssenisub regulation regulation pharmaceuticals regulation consumer healthcare region countryspecific laws regulations major consumer healthcare industry subject national regulation factors determining whether product may successfully comparable prescription medicines testing developed approved define information needed approval manufacturing labelling marketing products evaluate safety efficacy pharmaceutical products high standards technical appraisal frequently involve lengthy well governing testing approval manufacturing labelling approval process new product may launched marketing increasing level cooperation gsk consumer healthcare continues gain centralised regulatory exchange information among major regulatory authorities approvals overthecounter products since history encompassing development plans data support product making first otc industry european medicines registration postmarketing safety information inspections agency granted centralised approval weight loss medicine although evaluation benefit risk continue alli granted approval paramount considerations approval new drug countries line extension chewable product also granted usa enhanced focus fda safety centralised approval additionally gsk consumer healthcare medicines approval postmarketing phase embraced principle centralised applications achieved product fda announced four strategic priorities gsks first pangulf cooperation council approvals alli next five years advance regulatory science innovation niquitin permitting launch across seven markets strengthen safety integrity global supply chain gulf region strengthen compliance enforcement activities support value money public health address unmet public health needs special populations engaged key areas payers around world concerned cost interest healthcare pricing medicines requirement satisfy healthcare purchasers value money becoming europe new regulations aimed strengthening safety additional hurdle product acceptance monitoring medicines agreed eu legislators regulatory tests safety efficacy quality implemented discussions continue draft legislation improving citizens access reliable information price controls medicines strengthening eu laws protect citizens threats posed fake medicines european medicines many countries prices pharmaceutical products agency ema heads national medicines agencies controlled law governments may also influence prices hma published fiveyear strategic plans control national healthcare organisations may bear aimed mainly strengthening operation existing large part cost supplying medicines consumers eu regulatory network eu commission published report recent government healthcare reforms countries france operation ema preparation potential legislative spain germany may restrict pricing reimbursement proposal changes regulatory framework also continued review regulation clinical trials currently usa government price controls europe review expected conclude private sector purchases federal law requires pharmaceutical manufacturers pay prescribed rebates certain drugs regulatory environment emerging markets asiapacific eligible reimbursement several state federal continues evolve number countries continuing healthcare programmes us president congress develop regulatory review systems actively participate passed affordable care act aca reform us healthcare number specific regional national regulatory system drive cost improve quality increase access initiatives provide opportunities meaningful scientific millions americans without health insurance reforms regulatory dialogue industry agencies potential create positive changes us healthcare stakeholders continue include broader sets patient system expand access products however aca populations number countries medicine also increased prescribed rebates governmentrun development programmes order increase global patient access programmes changed balance private new innovative medicines optimise regulatory approvals public sector purchases despite passage aca pressure control healthcare costs continue beyond issues cross border trade acceleration generics market comparative effectiveness research pharmaceutical pricing continue part ongoing healthare debate usa fortunately positioned constructive contributor debates since increased recognition chronic disease primary driver healthcare spending pharmaceutical products deliver important interventions help hold healthcare costs gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp manufacturing supply gsks manufacturing covers pharmaceutical consumer vaccine manufacturing healthcare vaccines vaccine manufacturing managed separately gms integral part biologicals business particularly pharmaceutical global manufacturing supply gms complex requires use innovative technologies living people work gms across network microorganisms comprehensive quality assurance quality sites countries gms supports commercial ambition control procedures place ensure vaccines quality gsk delivering quality medicines consumer products safety due biological nature individual health authorities patients customers around world may subject vaccines second control guarantee highest scale manufacturing gsk huge manufacture quality standards billion packs per year different presentations gms supports gsks commercial ambition deliver quality including tablets creamsointments inhalers injections liquids medicines consumer healthcare products patients steriles supplied markets consumers around world billion spent gms production gms operates procurement operation behalf group spend billion annually external suppliers purchasing active ingredients chemical intermediates packaging components partfinished finished products internal customers sought every opportunity grow businesses focused costcompetitive supply quality product meet ambitions worked diligently leverage network sites contractors give us builtin flexibility sustain future growth adapt emerging commercial business models increasingly rigorous external regulatory environment continued leverage technology support process understanding control capability pharmaceutical launch global supply sites work closely rds development teams ensure right technical competencies place support rapid successful new product introduction sites serve focal point developing introducing new secondary manufacturing technologies primary supply sites pharmaceutical launch global supply division supply high quality competitively priced bulk actives focus improvements primary technologies processes sites antibiotics emerging markets supply division focus manufacturing products late stage life cycle allowing gsk compete effectively markets consumer healthcare manufacturing consumer healthcare manufacturing also managed gms apart coleford site managed directly nutritional healthcare consumer healthcare sites deliver highquality competitively priced products support rapid new product introduction highly innovative competitive business new technologies become fundamental platform driving innovation lowering costs providing flexibility operations continuously improving embedding new ways working simplifying business achieving greater efficiencies focus customer service including support new product launches strong compliance culture commitment health safety environment commitment developing people delivered strong results gsk even external environment become demanding gsk annual report pp weiver ssenisub world market pharmaceuticals global recession caused international financial crisis continued impact worlds economies although world market value top six therapeutic classes bn total many countries industry sectors saw improvement significant growth remained elusive recovery central nervous system fragile best cardiovascular antineoplasticimmunomodulatory following rise ftse index achieved alimentary tract metabolic modest gains usa dow jones industrial antiinfectives bacterial average rose stock exchanges across europe recorded viral fungal excluding vaccines mixed performances rise germany contrasting respiratory losses spain italy respectively asia chinese stock market posted annual decline note data based months th september almost nikkei japan one debt crisis greece spread economies data market share market growth rates gsk estimates spain portugal italy ireland romania moved towards based recent data independent external sources end year many governments introduced austerity including ims health appropriate valued sterling measures complement fiscal stimulus initiatives relevant exchange rates cuts cases severe rapid implemented across education healthcare public services government took different approach healthcare specific pricing cuts applied selected medicines vaccines measures affected pharmaceutical industry varying degrees depending companys exposure areas impacted time also saw implementation healthcare reform usa associated discounts price cuts pharmaceutical industry global pharmaceutical sales billion compared billion world market value geographic region bn total usa europe rest world emerging markets asia pacific japan canada total market growth cer basis usa europe rest world gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp gsk sales performance gsk delivered underlying sales growth excluding pandemic related products avandia valtrex despite ongoing impacts eu government austerity measures us healthcare reform reduced sales approximately million commentary gsks segmental sales performance uses performance measures set underlying sales growth underlying sales growth excludes sales pandemic products avandia valtrex management believes measure assists shareholders gaining clearer understanding groups sales performance prospects size nature loss sales products reconciliation group pharmaceutical turnover follows growth cer group turnover avandia valtrex pandemic products underlying group turnover growth cer pharmaceutical turnover avandia valtrex pandemic products underlying pharmaceutical turnover sales products segment emerging asia pacific trading usa europe markets japan unallocated total pandemic products avandia valtrex emerging asia pacific trading usa europe markets japan unallocated total pandemic products avandia valtrex white pillswestern markets white pillswestern markets refers sales tablets simple injectables excluding biopharmaceuticals vaccines north america europe cer growth order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates commentaries report presented terms cer unless otherwise stated gsk annual report pp weiver ssenisub us pharmaceuticals segment review making continued efforts change companys restated growth model improve levels openness transparency example cer voluntarily stopped corporate political contributions turnover became first company report voluntarily payments healthcare professionals usa named operating profit individual basis speaking consulting services emerging period significant patent expirations us business implementing new system making good progress transform us business model evaluating compensating professional sales representatives operations meet current future challenges new programme bonuses sales representatives work directly customers longer based sales usa billion primarily due achievement individual sales targets instead impact generic competition valtrex significant assessed scientific business knowledge feedback reduction sales pandemic related products lower sales customers region including demonstration companys avandia underlying sales excluding pandemic related products values overall performance business unit support avandia valtrex usa year programme fully implemented july despite discontinuation gsks promotion boniva sale wellbutrin xl impact us healthcare reform consistent values integrity transparency across product range underlying growth driven strong also sharpened focus support continuing medical performances number promoted medicines including education cme example implemented system flovent ventolin boostrix avodart limit grant applications approximately academic medical lovaza oncology products centres nationallevel professional medical associations new products launched since excluding flu pandemic cme providers support must directly accredited vaccines grew contributed sales recognised accrediting body fund cme notforprofit providers reduced turnover partially offset lower sga costs reflecting savings restructuring programme receipt although us healthcare business environment exclusive promotion rights boniva operating challenging also presents opportunities companies profit declined deliver truly innovative medicines market since launched new products us market usa healthcare market changing radically rapidly look forward regulatory decision benlysta significant proportion healthcare costs continue paid approved first new treatment lupus federal local governments large pharmacy benefit managers last years overall believe improvements making health plans dominate private market physicians cost structure operate enabling us consolidating practices medical centers group practices compete effectively evolving marketplace integrated delivery networks hospitals consolidating fewer three years ago research triangle park campus north carolina usa payers demanding higher quality care lower costs home number business functions increasingly linking reimbursement improved health outcomes implementation landmark healthcare reform legislation usa also began year result january medicaid drug rebates increased extended include medicaid managed care plans new formulations existing products also january eligibility certain government drug pricing programs expanded include additional hospitals health centers response evolving market conditions making fundamental changes us operations ensure deliver value customers patients healthcare providers payers demand changes enabling us effectively meet customer needs expectations better deploy resources support evolving specialised product portfolio example majority us pharmaceuticals sales representatives either customercentred portfolio focused responsibilities rather product specific responsibilities changes enabled us increase productivity sales force reducing size approximately since importantly new customercentric model aligns customers desire work us businessto business partner gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp europe pharmaceuticals segment review enter continuing pressure cost restated growth change valuebased medicine approach addition cer demonstration safety efficacy governments turnover agencies assess medicines value deliver healthcare system makes development effective dialogue operating profit governments regulators payers across europe absolutely vital within business continue place emphasis european pharmaceutical business delivered solid performance able demonstrate cost effectiveness gsk products despite significant government led austerity measures deliver new medicines vaccines address unmet medical price cuts need also demonstrable value much work although reported sales billion underlying targeted building evidence cost effectiveness performance excluding pandemic related products avandia medicines compared current treatments example valtrex flat creditable performance includes uk agreed innovative pricing agreement approximately million sales impact government price national institute clinical excellence nice cuts driven introduction new products growth advanced kidney cancer medicine votrient votrient products portfolio despite likely continued effective sunitinib current standard care government pricing pressure strong product portfolio comparative trials currently underway gives us confidence future performance business offered future financial rebate introduced five new products particular highlight duodart treatment combination avodart tamsulosin benign prostatic hyperplasia recently introduced brands avamys requip modutab tyverb volibris wellbutrin achieved double digit growth major product seretide asthma copd impacted price cuts achieved sales billion whilst maintaining leadership position respiratory market continue bring benefits product patients across europe portfolio vaccines also contributed growth synflorix pneumococcal conjugate vaccine winning several national tenders increasing sales million manage operating costs business also delivered improvements efficiency close control operating expenses delivered savings excess programme reduce diversity cartons labels leaflets used across range medicines delivered savings part initiative reduce different formats tablet blister packs reduction sga costs reflecting savings restructuring programme helped limit decline operating profit commitment work communities across europe support greater access build trust stakeholders continues example project bulgaria promote awareness vaccines among vulnerable ethnic minority groups collaboration health mediators general practitioners representatives regional health inspectorates initiative facilitates access groups national healthcare system focusing prevention health awareness particular benefit work improved rate immunisation group turn reduced impact outbreak measles gsk annual report pp weiver ssenisub emerging markets pharmaceuticals segment review continue introduce flexible pricing strategies work restated growth early stage however results initiatives far cer promising example significantly reduced prices turnover gsks newest innovative products including avodart avamys cervarix aim increasing affordability operating profit volumes sold middle income countries emerging markets pharmaceutical business continues least developed countries ldcs last year established perform strongly sales billion new developing countries market access business unit underlying growth markets excluding pandemic related new unit dedicated focus expanding access products avandia valtrex second medicines vaccines million people consecutive year following introduction gsks strategic live worlds poorest countries added benefit initiatives emerging markets business outgrown helping us build sustainable gsk businesses parts pharmaceutical market growth region estimated developing world currently little presence responsible implementing pricing policy delivered particularly strong performances latin america capping prices patented medicines ldcs grew china cis grew western price reinvesting profits respectively addition produced growth across medicines sold countries back countries three sectors emerging markets business innovative healthcare infrastructure brands new patent protected products classic brands nonpatent protected vaccines year also pleased announce signing advance market commitment amc pneumococcal innovative brands business showed consistent performance vaccines global alliance vaccines immunisation sales growth approximately billion gavi providing million doses synflorix sales respiratory medicine seretide million years reduced price protect children poorest grew particularly strong performances key countries across world invasive pneumococcal disease markets including china classic brands business also continues go strength strength sales growth billion including continued doubledigit growth augmentin years market vaccine sales million pandemic flu products pneumococcal vaccine synflorix performing particularly well excluding pandemic flu vaccines sales grew turnover main business sector vaccines innovative brands classic brands emerging markets pharmaceuticals operating profit increased turnover increase reflecting strong synflorix pandemic vaccine sales together benefit acquisitions partially offset increased sga investment across region operational highlights year include number new strategic alliances strengthened footprint key emerging markets number business acquisitions including laboratorios phoenix leading argentinian classic brands business number vaccine production alliances also concluded year including alliance jsc binnopharm russian pharmaceutical manufacturer enable local secondary manufacture number key gsk vaccines russia gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp asia pacificjapan pharmaceuticals segment review gsk japan delivered another strong year sales restated growth million underlying sales growth excluding pandemic cer products valtrex avandia growth driven turnover primarily adoair seretideadvair contributions newly launched products cervarix avolveavodart operating profit xyzal partially offset paxil sales decline declines mature respiratory products flixotideflovent sales asia pacific grew billion excluding serevent part reflected biennial sales pandemic related products avandia valtrex price reductions underlying growth asia pacific benefitted acquisitions stiefels dermatology portfolio ucbs asian vaccine franchise become important pillar business strong performances also delivered avamys company japan arepanrix became one two flu vaccines tykerb seretide vaccines ever allowed import japan received regulatory excluding flu pandemic approval january cervarix strong launch japan sales million product also recognised operating profit asia pacific improved billion one three vaccines would receive public funding reflecting improved sales synflorix cervarix japanese government onwards favourable impact product mix cost goods partially offset lower sales relenza operating profit japan increased billion reflecting higher cervarix pandemic vaccine sales middle income countries asia pacific region favourable impact product mix cost goods partially offset centre gsks flexible pricing initiatives example lower sales relenza part innovative pricing model monthly sales cervarix vaccine increased approximately six times philippines year gsk japan received approvals six compounds following price reduction similarly indonesia including revolade xyzal one new indication botox vietnam introduced equivalent pricing strategies spasticity addition oral pulmonary arterial hypertension vaccine resulted sixfold increase treatment volibris launched year number women vaccinated cervarix number one gsk japan established rare diseases development centre human papillomavirus vaccine south east asia malaysia april accelerate delivery medicines rare diseases securing regions first ever tender product treatment yet available part initiative year synflorix also growing well delivering sales million gsk increased investment japan investing japan chemical year also saw important strategic alliances signed major research company leading technology manufacture local pharmaceutical companies including donga south korea biopharmaceuticals savipharm vietnam japanese pipeline potential approvals pending potential approval filings includes new chemical entities includes new chemical entities line extensions new promotions reformulations gsk annual report pp weiver ssenisub viiv healthcare segment review improving paediatric care hiv restated growth cer turnover operating profit viiv healthcare celebrated first anniversary november business established gsk pfizer independent company focused delivering advances clinical outcomes enhancing quality life people living hiv companys unique structure wide portfolio available medicines provides financial stability investment capital required take sustainable longterm view hiv market overall sales hiv products viiv healthcare billion sales former pfizer products celsentri selzentry viracept combined sales million growth epzicomkivexa million partially offset reductions sales established hiv products including trizivir million combivir million lexivatelzir million epivir million continue impacted uptake newer alternative products strong growth celsentriselzentry compared supported wide acceptance genotypic testing across europe increasing firstline use usa country launches poland romania australia japan mexico upward trends part commitment address major unmet needs epzicomkivexa sales reflected role nucleoside reverse hiv viiv healthcare formed key partnerships elizabeth transcriptase inhibitors nrtis mainstay treatment hiv glaser pediatric aids foundation amfar improve care part strategic focus international markets countries paediatric hiv prevent mother child transmission mtct excluding europe north america viiv healthcare established virus fourth millennium development goal new independent local operating companies several important positive action children fund gave million geographies opened regional hubs asia pacific cis community projects support mothers children affected latin america result revenue international hiv prevent mtct request proposals region grew end year expanded funds reach scope viiv healthcare operating profits decreased primarily result us healthcare reform higher sga rd costs partially offset onetime royalty settlement higher sga costs primarily due amortisation acquired intangible assets also saw great progress building latestage pipeline october shionogiviiv healthcare announced start phase iii development programme novel integrase inhibitor sgsk phase iii trial fixed dose combination tri epzicomkivexa initiated february viiv healthcare committed supporting communities affected hiv epidemic one way company developing innovative approaches improve access medicines example july viiv healthcare first company make entire current future antiretroviral portfolio available generic manufacturers royaltyfree voluntary licences cover least developed low income countries subsaharan africa countries people hiv live similarly notforprofit pricing policy expanded countries year viiv healthcare also launched positive action southern initiative usa reduce healthcare disparities among communities greatest needs gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp consumer healthcare segment review year opened new bottle manufacturing plant restated growth coleford uk factory nutritional healthcare enabling us cer mould lucozade ribena bottles formulate drinks turnover fill bottles one plant bottleforming facility moulds billion pet bottles per year plastic chips investment operating profit eliminates roadhaulage trips miles former bottle supplier consumer healthcare sales grew billion significantly ahead consumer healthcare market growth recently announced intention accelerate growth estimated approximately delivered growth focus consumer healthcare business around portfolio three categories operate oral healthcare priority brands emerging markets two overthecounter otc medicines nutritional dimensions represent around current consumer healthcare healthcare sales base intend divest remaining sales million mostly consist european europe sales level last year sales billion american noncore otc brands aim divest products growth oral healthcare nutritional healthcare offset late subject interest realising appropriate value decline otc sales business usa grew shareholders expect use proceeds fund increased billion led oral healthcare returns shareholders growth particularly strong rest world grew finally part objective deliver sustainable business billion indian subcontinent continued largest array solar panels north america powers deliver new innovations horlicks brand launching regional distribution centre york pennsylvania almost three priority brands lucozade sensodyne breathe right doorsized solar panels cover rooftop equivalent eight resulting combined sales growth china delivered football fields generating kwhr per year solar array sales growth expanded consumer availability eliminate nearly tonnes carbon dioxide emissions per fenbid contac bactroban strong uptake newly launched year load environment would take mature lucozade continued good performance products trees absorb including sensodyne breathe right denture care brands accelerate research innovation key emerging solar panels cover rooftop gsks consumer markets opened oral healthcare research centre healthcare regional distribution centre york pennsylvania gurgaon india innovation centre beijing china middle east africa pakistan markets together delivered sales growth largely strong panadol eno sales growth south america grew sales also led strong panadol eno consumption lower growth japan australianew zealand respectively oral healthcare grew billion led strong performance sensodyne continued fastest growing toothpaste world position held last years remarkable record brand th year following launch india market sensodyne countries however aquafresh sales declined slightly biotene dry mouth treatment acquired grew strongly otc medicines recorded sales billion good performance smoking control products helped new tax tobacco japan substantial sales brazil governmentfunded smoking cessation initiative addition supplying products brazils initiative provided training smoking cessation clinics across country panadol leading paracetamol analgesic outside usa delivered strong sales growth helped rollout panadol advance optizorb technology dissolves five times faster regular paracetamol tablets dermatology products grew million respiratory tract products declined million nutritional healthcare grew million led horlicks modest growth ribena lucozade operating profit increased turnover increase reflecting efficiencies scale sga costs grew slowly sales gsk annual report pp weiver ssenisub pharmaceutical research development review group rd expenditure major restructuring focusing returns pharmaceutical rd million million representing total making fundamental changes allocate turnover company expects rd costs pharmaceutical rd investment terminating development major restructuring percentage turnover remain around areas low scientific financial return dismantling infrastructure reducing cost risk externalising parts earlystage discovery directing investment late stage delivering sustained asset progression new pipeline progress included chemical entities new vaccines entering phase iii since start seven assets filed regulators five projects early announced intention cease terminated phase iii development listed discovery research certain areas neurology adverse trial results feedback regulators pain depression instead concentrate activities end expect phase iii data around additional neurodegenerative neuroinflammatory diseases assets including treatments type type diabetes rare feel prospects successful registration launch diseases multiple cancer types differentiated medicines greater change led us exit five rd centres two largest verona italy pharmaceuticals rd segment comprises rd activities zagreb croatia operations transferred pharmaceuticals business excluding vaccines consumer healthcare external groups thereby preserving majority jobs local central costs table analyses group rd expenditure categories successfully outlicensed spun early stage neurology assets uk deals convergence pharmaceuticals proximagen group pharmaceuticals direct project costs changes actions achieved excl vaccines indirect costs reduction footprint since unallocated costs continue increase external nature discovery pharmaceuticals rd activities signed eight new collaborations inmarket pharmaceutical access novel discovery giving us total external discovery development engines complement dpus vaccines streamlined resourcing clinical trials contract corporate costs research organisations reducing two suppliers provides savings terms economies consumer healthcare scale also ensure consistency rigour clinical trials around globe rd major restructuring combined molecular discovery research mdr major restructuring preclinical development pcd create endtoend total rd scientific technical platform supporting discovery development efforts remit group remains create proportion pharmaceuticals rd investment made materials knowledge enable rd take ideas latestage portfolio continues grow direct generate hypotheses test preclinical clinical indirect costs settings ultimately launch new medicines sales new pharmaceutical products launched since developments pharmaceutical rd excluding pandemic flu vaccines grew million gsk rare diseases created enable us focus represented total pharmaceutical sales specialised area drug discovery development opportunities new treatments rare diseases growing growth cer increased scientific including genetic understanding allows researchers identify rare diseases likely veramyst respond therapeutic intervention signed two significant new cervarix rare disease alliances year amicus treatment coreg cr fabry disease fondazione telethon research develop lamictal xr novel stemcell derived treatments address rare genetic disorders requip xl using gene therapy carried patients stem cells rotarix new agreements demonstrate approach seeking synflorix innovative medicines add value patients payers treximet tykerb year also made progress commitment encourage others new research neglected tropical diseases research centre tres cantos spain released results yearlong screening two million compounds gsks chemical library seek could inhibit malaria parasite p falciparum investment pipeline progress made data publically available online globally people work rd many molecule structures released proprietary based major rd centres uk usa belgium china gsk therefore information released entirely new people work pharmaceuticals rd course research community managed projects trials humans gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp responsible business creating successful sustainable research innovation undertaking research innovating may explore business financial apply new technologies constructively engage stakeholders results place great importance concerns may arise ensure products subject rigorous scientific evaluation testing safety achieve effectiveness quality comply exceed achieve running responsible regulations legal standards applicable research valuesbased business embedded development products read strategy products customers promote products line high ethical medical scientific standards comply applicable laws regulations read working hard build culture decisions guided values caring environment operate environmentally responsible manner commit transparency systematic management environmental impacts show respect people measurement performance setting challenging always demonstrate highest integrity conduct performance targets improve efficiency activities minimise material energy use waste generated patient focused aim find opportunities use renewable materials know research development manufacture recycle waste read sale products raise ethical issues aim employment practices open tackle understand important treat employees respect dignity encourage communicate stakeholders seeking understand diversity ensure fair treatment phases views transparent setbacks employment provide safe healthy working experienced well progress made environment support employees perform full potential example commitment putting patients first means take responsibility performance reputation focusing improving access medicines vaccines business read patients irrespective live ability pay human rights believe right thing contribute committed upholding un universal declaration sustainable business growth human rights oecd guidelines multinational enterprises ultimately believe responsible business good society core labour standards set international labour good gsk helps us operate efficiently gain organization expect standards suppliers trust stakeholders create products patients contractors business partners working gsks behalf healthcare payers really need foster right conditions read cr report expansion business leadership advocacy read approach performance responsible business establish challenging standards corporate issues including access medicines research business ethics responsibility appropriate complexities specific needs environment wwwgskcomresponsibility business building external guidelines experience corporate responsibility report cr report share best practice seek influence others published st march remaining competitive order sustain business read cr report principles engagement stakeholders principles sum approach responsible business want understand concerns interest underpinned values provide guidance employees corporate responsibility issues engage range standards gsk committed stakeholders communicate openly access medicines addressing cr issues ways aim meet needs continue research develop medicines treat different groups allowing us pursue legitimate business diseases developing world find sustainable goals read cr report ways improve access medicines disadvantaged people community investment seek partnerships support activity read make positive contribution communities operate invest health education programmes standards ethical conduct partnerships aim bring sustainable improvements expect employees meet high ethical standards aspects underserved people developed developing world business conducting activities honesty read integrity adhering corporate responsibility principles complying applicable laws regulations read gsk annual report pp weiver ssenisub responsible business improving access medicines work communities access healthcare developing world invest community partnership programmes seek easy solutions challenge providing improve access medicines healthcare improve lives sustainable access healthcare developing countries poverty people across world aim make real difference single biggest barrier many countries people communities working partners find innovative solutions enough food access clean water supply hospitals clinics healthcare challenges believe business important receive treatment healthcare professionals care role play society strive leverage resources way delivers shared value communities business partner support organisations whose goals committed playing full part addressing objectives reflect mission improving quality human life healthcare challenges developing world taking innovative responsible sustainable approach global community investment million gsk making vital contribution developing country healthcare compares million likeforlike basis action number areas including preferential pricing increase due expansion us patient assistance antiretrovirals tiered pricing vaccines medicines programme scale donation albendazole investing rd targets diseases particularly affecting lymphatic filariasis lf programme donation hn vaccine developing world see flexible ip pursuing world health organization plus increased grants hiv open innovation strategy community investment activities aids reinvestment initiative ldcs partnerships foster effective healthcare capacity building giving comprised product donations million cash see seeking innovative partnerships solutions giving million inkind donations million plus costs cover contribution improving access medicines million manage deliver community programmes extensively corporate responsibility report almost countries product donations include million gsks patient assistance programmes million worth clear leader access medicines atm albendazole lf programme million humanitarian indexes published atm foundation product donations since product donations continue build product pricing partnership valued cost average cost goods rather wholesale price commitments help improve healthcare developing wac accurate reflection cost gsk world expanded commitments un believe first pharmaceutical company adopt defined list least developed countries ldcs establishing practice comparative purposes total value donations developing countries market access operating unit using wac products would million compared focus ldcs broaden patient access gsk medicines million help build presence developing countries operate single charitable foundation much achieved significant increase resources community investment programmes number global community still needed support rd countrybased foundations grants included provide access resultant medicines vaccines sustainable investment total progress made significant barriers stand way better access healthcare tackled shared cash giving targeted primarily health education responsibility sectors global society governments initiatives follows international agencies charities academic institutions pharmaceutical industry others health access medicines developed world education programmes usa arts culture working provide access medicines people environment limited financial resources without prescription medicine insurance uninsured americans qualify medicare medicaid gsk ten pharmaceutical companies created global health programmes together rx access programme qualified individuals developing countries millions people continue suffer offering reductions pharmacy cost die preventable treatable diseases global health medicines addition gsk offers several patient assistance programmes designed improve health quality life programmes help lowincome uninsured americans people communities provision medicines access gsks oncology specialty products vaccines education advocacy investment disease prevention prescription drugs gsks patient assistance programmes provided healthcare infrastructure global programmes products patients longterm commitments designed scaleable replicable programmes countries sustainable also introduced orange cards providing discounts working partnership ngos leading health certain gsk prescription medicines eligible patients number organisations believe possible achieve significant countries nature discounts varies longlasting improvements healthcare section highlights countries ways healthcare systems operate major health programmes gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp responsible business eliminating lymphatic filariasis lf local programmes effort eliminate lf one worlds disabling diseases support communities many different markets continued close partnership governments countries operate programmes designed fit local disease endemic world health organization circumstances cultures aligned overall goal partner organisations founding partner leader supporting access medicines healthcare local community effort committed donating much anti priorities vary community community population parasitic drug albendazole required reach one billion population often common challenges address people risk countries million albendazole whether terms particular health need human treatments donated countries donated almost institutional capacity required effectively tackle needs two billion albendazole treatments since global elimination uk contributed million continuing programme started programme charitable activities supporting organisations positive action hivaids health medical research science education arts positive action created first environment included uk impact awards scheme pharmaceutical company programme kind support provides small charities grants consulting support communities affected hiv aids auspices work addressing health needs local communities viiv healthcare new hivfocused company programme programmes north america national local level targets funds towards communityfocused projects reach focused improving public education areas science affected hiv particularly marginalised vulnerable mathematics increasing access healthcare children populations positive action works communities enable homeless gsks impact awards recognise organisations tackle stigma discrimination test innovations significantly improved health local communities education care treatment deliver greater involvement philadelphia research triangle park north carolina total living hiv positive action children fund launched funding north american programmes million make million available years help prevent mothertochild transmission hiv support orphans argentina pro mujer programme works lowincome vulnerable children supported projects end women access affordable financial services latest call proposals made broadening reach healthcare provides access small loans set scope response babies children affected hiv businesses well training affordable healthcare services glaxosmithkline african malaria partnership gsk returned communitymark excellence african malaria partnership programme alleviate community investment mortality suffering malaria brings affected communities information gsk grants programmes africa four new malaria grants awarded available wwwgskcom community programmes provide health education affected populations train community health workers employee involvement partnerships save children uk kenya family health employees encouraged contribute local international ghana african medical research foundation communities employee volunteering schemes amref tanzania planned parenthood federation nigeria support includes employee time cash donations charities employees volunteer matching gift programmes humanitarian product donations working nonprofit partners americares direct relief us gsk matching gift program matched international map international interchurch medical assistance employee gifts value million plus project hope supported humanitarian relief efforts million united way campaign gsks give programme community healthcare countries provided grants organisations us employees volunteered ukbased nonprofit responded healthcare needs many communities organisations via gsk making difference programme affected disasters including devastating earthquake struck haiti january gsk donated supplies medicines groupwide volunteer initiative launched give valued million included shipments every gsk employee one paid day year volunteer significant volumes antibiotics well respiratory good cause continued employees supporting diabetes treatments consumer division provided range wide range charities projects including work local schools products including toothpastes antacids pain relievers shelters homeless community gardens nursing homes vitamins cholera outbreak responded aiding communities affected natural disasters specific request antibiotics donated gsk pulse volunteer partnership launched enables british red cross support deployment mass sanitation gsk employees make difference communities patients unit serving people living temporary relief need around world volunteers work fulltime one camps following earthquake chile response partner nonprofit nongovernmental organisations ngos urgent request supplied doses hepatitis vaccine experience volunteers address clear ngo need antibiotics dental hygiene kits developing leadership capabilities pakistan provided medicines local stocks pulse deployed volunteers countries work thousands people affected flooding also made cash ngos volunteers continue receive full gsk salary donations amounting including contribution three six month assignment figure world food programme support emergency food supply along operating costs managing programme represented total inkind donation million total value international humanitarian product donations million average cost gsk annual report pp weiver ssenisub responsible business environmental sustainability central fund finance energy saving projects accelerated progress since completed projects committed integrating environmental sustainability avoid around tonnes greenhouse gas emissions business especially conserving resources year addressing climate change see opportunity well responsibility also increasing investment onsite generation renewable energy supported renewable energy fund created strategy plans gsk consumer healthcare installed north americas revised environmental sustainability strategy largest roof mounted solar photo voltaic system regional building strategy originally introduced new distribution centre york pennsylvania save nearly strategy recognises impacts across entire value chain tonnes carbon dioxide emissions per year raw materials disposal products objective benefit environment engage employees tackling key issues gsks global operations certified carbon trust standard benefit gsk financially potentially saving million year first company achieve recognition excellence reduced energy materials distribution costs carbon management global operations analysis gsks impacts shows need concentrate water three main areas water particularly important natural resource recognise carbon dioxide emissions contribute gsk play positive role managing sustainably climate change endorsed united nations ceo water mandate water use reduced water consumption almost million litres despite significant business growth vaccines manufacturing environmental stewardship covers use materials business net water consumption fell per sales generation waste pollution cumulative reduction since exceeding target set ambitious goals key impacts including reduction carbon footprint reduction water use also exceeded targets improving quality across value chain zero waste landfill waste water targets detailed corporate responsibility report environmental stewardship climate change energy aim use materials efficiently safely minimising waste longterm vision entire value chain carbon pollution avoiding harm people environment neutral ambitious target means net greenhouse gas emissions manufacturing increasing efficiency use materials priority distributing using disposing products including longterm aspiration achieve mass efficiency sourcing raw materials new pharmaceutical products transferred rd manufacturing five times typical level need act beyond operations pharmaceutical industry reduce input materials carbon footprint stems supply chain waste average mass efficiency new products derives propellants customers use inhalers period reached confirmed global carbon footprint review entire value chain carried first time improvements efficiency solvent use also reduced amount volatile organics released air per gsks carbon footprint million tonne coe per annum sales cumulatively since packaging provides opportunities conserve resources began implement sustainable packaging materialssupply chain strategy developed also began update green packaging guide designers managers us product use american institute chemical engineers presented industrial production operations practice award sustainable engineering operational distribution sustainability team work embedding sustainability product end life rd manufacturing environmental management manage environmental issues well occupational health met goal eliminating use chlorofluorocarbons safety using management system aligned recognised cfcs products end reduced international standards business accountable greenhouse emissions associated inhaler products sustainability plans performance central audit group million tonnes carbon dioxide equivalents includes environmental issues routine audits sites approximately million tonnes research business processes working increasingly closely programmes way find ways reduce impacts suppliers contract manufacturers reduce environmental products impacts supply chain reduced energy consumption operations read environmental performance transport greenhouse gas emissions relative aspects sustainability corporate responsibility sales cumulative reduction energy report wwwgskcom emissions target mainly progress slow early years fiveyear period gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp responsible business ethical conduct performance reward committed creating strong ethical culture gsk performance development planning process means emphasising values developing robust policies employees businessaligned objectives behavioural recruiting engaging right people equipping goals reward systems geared promote high information need make ethical decisions performance help attract retain best people putting patients first core principle ethical performancebased pay bonuses sharebased equity plans pharmaceutical company align employee interests business targets code conduct sets fundamental standards communication employee involvement employees supported employee guide business communication channels designed keep employees conduct helps employees make ethical decisions informed engaged involved activities across areas emphasises gsks key values organisation encourage twoway open honest communication employees launched c ommit transparency new updated global intranet portal connectgsk respect people feedback monitoring mechanisms part every major lways demonstrate highest integrity conduct communication event qa feedback facilities b e patient focused core feature web communications channels also introduced idea engine online tool allows stress commitment performance integrity employees submit ideas recommendations means employees must understand values stand well policies procedures business evolves changes affect underpin approach employees remain committed consulting changes via number internal consultation forums internal compliance systems designed identify discussions european employee consultation forum address breaches codes reinforce gsks values similar bodies countries national practice continual external pressure enhance systems compliance oversight audits helping drive change employee numbers region fully investigate suspected breaches take appropriate disciplinary action including dismissal appropriate reviewed strengthened approach usa preventing detecting addressing bribery corruption europe launched dedicated antibribery corruption unit rest world ensure take consistent approach across gsk strengthens monitoring capability also introduced third party code conduct applies inclusion diversity gsk suppliers sets standards expect committed employment policies free discrimination suppliers meet covers ethical conduct labour practices existing potential employees grounds race environmental health safety standards management colour religion belief gender sexual orientation gender identity help suppliers understand interact appropriately expression age national origin genetic makeup disability gsk staff code includes key principles employee chronic health conditions gsk committed offering people guide business conduct policy receiving gifts disabilities access full range recruitment career due diligence process potential acquisitions takes account opportunities every effort made retain support employees ethical risks integrate ethics compliance requirements become disabled working gsk details standard practice newly acquired businesses seek enter diversity measures see corporate responsibility report joint ventures organisations share values healthy safe high performance employees meet mission strategy employee health performance initiatives focus health factors enable recruitment talent management leadership develoment employees perform highest level sustaining energy like every year recruiting retaining developing engagement programmes developed deliver employees critical enhancing sustaining health strategy range traditional immunisations performance reputation proactive talent acquisition initiatives smoking control weight management cuttingedge underpin ability attract specialist leadership talent programmes areas team personal resilience externally assessment process aligned core set ergonomics energy performance programmes competencies ethics integrity central available many languages designed address root need good succession plans senior roles causes excessive work pressure low energy engagement critical positions across organisation maintain work home complemented commitment robust leadership strategy identify develop highly skilled flexible thinking way deliver work enables leadership cadre use systematic disciplined approach employees best work environment helps leadership development providing tools programmes help integrate work personal lives details leaders master skills needed meet customer employee scope impact programmes see corporate investor expectations provided training nearly responsibility report gsk leaders worldwide also developed new programmes future senior leaders senior executivespp weiver ssenisub financial review pharmaceutical turnover respiratory growth rates included review turnover constant respiratory sales increased billion exchange rates cer unless otherwise stated calculation seretideadvair sales grew billion strong growth underlying turnover described sterling growth japan million emerging markets rates may found tables pharmaceutical turnover million sales usa level billion therapeutic areas geographic segment grew europe billion pharmaceutical turnover declined billion excluding several respiratory products delivered growth including pandemic products avandia valtrex underlying turnover avamysveramyst million ventolin increased million flovent million segmental analysis antivirals turnover reported table represents sales invoiced antivirals decreased billion gsks local entity customers local market plus relenza sales million million copromotion income within market previous year significant government pandemic orders received valtrex sales declined million restated growth reflecting generic competition usa europe cer central nervous system cns usa cns sales decreased billion europe emerging markets majority gsks cns franchise impacted generic asia pacificjapan competition usa wellbutrin decline primarily viiv healthcare reflected sale wellbutrin xl usa biovail second quarter cardiovascular urogenital cardiovascular urogenital sales increased billion cer represents growth constant exchange rates represents growth reflecting continued strong growth key products arixtra actual exchange rates turnover quarter given pages million avodart million sales usa declined billion primarily due lovaza million generic competition valtrex significant reduction sales pandemic related products lower sales avandia excluding metabolic products underlying turnover grew despite metabolic sales decreased billion discontinuation gsks promotion boniva sale wellbutrin avandia product sales declined million xl may impact us healthcare reform across rd september european medicines agency suspended product range new products excluding pandemic vaccines marketing authorisation rosiglitazone containing products launched since grew contributed sales including avandia us food drug administration europe pharmaceuticals sales declined billion primarily announced additional measures ensure benefits avandia due impact significant reduction sales pandemic continue outweigh risks including risk evaluation related products generic competition valtrex lower sales mitigation strategy rems programme result gsk expects avandia excluding products underlying sales flat global sales rosiglitazone containing products including avandia reflecting impact government austerity measures minimal future emerging markets pharmaceutical sales grew billion oncology emesis strong growth across product categories also oncology emesis sales increased billion helped pandemic related product sales million tyverbtykerb million grew strongly million asia pacificjapan pharmaceutical sales grew segments newly launched oncology products votrient arzerra billion excluding pandemic related products valtrex promacta delivered sales million million avandia underlying sales grew emerging markets million respectively asia pacificjapan vaccines pharmaceutical turnover therapeutic area total vaccine sales grew billion including billion pharmaceutical turnover declined impact pandemic vaccine sales million excluding flu generic competition valtrex lower avandia pandemic pandemic vaccine sales growth several new vaccines product sales partly offset growth key products contributed growth including synflorix doubling seretideadvair avamysveramyst avodart lovaza tyverbtykerb million boostrix million cervarix ventolin vaccines franchise million sales hepatitis vaccines grew million infanrixpediarix grew million seasonal flu sales grew million rotarix sales million product continues recover market share lost following temporary suspension several markets earlier year gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review pharmaceutical turnover therapeutic area total usa europe emerging markets rest world therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir cer represents growth constant exchange rates represents growth actual exchange rates turnover quarter given financial record pages gsk annual report pp weiver ssenisub financial review dermatologicals results major restructuring dermatology sales billion including heritage gsk total results products acquired business acquisitions october board approved implementation principally stiefel july estimated sales growth detailed formal plan gsk announced significant new business proforma basis excluding acquisitions operational excellence restructuring programme second formal approximately addition gsks heritage consumer plan representing significant expansion operational dermatology portfolio reported within consumer healthcare excellence programme approved board announced contributed sales million february expansion approved board viiv healthcare hiv announced february sales hiv products viiv healthcare restructuring programme comprising detailed formal billion sales former pfizer products selzentry plans covers areas gsks business including manufacturing viracept combined sales million growth selling rd infrastructure estimated total cost epzicomkivexa million offset reductions approximately billion expanded programme expected sales hiv products including trizivir deliver annual pretax savings approximately billion million combivir million epivir time substantially complete approximately million costs incurred st december approximately expected incurred consumer healthcare turnover balance total approximately costs expected cash expenditures expected restated growth accounting writedowns total cer uncertainties exist exact amount timing cash overthecounter outflows result potential future exchange rate medicines fluctuations many elements restructuring programme oral healthcare subject employee consultation procedures making nutritional healthcare difficult predict precision procedures completed however majority remaining cash payments expected made given extent cost cer represents growth constant exchange rates represents growth operational excellence restructuring programme management actual exchange rates turnover quarter given believes material impact gsks operating results total consumer healthcare sales billion manner gsks business conducted gsk presents significantly exceeding market growth estimated gsk restructuring costs incurred solely direct result approximately sales rest world grew operational excellence restructuring programme billion driven strong growth india china amounted million tax million grew respectively europe sales level separate column income statement titled last year sales billion business major restructuring usa grew billion addition restructuring costs operational excellence otc medicines programme major restructuring column income statement includes restructuring costs incurred solely direct otc product sales grew billion driven result restructuring programmes follow relate sales panadol nicotine replacement therapy products material acquisitions operations acquired business dermatology products partly offset lower respiratory tract overlap extensively gsks existing operations products lower sales alli restructuring activities follow relate oral healthcare acquisitions nature undertaken sales oral healthcare products rose billion sensodyne operational excellence programme also carried performed strongly denture care sales also grew sales aquafresh following detailed formal plan management therefore considers declined slightly appropriate present costs restructuring activities nutritional healthcare manner restructuring costs incurred nutritional healthcare sales grew billion driven strong direct result acquisition stiefel laboratories inc performance horlicks growth lucozade sales july million million restructuring costs incurred direct result acquisition reliant pharmaceuticals inc acquisition since october meets criteria set charged paid gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review groups results costs operational excellence operating profit total results programme acquisitionrelated restructuring programmes total results include restructuring costs related operational meeting criteria described also presented excellence programme acquisitions reliant stiefel separate column income statement described results major restructuring presentation growth gsk intends apply consistently future major restructuring cer programmes material impact gsks operating turnover results manner gsks business conducted cost sales adopted show clearly groups results selling general costs restructuring programmes administration management believes presentation assists shareholders research gaining clearer understanding groups financial development performance making projections future financial performance results include costs virtue operating size nature limited comparative value presentation income also consistent way management assesses groups operating profit financial performance cost sales restructuring costs incurred solely direct result operational excellence programme restructuring cost sales increased turnover programmes following reliant stiefel acquisitions reflecting impact generic competition higher margin reported major restructuring column income products usa principally valtrex lower avandia sales us statement restructuring costs principally arisen healthcare reforms european austerity price cuts inventory impairments property plant equipment termination asset writedowns partially offset savings employment contracts staff made redundant part operational excellence programme lower restructuring costs restructuring activities set note financial million million statements major restructuring programme asset impairments selling general administration staff redundancies together accounted million sga costs percentage turnover increased million restructuring costs incurred reported percentage points excluding legal costs major restructuring column million million sga costs restructuring costs arise solely direct result turnover increase percentage points operational excellence programme restructuring reflected sterling cer increase sga flat programmes following relating acquisitions meeting sterling turnover growth sga included restructuring costs criteria described continue reported operating million million investment growth markets expenses within results major restructuring costs full year impact acquisition stiefel partly offset included restructuring costs related minor acquisitions operational excellence savings usa europe lower million income million cost related exchange losses intercompany transactions advertising restructuring activity initiated commencement promotion declined selling distribution increased operational excellence programme none restructuring general administration excluding legal increased activity material impact gsks operating results research development manner business conducted rd expenditure total turnover remaining costs million arose reflecting increase expenditure sterling cer miscellaneous expenditures incurred solely direct result flat sterling turnover growth included restructuring restructuring programmes including termination costs million million viiv healthcare rd leases accelerated depreciation site closure costs consultancy investments lower intangible asset impairments million project management fees costs arising gsks million savings operational excellence ongoing operating activities reported major programme addition comparison prior year restructuring column unfavourably impacted oneoff recognition recoverable balance anticipated duration operational excellence programme gsk currently expect incur material operating income restructuring costs except related programme operating income million million acquisitions meeting criteria described primarily reflecting royalty income million unanticipated material restructuring costs arise million income transfer genentech period gsk would expect include also major exclusive promotion rights boniva usa asset disposals restructuring column million million partially offset equity investment impairments million million gsks operating profit profit taxation taxation profit income included disposal wellbutrin xl various year discussed terms total results asset disposals aspen pharmacare royalty dispute settlement include major restructuring costs results gain million accounting gain million major restructuring creation viiv healthcare gsk annual report pp weiver ssenisub financial review operating profit total results cost sales operating profit restructuring charges million cost sales increased turnover million year ended st december reflecting impact generic competition higher margin million decrease cer decrease products usa principally valtrex lower avandia sales sterling terms compared excluding legal costs us healthcare reforms european austerity price cuts million million operating profit inventory asset writedowns partially offset savings million decline cer terms sterling operational excellence programme company terms principally reflecting decline turnover higher cost expects cost sales percentage turnover sales higher rd expenditure lower operating income remain around profit taxation total results selling general administration sga costs percentage turnover increased percentage net finance costs points primarily reflecting higher legal charges million million see note financial statements finance income provisions details interest finance income excluding legal costs sga costs turnover unwinding discounts assets decrease percentage points reflected fair value adjustments hedges sterling cer decline expenditure compared prior year flat sterling turnover growth decline expenditure reflected operational excellence savings usa europe finance costs lower exchange losses intercompany transactions partially interest costs offset investment growth markets full year impact unwinding discounts liabilities acquisition stiefel fair value adjustments hedges advertising promotion declined selling distribution finance expense declined general administration excluding legal declined collectively items accounted decline total sga company expects sga costs excluding legal profit disposal interest associates charges around turnover profit disposal interest associates million research development million profit arose sale rd expenditure total turnover million quest shares subsequent yearend reflecting flat expenditure flat sterling turnover growth group sold entire shareholding quest give rise included savings operational excellence programme pretax profit disposal associates approximately lower intangible asset impairments million million million tax million higher viiv healthcare rd investment share tax profits associates joint ventures comparison prior year unfavourably impacted share tax profits associates million oneoff recognition recoverable balance million arose principally groups holding company expects rd costs percentage turnover quest remain around profit taxation total results operating income taking account net finance costs profit disposal operating income million million interest associates share profits associates total primarily reflecting royalty income million profit taxation million compared million income transfer genentech million cer decline exclusive promotion rights boniva usa asset sterling decline disposals million million partially offset equity investment impairments million operating profit results major million income included disposal wellbutrin xl restructuring various asset disposals aspen pharmacare royalty dispute settlement gain million accounting gain results major restructuring set million creation viiv healthcare company expects operating income around million growth excluding profit arising proposed consumer healthcare cer divestments noncore otc brands turnover cost sales selling general administration research development operating income operating profit gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review operating profit results major restructuring lower tax charge reflects higher legal charges operating profit major restructuring year ended billion billion st december million decline cer terms charge taxation total profits amounted million decrease sterling terms excluding legal costs represented effective tax rate million million operating profit million decline cer terms decrease sterling terms charge taxation profit major restructuring principally reflecting decline turnover higher cost sales charges amounted million represented effective higher rd expenditure lower operating income partly tax rate gsk currently expects offset reduced sga costs operating profit margin excluding legal tax rate profits excluding profit disposal costs operating income company quest shareholding around however tax due expects operating profit margin excluding legal costs profit realised disposal shareholding quest operating income around percentage point lower expected increase overall tax rate around excludes effect tax may arise proposed profit taxation results major consumer healthcare divestments noncore brands restructuring gsk continues believe made adequate provision net finance costs liabilities likely arise open assessments ultimate liability matters may vary amounts provided finance income dependent upon outcome litigation proceedings negotiations relevant tax authorities interest income unwinding discounts assets profit year fair value adjustments hedges growth cer total profit taxation finance costs year interest costs total profit attributable unwinding discounts liabilities shareholders fair value adjustments hedges basic earnings per share pence p p finance expense basic earnings per ads us results major restructuring profit taxation year net interest payable year million results major restructuring million company expects similar charge profit attributable shareholders profit disposal interest associate adjusted earnings per share pence p p profit disposal interest associates million adjusted earnings per ads us million profit arose sale weighted average number million quest shares subsequent yearend gsk shares millions sold entire shareholding quest give rise diluted total earnings per share pence p p pretax profit disposal associates approximately million million tax diluted total earnings per ads us diluted weighted average number share tax profits associates joint ventures shares millions share tax profits associates million million arose principally groups holding total results including restructuring costs produced basic eps quest diagnostics inc p compared p decline cer terms decline sterling terms excluding major profit taxation results major restructuring restructuring costs eps p compared p taking account net finance costs profit disposal decline cer decrease sterling interests associates share profits associates profit terms percentage point currency benefit arose tax major restructuring million compared weakness sterling major international currencies million cer decline compared last year partly offset strengthening decline sterling terms sterling euro taxation charge dividend board declared fourth interim dividend pence per share resulting dividend year pence pence uk corporation tax uk statutory rate increase pence per share equivalent less double taxation relief interim dividend receivable adr holders cents per ads based exchange rate exdividend date th february record date th february overseas taxation payment date th april current taxation deferred taxation taxation total profits gsk annual report pp weiver ssenisub financial review critical accounting policies reconciliation gross turnover net turnover us pharmaceuticals business follows consolidated financial statements prepared accordance ifrs adopted use european union also ifrs issued iasb following accounting policies approved restated restated board described note financial statements accounting principles policies management required gross turnover make estimates assumptions affect amounts assets chargebacks liabilities revenue expenses reported financial statements managed care medicare actual amounts results could differ estimates part gpo critical accounting policies adopted relate following areas rebates turnover us government taxation state programmes legal disputes cash discounts customer returns property plant equipment prior year adjustments goodwill items intangible assets total deductions pensions postemployment benefits net turnover information judgements estimates made areas given note financial statements key accounting information relating restated following judgements estimates changes segmental reporting set note financial statements segment information respect turnover accounting policy groups largest business us pharmaceuticals us market rebates given us government state programmes complex arrangements rebates discounts allowances increased year result us healthcare reform following briefly describes nature arrangements amendments additional expense arising new existence groups us pharmaceuticals business legislation include managed medicaid sales discounted feeforservice rates increase basic medicaid rebate gsk arrangements certain indirect customers whereby new definition average manufacturers price incremental customer able buy products wholesalers consumer price index penalty line extensions reduced prices chargeback represents difference invoice price wholesaler indirect customers total accruals rebates discounts allowances returns contractual discounted price accruals estimating chargebacks us pharmaceuticals business follows calculated based terms agreement historical st experience product growth rates st december december customer rebates offered key managed care group restated purchasing organisations gpo direct indirect customers arrangements require customer achieve chargebacks certain performance targets relating value product managed care medicare part purchased formulary status predetermined market shares relative gpo rebates competitors accrual customer rebates estimated based us government state programmes specific terms agreement historical experience cash discounts product growth rates customer returns us medicaid programme stateadministered programme providing assistance certain poor vulnerable patients total medicaid drug rebate program established reduce state federal expenditure prescription drugs accrual rebates us government state programmes patient affordable care act became law increased result us healthcare reform implemented gsk participates providing rebates states accruals medicaid rebates calculated based specific terms monthly process operated monitor inventory levels individual state agreements using combination historical wholesalers abnormal movements process uses gross experience product population growth anticipated price sales volumes prescription volumes based third party data increases impact contracting strategies sources information received key wholesalers aim cash discounts offered customers encourage prompt maintain inventories consistent level year year payment accrued time invoicing based pattern consumption adjusted subsequently reflect actual experience basis us pharmaceutical inventory levels wholesalers historical experience customer returns gsk distribution channels st december records accrual estimated sales returns applying historical estimated amount approximately one month turnover experience customer returns amounts invoiced together calculation uses third party information accuracy market related information stock levels wholesalers totally verified believed sufficiently reliable anticipated price increases competitor activity purpose gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial position resources financial position property plant equipment gsks business sciencebased technologyintensive highly regulated governmental authorities group allocates assets significant financial resources renewal maintenance noncurrent assets property plant equipment minimise risks interruption property plant equipment production achieve compliance regulatory standards goodwill number processes use chemicals hazardous materials intangible assets total cost groups property plant equipment investments associates joint ventures st december million net book investments value million land buildings represented deferred tax assets million plant equipment million assets derivative financial instruments construction million gsk invested million noncurrent assets new renewal property plant equipment mainly related large number projects renewal improvement total noncurrent assets expansion facilities various worldwide sites property current assets mainly held freehold new investment financed group liquid inventories resources st december gsk capital contractual current tax recoverable commitments future expenditure million operating trade receivables lease commitments million gsk believes facilities derivative financial instruments adequate current needs liquid investments group observes stringent procedures uses specialist cash cash equivalents skills manage environmental risks activities assets held sale environmental issues sometimes dating operations total current assets modified discontinued reported environmental total assets sustainability note financial statements legal proceedings liabilities goodwill current liabilities shortterm borrowings goodwill increased year million st december million increase primarily trade payables reflects goodwill arising acquisition laboratorios derivative financial instruments phoenix saicyf million impact current tax payable strengthening overseas currencies shortterm provisions intangible assets total current liabilities intangible assets include cost intangibles acquired noncurrent liabilities third parties computer software net book value longterm borrowings intangible assets st december deferred tax liabilities million million increase pensions postemployment benefits reflects additions million business combinations provisions currency movements partly offset amortisation derivative financial instruments impairment existing intangibles noncurrent liabilities investments total noncurrent liabilities gsk held investments including associates joint ventures total liabilities carrying value st december million net assets million market value st december million million largest equity investments two associates quest diagnostics inc share capital book value st december million share premium account million aspen pharmacare holdings limited retained earnings book value st december million reserves million investments include equity stakes shareholders equity companies group research collaborations provide access biotechnology developments potential interest noncontrolling interests interests companies arise business divestments total equity derivative financial instruments assets gsk noncurrent current derivative financial instruments held fair value million million small decrease primarily reflects decrease net investment hedging volumes gsk annual report pp weiver ssenisub financial position resources inventories net debt decreased million due free cash flow inventory million decreased million generated company exceeding amounts paid year decrease reflects initiatives reduce manufacturing dividends shareholders invested new businesses cycle times reduce stockholding days efficient movements net debt use inventory throughout supply chain trade receivables trade receivables million decreased net debt beginning year reflecting recovery significant levels hn debt decreaseincrease cash bank overdrafts year specific actions taken reduce overdue cash inflow liquid investments receivables part group initiative reduce working net increase longterm loans capital reductions partly offset strengthening net repayment shortterm loans yearend foreign exchange rates debt subsidiary undertakings acquired exchange movements derivative financial instruments liabilities movements gsk held current noncurrent derivative financial instruments held fair value million million current net debt end year relating primarily hedging exchange translation currency assets consolidation small increase reflects marginally total equity higher currency volatility euro us dollar yen summary movements equity set trade payables trade payables amounting million increased reflecting working capital initiatives total equity beginning year extend supplier terms towards groups day term objective total comprehensive income year strengthening yearend foreign exchange rates dividends shareholders provisions ordinary shares issued group carried deferred tax provisions shortterm changes noncontrolling interests noncurrent provisions million st december put option noncontrolling interest million respect estimated future consideration received shares transferred liabilities million million related esop trusts legal disputes provision made legal ordinary shares acquired esop trusts disputes indemnified disposal liabilities costs sharebased incentive plans restructuring programmes extent balance tax sharebased incentive plans sheet date legal constructive obligation existed could distributions noncontrolling interests reliably estimated total equity end year pensions postemployment benefits st december total equity decreased group accounts pension postemployment million st december million arrangements accordance ias deficits net decrease arose principally increased provision surpluses allowing deferred taxation million legal charges year million pension arrangements million million unfunded postemployment share purchases liabilities pension liabilities decreased following increase employee share ownership plan esop trusts acquired asset values uk usa deficit reduction contributions million shares gsk plc million shares company decrease longterm inflation rate held trusts satisfy future exercises options awards partly offset reductions rate used discount uk pension group share option award schemes proportion liabilities rate used discount us shares held trusts respect awards pension liabilities rules scheme require gsk satisfy exercises market december uk scheme purchased insurance contract purchases rather issue new shares shares held guarantee payment specified pensioner liabilities trusts matched options awards granted contract valued billion st december st december esop trusts held million net debt million gsk shares future exercise share options share awards carrying value million million deducted reserves market value shares million cash cash equivalents million liquid investments borrowings repayable within one year borrowings repayable one year net debt gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial position resources gsk purchase shares nil commitments respect loans future interest payable rd february gsk announced company intends loans disclosed taking account effect repurchase billion shares depending market derivatives group entered number conditions factors exact amount timing research collaborations develop new compounds future purchases whether shares held pharmaceutical companies terms arrangements treasury shares cancelled determined company include upfront fees equity investments loans commitments dependent market conditions factors st fund specified levels research addition group december gsk held million shares treasury shares often agree make payments future milestones million shares cost million achieved agreements relate compounds million deducted retained earnings early stages development milestone payments continue number years compounds move successfully shares purchased period st january development process generally closer product rd february period th february marketing approval greater possibility success th february million shares purchased amounts shown within intangible assets represent cost million maximum would paid milestones achieved commitments contingent liabilities include billion relates externalised projects financial commitments summarised note financial discovery portfolio number new commitments statements commitments contingent liabilities made licensing agreements including obligations respect short longterm debt set arrangements amicus therapeutics inc amplimmune inc note financial statements contingent liabilities apeiron biologics ag fondazione telethon isis pharmaceuticals note financial statements net debt inc shionogi co limited amounts provided pensions postretirement benefits gsk reached agreement trustees uk set note financial statements pensions pension schemes make additional contributions five postemployment benefits amounts provided restructuring year period eliminate pension deficit identified programmes legal environmental disputes set st december actuarial funding valuation table note financial statements provisions shows commitment excludes normal ongoing annual funding requirement approximately million contractual obligations commitments information pension obligations see note financial following table sets groups contractual obligations statements pensions postemployment benefits commitments st december fall due payment contingent liabilities total yr yrs yrs yrs following table sets contingent liabilities comprising discounted bills performance guarantees letters credit loans items arising normal course business interest loans expected expire finance lease obligations finance lease charges total yr yrs yrs yrs operating lease commitments guarantees intangible assets contingent liabilities property plant equipment total business combinations investments normal course business gsk provided various purchase commitments indemnification guarantees respect business disposals pensions legal disputes subsequently arisen provision commitments made outflow resources considered probable total reasonable estimate made likely outcome dispute included note financial statements provisions groups policy provide settlement costs asserted claims environmental disputes outflow resources considered probable reliable estimate may made prior point liability recorded legal environmental costs discussed risk factors pages note financial statements legal proceedings gsk continues believe made adequate provision liabilities likely arise open taxation assessments ultimate liability matters may vary significantly amounts provided dependent upon outcome litigation proceedings negotiations relevant tax authorities discussed note financial statements taxation gsk annual report pp weiver ssenisub financial position resources cash flow free cash flow used gsks management planning summary consolidated cash flow set reporting purposes discussions presentations investment analysts rating agencies gsks free cash flow measure defined ifrs measure may directly comparable similarly described measures used net cash inflow operating activities companies reconciliation net cash inflow operating net cash outflow investing activities activities closest equivalent ifrs measure free net cash outflow financing activities cash flow shown decreaseincrease cash bank overdrafts reconciliation free cash flow exchange adjustments cash bank overdrafts beginning year net cash inflow operating activities cash bank overdrafts end year purchase property plant equipment cash bank overdrafts end year purchase noncurrent intangible assets comprise disposal property plant equipment interest paid cash cash equivalents interest received overdrafts dividends received joint ventures associated undertakings distributions noncontrolling interests net cash inflow operating activities taxation paid million decrease million free cash flow reflecting higher legal settlements year partly offset net working capital reduction investment appraisal gsk formal process assessing potential investment net cash outflow investing activities million proposals order ensure decisions aligned groups decrease million primarily reflected lower overall strategy process includes analysis impact business purchases million business project earnings return invested capital assessment purchases million primarily stiefel laboratories inc return based discounted cash flows discount rate addition purchases property plant equipment lower used perform financial analysis decided internally allow million determination extent investments cover groups free cash flow cost capital specific investments discount rate may free cash flow amount cash generated business adjusted take account country risk weightings meeting obligations interest tax dividends paid capital expenditure financial investment noncontrolling interests capital expenditure non cash payments tangible intangible fixed assets amounted current tangible intangible assets million million disposals realised million million cash payments acquire equity investments million million made year sales equity investments realised million million future cash flow group expects future operating cash flow sufficient fund operating debt service costs satisfy normal levels capital expenditure meet obligations existing licensing agreements meet expenditure arising major restructuring programmes precise timing uncertain outlined note financial statements major restructuring programmes meet routine outflows including tax dividends subject risk factors discussed pages free cash flow adversely impacted legal settlements gsk may time time additional demands finance million million free cash flow excluding legal acquisitions share repurchases access settlements million compared sources liquidity short longterm capital markets million improvement reflecting reduction working banks financial institutions addition cash capital lower expenditure property plant equipment flow operations needs gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial position resources payment policies liquidity group companies responsible monitoring managing st december cash liquid investments working capital terms sales collections supplier held follows payments reflect local commercial practice uk company uk subsidiaries policies ensure suppliers paid time particular bank balances deposits uk companies seek us treasury treasury repo money market funds settle terms payment suppliers agreeing corporate debt instruments terms transaction government securities ensure suppliers made aware agreed terms payment abide terms payment centrally managed cash reserves amounted billion policy permits arrangements accelerated payment st december available within months excludes small suppliers billion centrally managed cash held viiv healthcare owned subsidiary also billion undrawn payment performance committed facilities date short term overdrafts st december average number days payable loans repayable within one year million outstanding represented trade payables parent company net debt billion st december table nil nil respect company uk summarises cash gross debt effects hedging subsidiaries aggregate days days treasury policies gsk reports sterling pays dividends sterling profits cash liquid investments role corporate treasury manage monitor gross debt fixed external internal funding requirements financial risks floating support strategic objectives treasury activities governed noninterest bearing policies procedures approved board directors net debt recently th october treasury management group tmg chaired chief manage net borrowing requirements portfolio financial officer meets monthly basis review treasury longterm borrowings including bonds together short activities members receive management information relating term finance billion commercial paper programme treasury activities billion committed facilities facilities last renewed october consider level committed capital management facilities adequate given current liquidity requirements gsk operates global basis primarily subsidiary information facilities see note financial companies established markets trade statements net debt also benefit strong positive cash significant levels patent trademark protection products flow operating units compete largely product efficacy differentiation rather price selling margins sufficient cover normal operating european medium term note programme costs operations cash generative billion st december billion notes issue programme also us shelf operating cash flow used fund investment research registration statement st december development new products also used make routine billion billion notes issue programme outflows capital expenditure tax dividends repayment tmg monitors cash flow forecast monthly basis maturing debt extent determined board share repurchases part new longterm share longterm borrowings mature dates buyback programme depending market conditions longterm debt ratings remained stable since factors expect repurchase billion shares february currently rated stable outlook standard poors stable outlook moodys investors policy borrow centrally using variety capital market service moodys shortterm debt ratings p issues borrowing facilities meet anticipated funding standard poors moodys respectively requirements borrowings together cash generated operations onlent contributed equity certain subsidiaries used pay dividends make acquisitions gsk make share repurchases details see note financial statements financial instruments related disclosures gsk annual report pp weiver ssenisub financial position resources maturity profile gross debt equivalent gbp bonds eur bonds usd bonds bank borrowings leases treasury operations interest rate risk management objective treasury activity manage posttax net policy interest rate risk management limits amount cost income financial operations benefit earnings floating rate interest payments prescribed percentage corporate treasury operate profit centre use trading profit variety financial instruments finance operations use series interest rate swaps redenominate one derivative financial instruments manage market risks external borrowings interest rate coupon required gsk operations derivatives principally comprising forward duration swap matches duration principal foreign currency contracts interest rate currency swaps instrument interest rate derivative instruments accounted used swap borrowings liquid assets required fair value cash flow hedges relevant assets liabilities currencies manage exposure funding risks changes foreign exchange interest rates counterparty risk management policy counterparty risk management work select hold issue derivatives speculative purposes group relationship banks global counterparty limits assigned treasury policies specifically prohibit activity transactions gsks banking investment counterparties based financial instruments undertaken manage risks arising longterm credit ratings moodys standard poors underlying business activities speculation corporate treasurys usage limits monitored daily foreign exchange management corporate compliance officer cco operates independently foreign currency transaction exposures arising internal corporate treasury breach limits reported external trade flows hedged exposure overseas cfo immediately cco also monitors credit rating operating subsidiaries transaction risk minimised matching counterparties changes ratings occur notifies local currency income local currency costs corporate treasury changes made investment levels authority limits appropriate full counterparty analysis purpose internal trading transactions matched presented tmg annually approval centrally manage intercompany payment terms reduce foreign currency risk exceptional foreign currency cash flows financial assets liabilities hedged selectively management corporate treasury analysis net debt given note financial manage cash surpluses borrowing requirements statements net debt analysis financial assets liabilities subsidiary companies centrally using forward contracts hedge carrying value fair value given note financial future repayments back originating currency statements financial instruments related disclosures seek denominate borrowings currencies continue benefit strong positive cash flow principal assets cash flows primarily denominated operating activities net debt decreased year us dollars euros sterling certain borrowings st december reflecting benefits ongoing swapped currencies required restructuring programme success working capital initiatives borrowings denominated swapped foreign currencies match investments overseas assets may treated financial assets liabilities st december hedge relevant assets forward contracts also used representative treasury policies strategies approved major currencies reduce exposure investment board directors recently th october overseas group assets see net investment hedges section gsk raise debt capital markets make note details tmg reviews ratio share repurchases borrowings assets major currencies gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review accordance us sec disclosure requirements following cns discussion compares results year st december cns sales decreased billion results year st december majority gsks cns franchise impacted generic financial information discussion follows presented competition usa wellbutrin decline primarily basis gsk organised managed reflected sale wellbutrin xl usa biovail second quarter exchange cardiovascular urogenital currencies influence groups results remain cardiovascular urogenital sales increased billion us dollar euro japanese yen continued strong growth key products arixtra average sterling exchange rates weaker million avodart million lovaza us dollar euro yen compared million partly offset generic competition yearend sterling exchange rates stronger coreg three currencies compared st december metabolic pharmaceutical turnover metabolic sales decreased billion growth rates included review turnover constant sales avandia million continued decline exchange rates cer unless otherwise stated sterling growth across regions bonvivaboniva sales declined usa rates may found tables pharmaceutical turnover grew europe rest world therapeutic areas geographic region oncology emesis pharmaceutical turnover grew billion pharmaceuticals growth helped sales pandemic products regional oncology emesis sales increased billion basis usa declined reflecting continued erosion several tyverbtykerb million grew strongly europe products due generic competition strong performances rest world following product approvals gained delivered europe emerging markets asia zofran declined result generic competition pacificjapan sales contribution stiefel acquired nd july totalled million vaccines vaccine sales increased billion pharmaceutical turnover therapeutic area pandemic vaccine sales million recorded gsk turnover grew impact us generic year delivered fourth quarter gsk competition range gsks products lower avandia sales partnered governments respond hn pandemic declining hiv business offset strong growth key products seretideadvair avodart lovaza relenza sales gsks new synflorix vaccine totalled million reflecting vaccines franchise including hn pandemic vaccine launches several markets beginning shipments brazilian government part year billion agreement respiratory signed august strong contributors growth respiratory sales increased billion year included boostrix million cervarix million rotarix million partially seretideadvair grew billion especially strong offsetting performances sales infanrixpediarix fell growth emerging markets million million primarily result continued impact japan million ventolin sales grew increased competition dtpa sector usa hepatitis million driven performance usa sales vaccines sales also fell million part due doubled million veramyst sales rose competitor product returning us market million antivirals antivirals increased billion relenza sales million million reflecting successful capacity expansion meet government orders across world strong retail performance japan million sales valtrex declined billion result generic competition product usa began november sales hiv medicines totalled billion year epzicom sales grew million offset declines across rest portfolio viiv healthcare specialist hiv company established gsk pfizer officially launched rd november gsk annual report pp weiver ssenisub financial review pharmaceutical turnover therapeutic area total usa europe rest world therapeutic area growth growth growth growth major products cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis engerix fendrix havrix twinrix infanrix pediarix rotarix synflorix stiefel products cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review regional analysis consumer healthcare turnover turnover reported table represents sales invoiced gsks local entity customers local market plus growth total cer copromotion income within market overthecounter growth medicines cer alli usa breathe right europe cold sore franchise emerging markets nicotine replacement therapy asia pacificjapan panadol franchise trading tums oral healthcare aquafresh franchise cer represents growth constant exchange rates represents growth biotene actual exchange rates including stiefel denture care sensodyne franchise usa sales usa declined billion principally reflecting nutritional healthcare continued decline avandia competition lucozade infanrixpediarix return market competitor horlicks hepatitis franchise generic competition ribena significant products lamictal imigran valtrex requip coreg addition wellbutrin xl sold biovail cer represents growth constant exchange rates represents growth q declines partly offset significant sales actual exchange rates relenza pandemic vaccines doubling ventolin sales total consumer healthcare sales year rose good growth lovaza contributions recently billion growth regions categories launched products boostrix rotarix otc medicines europe otc product sales grew billion driven sales sales europe increased billion continued growth panadol million alli seretide relenza particularly strong vaccines growth doubled million result launches throughout europe driven pandemic vaccine offsetting impact generic began april sales nicotine replacement therapy competition number products continued price cuts products declined governments across region oral healthcare emerging markets sales oral healthcare products rose billion sensodyne sales emerging markets increased billion performed strongly sales million denture care strong growth across region therapeutic areas helped sales grew million sales aquafresh declined acquisitions ucb bms businesses different reduction us white trays market offset growth us countries region aquafresh toothpaste brands helped launch asia pacificjapan new isoactive product sales asia pacificjapan grew billion reflecting nutritional healthcare continued seretideadvair growth strong relenza sales particularly nutritional healthcare sales grew billion driven retail market japan strong vaccines growth strong performance horlicks million partly offset decline lucozade sales million impacted lower sales impulse market uk market gsk annual report pp weiver ssenisub financial review results major restructuring operating profit total results total results total results include restructuring costs related operational october gsk announced significant new operational excellence programme acquisitions reliant stiefel excellence restructuring programme second formal plan representing significant expansion operational excellence growth cer programme approved board announced february turnover cost sales addition costs operational excellence programme selling general major restructuring column income statement includes administration restructuring costs incurred solely direct result research restructuring programmes follow relate material development acquisitions operations acquired business overlap operating extensively gsks existing operations income acquisition stiefel laboratories inc july operating profit acquisition meets criteria set acquisition costs incurred direct result cost sales related restructuring programme included major restructuring column restructuring costs expected cost sales percentage turnover reduced marginally incurred direct result acquisition estimated turnover principally reflecting impact approximately million million charged generic competition higher margin products usa restructuring costs incurred direct result changes product mix offset benefits restructuring acquisition reliant pharmaceuticals inc programme lower restructuring costs million acquisition since october meets criteria set million charged paid selling general administration restructuring costs incurred solely direct result sga costs percentage turnover increased operational excellence programme restructuring percentage points included full year legal charges programmes following reliant stiefel acquisitions million million charges related reported major restructuring column income major restructuring programme million statement set note financial statements million excluding legal restructuring major restructuring programme asset impairments staff costs sga costs turnover redundancies together accounted million reflected investment growth markets acquisition million restructuring costs incurred remaining costs stiefel increased pension costs donation hn product million arose miscellaneous expenditures exchange losses intercompany transactions incurred solely direct result restructuring programmes compared exchange gains last year partially offset costs arising gsks ongoing operating activities benefits current restructuring programme reported major restructuring column research development latest position results major restructuring rd expenditure total turnover total results see results major restructuring total results included million intangible asset writeoffs financial review million partially offset lower charges relating major restructuring programme million gsks operating profit profit taxation taxation profit million provision release due reassessment year discussed terms total results receivable balance increased investment vaccines rd include major restructuring costs results late stage pharmaceutical rd broadly offset savings major restructuring restructuring programme operating income operating income million including gains asset disposals million million primarily reflecting disposal wellbutrin xl various assets aspen pharmacare royalty income million million royalty dispute settlement gain million onetime accounting gain million creation viiv healthcare partially offset equity investment impairments million operating profit total results total operating profit year million increase cer sterling terms compared operating profit margin increased percentage points reflecting higher operating income broadly flat rd expenditure partially offset increases cost sales sga gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review profit taxation total results selling general administration sga costs percentage turnover increased net finance costs percentage points including full year legal charges million increase reflected investment growth markets finance income acquisition stiefel increased pension costs donation interest finance income hn product exchange losses intercompany unwinding discounts assets transactions compared exchange gains last year partially fair value adjustments hedges offset benefits current restructuring programme research development rd expenditure total turnover finance costs included million intangible asset writeoffs interest costs million partially offset provision release due unwinding discounts liabilities reassessment receivable balance increased investment fair value adjustments hedges vaccines rd latestage pharmaceutical rd broadly offset savings restructuring programme operating income profit disposal interest associate operating income million including gains profit disposal interest associate million asset disposals million million million shares groups holding quest diagnostics primarily reflecting disposal wellbutrin xl various inc sold first quarter assets aspen pharmacare royalty income million million royalty dispute settlement gain share tax profits associates joint ventures million onetime accounting gain million share tax profits associates million creation viiv healthcare partially offset equity million arises principally groups holding investment impairments million operating quest income profit disposal associates amounted profit taxation total results million taking account net finance costs profit disposal operating profit results major restructuring interest associates share profits associates operating profit major restructuring year total profit taxation million compared million cer decline sterling terms million cer increase compared operating profit margin sterling increase compared margin decline margin primarily due generic competition usa operating profit results major impacted cost goods increased investment support restructuring groups diversification strategy impacted sga partly offset results major restructuring set higher level operating income information operating profit major restructuring growth provided note segment information cer turnover cost sales selling general administration research development operating income operating profit cost sales cost sales increased turnover principally reflecting impact generic competition higher margin products usa changes product mix partly offset benefits restructuring programme gsk annual report pp weiver ssenisub financial review profit taxation results major profit year restructuring growth net finance costs cer total profit taxation finance income year interest income total profit attributable unwinding discounts assets shareholders fair value adjustments hedges basic earnings per share pence p p basic earnings per ads us results major restructuring finance costs profit taxation year interest costs results major restructuring unwinding discounts liabilities profit attributable shareholders fair value adjustments hedges adjusted earnings per share pence p p adjusted earnings per ads us weighted average number shares millions profit disposal interest associate profit disposal interests associates million diluted total earnings per share pence p p million quest shares sold first quarter diluted total earnings per ads us diluted weighted average number share tax profits associates joint ventures shares millions share tax profits associates million million arises principally groups holding total results including restructuring costs produced basic eps quest diagnostics inc p compared p growth cer terms growth sterling terms excluding major profit taxation results major restructuring restructuring costs eps p compared p taking account net finance costs profit disposal interests associates share profits associates profit dividend tax major restructuring million compared board declared fourth interim dividend pence per million cer decline increase share resulting dividend year pence four pence sterling terms increase pence per share taxation uk corporation tax overseas taxation current taxation deferred taxation taxation total profits charge taxation total profits amounted million represented effective tax rate charge taxation profit major restructuring charges amounting million represents effective tax rate groups balance sheet st december included tax payable liability million tax recoverable asset million th november irs conceded asserted tax deficiencies penalties arising reclassification intercompany financing arrangement debt equity resulting additional tax cost gsk latest position taxation see taxation financial review gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp risk factors risks uncertainties relevant groups also increasing pressure healthcare budgets business financial condition results operations may average age population developed markets increases affect groups performance ability achieve objectives absolute population developing markets grows payers factors among group believes could therefore increasingly demanded greater incremental benefit cause actual results differ materially expected drugs agreeing reimburse suppliers prices suppliers historical results risks uncertainties consider appropriate failure develop commercially successful may affect groups performance ability achieve products develop additional uses existing products objectives currently known group reasons could materially adversely affect groups deemed immaterial financial results group reviews assesses significant risks regular basis intellectual property protection implemented oversight programme help ensure competition generic manufacturers system internal control place system includes group faces intense competition manufacturers policies procedures communication training programmes generic pharmaceutical products major markets generic supervision monitoring processes escalating issues products often enter market upon expiration patents data appropriate level senior management system helps exclusivity periods groups products introduction generic facilitate groups ability respond appropriately risks products particularly usa group highest achieve group objectives helps ensure compliance turnover margins typically leads dramatic loss sales applicable laws regulations internal policies groups reduces groups revenues margins proprietary management risks discussed pages products group eleven pharmaceutical products corporate governance million annual global sales among products possible however group implement controls augmentin lamictal ir ventolin valtrex respond risks may face generic competition usa certain markets europe assurance steps group taken address certain risks addition detailed timing impact entry manage risks effectively six principal risks followon product seretideadvair contains might affect gsks business broken following areas active ingredients uncertain risk rd deliver commercially successful generic drug manufacturers also exhibited readiness new products market generic versions many groups important group operates highly competitive markets products prior expiration groups patents efforts may pharmaceuticals vaccines businesses faces competition involve challenges validity enforceability patent proprietary products large international manufacturers assertions generic product infringe groups producers generic pharmaceuticals significant product patents group successful defending attack innovations technical advances intensification price patents maintaining exclusive rights market one competition competitors may materially adversely affect major products particularly usa europe groups groups financial results group always predict financial results would adversely affected expiration dates timing impact competitive products potential patents groups major products description impact sales groups products light competitive litigation settlements may affect dates generic environment group operates continued development versions groups products may introduced set commercially viable new products well development legal proceedings involving patent challenges set additional uses existing products critical groups ability note financial statements legal proceedings replace sales older products decline upon expiration potential changes intellectual property laws exclusive rights increase overall sales regulations developing new products costly lengthy uncertain process proposals change existing patent data exclusivity laws new product candidate fail stage development regulations major markets group sells products process one late stage product candidates could fail continuing feature political process countries receive regulatory approval include proposals could effect making prosecution patents new products difficult time new product candidates may appear promising development consuming could adversely affect exclusivity period significant investment group economic human groups products including biological products resources may fail reach market limited proposals enacted may materially adversely affect commercial success example could result groups financial results example part efficacy safety concerns inability obtain necessary comprehensive healthcare reform usa new regulations regulatory approvals difficulty manufacturing excessive followon biologics introduced allow sufficiently manufacturing costs erosion patent terms result similar biologic able rely innovators approval lengthy development period infringement patents following year data exclusivity period addition current intellectual property rights others inability differentiate administration usa proposed reducing years product adequately competes seven period time pharmaceutical companies may keep furthermore health authorities us fda european products exclusive generic competition medicines agency japan pharmaceuticals medicines device agency increased focus safety product differentiation assessing benefitrisk balance drugs made difficult pharmaceutical products gain regulatory approval gsk annual report pp weiver ssenisub risk factors weakness intellectual property protection instances third parties may perform analyses published certain countries clinical trial results although necessarily accurate countries group operates patent meaningful may raise questions regarding safety protection may significantly weaker usa pharmaceutical products may publicised media european union developing countries reduced may result product liability claims group currently threatened reduce effective patent protection defendant number product liability lawsuits including class pharmaceutical products generally particular therapeutic actions involve substantial claims damages related areas facilitate early competition within markets groups pharmaceutical products litigation particularly generic manufacturers loss patent protection including usa inherently unpredictable class actions sweep together reducing scope patent rights compulsory licensing persons prescribed groups products inflate government forces manufacturer license potential liability force numbers claims pain intellectual property competitor could materially adversely suffering punitive damages frequently asserted product affect groups financial results markets absence liability actions allowed represent potentially open adequate patent protection could limit opportunity rely ended exposure thus could materially adversely affect markets future sales growth groups products groups financial results risk substantial adverse outcome litigation antitrust litigation government investigations usa become increasingly common patent see note financial statements legal proceedings infringement actions prompt claims antitrust laws discussion proceedings governmental investigations violated initial prosecution patent currently involving group proven could give rise litigation involving defence patent claims civil criminal liabilities unfavourable resolution direct indirect purchasers payers typically filed similar future proceedings investigations may material class actions relief sought may include treble damages adverse effect groups financial condition results restitution claims damages adverse antitrust verdicts subject operations group made material provisions automatic trebling usa similarly antitrust claims may prior years related legal proceedings investigations brought following settlement patent litigation alleging reduced earnings settlements anticompetitive violation antitrust laws successful antitrust claim group could materially future group may also make additional significant adversely affect groups financial results provisions related legal proceedings investigations would reduce earnings many cases group believes sales marketing regulation practice plaintiff bar claim damages amounts group operates globally complex legal regulatory bear reasonable relationship underlying harm allegedly environments often vary among jurisdictions failure caused groups products actions accordingly may comply applicable laws rules regulations potentially misleading group quantify based jurisdictions may result civil criminal legal proceedings amount damages claimed potential exposure claims rules regulations change governmental proceedings investigations type described note interpretation rules regulations evolve prior conduct financial statements legal proceedings may called question recent insurance loss experience including pharmaceutical usa example group responding federal product liability exposures increased cost reduced state governmental investigations pricing marketing capacity insurers provide coverage pharmaceutical reimbursement prescription drug products companies generally including group investigations could result related restitution civil litigation behalf federal state governments well related order contain insurance costs recent years group proceedings initiated group behalf continued adjust coverage profile accepting greater degree consumers private payers proceedings may result uninsured exposure areas lesser degree others trebling damages awarded fines respect violation order optimise value insurance markets addition law criminal proceedings may also initiated group claims made insurance policies insurers regularly consequences could materially adversely affect reserve right deny coverage various grounds groups financial results product liability litigation preclinical clinical trials conducted development potential products determine safety efficacy products use humans following approval regulatory authorities notwithstanding efforts group makes determine safety products regulated clinical trials unanticipated side effects may become evident drugs vaccines introduced marketplace gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp risk factors governmental payer regulatory controls addition cases group may voluntarily cease pricing marketing product face declining sales based concerns pharmaceutical products subject price controls pressures efficacy safety example decline sales restrictions many markets including japan germany avandia beginning following publicity around questions spain france italy governments intervene directly regarding risks associated product whether setting prices scientifically justified even absence regulatory action development postapproval adverse event profile addition markets major purchasers pharmaceutical product product class may materially adversely affect products whether governmental agencies private health care groups financial results providers economic power exert substantial pressure prices terms access formularies group risk interruption product supply accurately predict whether existing controls pressures restrictions manufacture pharmaceutical products constituent increase whether new controls pressures restrictions materials requires compliance good manufacturing practice introduced measures may materially adversely affect regulations groups manufacturing sites subject groups ability introduce new products profitably review approval fda regulatory agencies financial results compliance failure suppliers key services materials groups manufacturing facilities could lead product recalls example usa group highest margins seizures interruption production delays approvals sales country government price new products pending resolution manufacturing issues controls private sector purchases federal law requires noncompliance also result fines disgorgement pharmaceutical manufacturers pay prescribed rebates certain profits interruption supply incurring fines drugs eligible reimbursement several state disgorgement could materially adversely affect groups federal healthcare programmes primarily medicare medicaid financial results pricing pressures likely increase us governments share national health spending continues increase additionally although group undertakes business continuity planning due passage comprehensive health care reform single sourcing certain components bulk active materials us governments role providing subsidising health insurance finished products creates risk failure supply expected significantly expand indicates event regulatory noncompliance physical disruption growing role leverage government bring bear manufacturing sites groups rebate liability respect us federal programs unaffiliated thirdparty suppliers provide number goods recent years number states also proposed services groups operations many services implemented various schemes control prices low example services provided clinical research organisations income senior citizens programmes including increasing support development key products important rebate liability pharmaceutical companies importation operations groups businesses materials provided countries bulk purchases drugs given new state thirdparty suppliers necessary commercial production mandates contained us health care reform law products including speciality chemicals commodities increase number medicaid eligible participants components necessary manufacture packaging economic pressures state government budgets pricing pressures many groups pharmaceutical consumer healthcare groups products likely increase trends products group believe may materially adversely affect groups financial results thirdparty relationships individually significant context overall group failure thirdparty supplier fulfil regulatory controls contractual obligations timely manner may result delays group must comply broad range regulatory controls service interruptions may materially adversely affect testing approval manufacturing marketing many groups financial results pharmaceutical vaccine consumer healthcare products particularly usa countries european union taxation treasury affect cost product development also time groups effective tax rate driven rates tax required reach market uncertainty successfully jurisdictions higher lower applied detailed health authorities increased uk addition many jurisdictions uk belgium focus safety assessing riskbenefit balance usa currently offer regimes encourage innovation new drugs context initial product approval also scientific endeavours providing tax incentives example rd context approval additional indications review tax credits furthermore given scale international nature information regarding marketed products stricter regulatory groups business intragroup transfer pricing inherent controls also heighten risk changes product profile tax risk international businesses changes tax withdrawal regulators basis postapproval concerns laws application respect matters transfer product safety could reduce revenues result pricing foreign dividends controlled companies rd tax credits product recalls product liability lawsuits also greater restriction tax relief allowed interest intragroup regulatory scrutiny especially usa advertising debt could increase groups effective tax rate materially promotion particular directtoconsumer advertising adversely affect financial results gsk annual report pp weiver ssenisub risk factors tax charge included financial statements groups global political economic conditions best estimate tax liability time audits described many worlds largest economies tax authorities concluded degree uncertainty including major markets group operates regarding final tax liability period groups policy financial institutions recent past faced extreme financial submit tax returns within statutory time limits engage difficulty including decline asset prices liquidity problems tax authorities ensure groups tax affairs current limited availability credit although many economies possible differences interpretation tax recovered economic recovery pace legislation regulation resolved quickly possible proved uneven exceptional cases matters settled agreement continued economic weakness may material adverse effect tax authorities gsk may resolve disputes groups sales results operations financial condition formal appeals proceedings example canadian ability raise capital groups businesses including tax authorities currently seeking leave appeal court pharmaceuticals consumer healthcare may particularly decision respect transfer pricing discussed note sensitive declines consumer spending addition financial statements taxation renewed declines asset prices may result lower return group deals high value transactions frequent basis groups financial investments may cause value may result increased risk financial loss due groups investments pension plans decrease requiring mismanagement cash entering high risk positions group increase funding pension plans hedge transactions could materially adversely group conducts substantial portion operations outside affect groups financial results uk groups management foreign exchange rates discussed business review foreign exchange management number risks could affect see fluctuations exchange rates sterling financial condition results group follows currencies especially us dollar euro antibribery corruption japanese yen could materially adversely affect groups financial results groups extensive increasing international operations may give rise possible claims bribery corruption failure group control changes inflation interest comply applicable legislation us foreign rates foreign currency exchange rates controls corrupt practices act recently enacted uk bribery act economic factors affecting businesses possibility could expose group senior officers civil criminal political unrest legal regulatory changes nationalisation sanction including fines prosecution potential debarment jurisdictions group operates public procurement reputational damage could materially adversely affect groups financial results group operates number middle eastern north compliance mechanisms monitoring programmes african markets subsequent yearend experiencing group place may adequately prevent detect possible political unrest events may lead business disruption violations applicable antibribery corruption legislation liquidity problems could adversely impact groups results risk concentration sales wholesalers environmental liabilities usa similar pharmaceutical companies group environmental laws various jurisdictions impose actual sells products small number wholesalers addition potential obligations group remediate contaminated hospitals pharmacies physicians groups sales sites group also identified potentially three largest wholesalers amounted approximately responsible party us comprehensive environmental groups us pharmaceutical sales st december response compensation liability act number sites group trade receivables due three wholesalers remediation costs relating groups use ownership totalling million st december million sites failure manage properly environmental risks could group exposed concentration credit risk respect result additional remedial costs may materially adversely wholesalers one affected financial affect groups financial results see note financial difficulty could materially adversely affect groups statements legal proceedings discussion environmental financial results related proceedings group involved accounting standards new revised accounting standards rules interpretations issued time time international accounting standards board could result changes recognition income expense may materially adversely affect groups financial results international financial reporting standards changes market valuation certain financial instruments require gains losses instruments reflected groups reported results gains losses actually realised could significant impact income statement given period accounting deferred taxation intercompany inventory may give rise volatility depending upon group entity owns inventory gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp risk factors regulators regularly review financial statements listed attraction retention companies compliance accounting regulatory group relies heavily recruiting retaining talented requirements group believes complies employees range skills meet objectives group appropriate regulatory requirements concerning financial faces intense competition qualified individuals supply statements disclosures however companies people specific skills specific geographic regions may experienced investigations potential noncompliance limited particularly given groups plans expand operations accounting disclosure requirements resulted emerging markets biologicals consumer healthcare restatements previously reported results sometimes inability attract staff specific technical leadership significant penalties investigation required skills retain key employees ensure effective succession planning restatement could materially adversely affect groups critical positions may materially adversely affect groups financial results financial results protection electronic information assets implementing groups strategic priorities group relies critical sensitive data personally group established three strategic priorities grow identifiable information trade secrets intellectual property diversified business deliver products value simplify corporate strategic plans security type data exposed operating model group may able implement increasing external threats group also subject various strategic priorities fully even group able implement standards protection personally identifiable information strategic priorities strategic priorities may deliver failure implement appropriate safeguards adequately protect expected benefits unauthorised unintentional access acquisition use modification loss disclosure critical sensitive data may example strategic priority grow diversified business adversely affect groups operations involves expanding groups business emerging markets groups pharmaceutical sales emerging markets grew alliances acquisitions nearly billion represented groups part groups strategy diversify new product pharmaceutical turnover guarantee areas markets group grown expects groups sales emerging markets continue grow continue grow part acquisitions business markets continue experience relatively high growth alliances intense competition alliance acquisition rates emerging markets may especially vulnerable candidates pharmaceutical industry group aftereffects recent global financial crisis may may unable make deals acceptable terms limited resources spend healthcare competition acquiring forming alliances companies group markets staff skills training suitable may assume significant debt become subject unknown employment enterprise groups may intense contingent liabilities fail realise benefits expected emerging markets group may required rely transactions example pharmaceutical companies third party agents may put group risk liability including group may consider acquiring emerging markets lack sufficient protection crimes involved patent disputes product liability litigation government counterfeiting failure continue expand business investigations legal proceedings whose outcome emerging growth markets could materially adversely affect subject considerable uncertainty assumption debt groups financial results unknown contingent liabilities failure realise expected benefits may materially adversely affect groups addition group undertaking restructuring programme financial results estimated cost approximately billion expected deliver annual pretax savings approximately process integrating companies group may acquire billion time substantially complete may result disruption ongoing business effort group may able execute fully transformation integrating organisations different locations among business furthermore changes groups structure things differing systems corporate cultures may divert operations revenues costs efficiency resulting attention resources result loss key employees restructuring activities strategic initiatives could result adverse consequences may materially higher expected costs difficulties failure realise adversely affect groups financial results expected cost savings end restructuring programme achieve maintain competitive cost base could materially adversely affect groups financial results gsk annual report pp noitarenumer dna ecnanrevog board sir christopher gent professor sir roy anderson larry culp aged simon dingemans aged aged aged appointed st july appointed th january appointed st june appointed st october nonexecutive director executive director chief chairman nonexecutive director larry president chief financial officer designate sir christopher non sir roy professor infectious executive officer danaher simon joined gsk executive director ferrari spa disease epidemiology corporation prior joining goldman sachs chief executive faculty medicine imperial danaher held positions managing director officer vodafone group plc college london accenture previously partner years retirement july member international andersen consulting experience investment nonexecutive director advisory board hakluyt banking including recently lehman brothers holdings co ltd trustee leader goldman sachs inc member kpmgs natural history museum european business chairmans advisory group london fellow head uk senior adviser bain co royal society foreign investment banking member advisory associate member board reform institute medicine us national academy sciences french academy sciences former positions sir crispin davis aged include rector imperial appointed st july college chief scientific nonexecutive director adviser ministry sir crispin chairman defence uk director starbev netherlands bv member citigroups andrew witty aged julian heslop aged global advisory board appointed st january appointed st april serves council oxford chief executive officer chief financial officer university previously andrew named chief julian joined glaxo wellcome chief executive officer reed executive officer designate financial controller april elsevier plc prior gsk october january appointment chief executive appointed chief executive appointed senior vice president aegis group plc officer ceo st may operations controller prior joined guinness plc joined group joining group held member held senior dr stephanie burns senior finance roles grand main board group positions asia africa aged metropolitan julian retire managing director usa immediately prior appointed th february chief financial officer united distillers earlier appointed ceo andrew executive director st career worked procter president pharmaceuticals nonexecutive director march gamble europe position held stephanie chairman president north january chief executive officer dow american food division board member phrma corning corporation sits president european federation us presidents export pharmaceutical industries council also chair associations appointed american chemistry lead nonexecutive board council officer member department society chemical industry business innovation america section skills board member board society insead business school womens health research january dr burns holds phd member prime ministers organic chemistry business advisory group iowa state university member singapore economic development boards international advisory council adviser governor guangzhou china gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp board sir deryck maughan dr daniel podolsky tom de swaan aged aged aged appointed st january appointed st june appointed st july nonexecutive director nonexecutive director nonexecutive director tom chairman sir deryck partner daniel president supervisory board kohlberg kravis roberts co university texas southwestern vanlanschot bankiers member nonexecutive director medical center holds board directors thomson reuters blackrock phillip obryan montgomery jr zurich financial services inc well serving md distinguished presidential nonexecutive director board directors lincoln chair academic administration kpmgs public interest center formerly doris bryan committee also vice chairman chief executive wildenthal distinguished chair chairman supervisory officer citigroup international medical science member board chairman audit salomon brothers inc institute medicine committee royal ahold us national academy sciences member supervisory board royal dsm previously member managing board chief financial officer abn amro james murdoch aged appointed th may nonexecutive director james chairman chief executive europe asia dr moncef slaoui aged sir robert wilson news corporation also appointed th may aged nonexecutive chairman chairman research appointed st november bskyb member board development news corporation moncef joined gsk biologicals nonexecutive director nonexecutive director engineered senior independent director sothebys previously served development sir robert nonexecutive chief executive officer robust vaccines pipeline chairman bg group plc bskyb subsequently led worldwide previously executive also chairman chief business development chairman rio tinto plc executive officer star tv pharmaceuticals retirement october appointment lead rd chairman economist june moncef group given overall responsibility gsks oncology business next twelve months responsibility gsk biologicals also transition member board agency science technology research astar phd molecular biology immunology universit libre de bruxelles gsk annual report pp noitarenumer dna ecnanrevog corporate executive team cet john clarke julian heslop president consumer healthcare chief financial officer john responsible julian became chief financial consumer healthcare business officer april head produces oral healthcare finance function overthecounter nutritional responsible activities healthcare products joined financial reporting control beecham tax treasury finance systems andrew witty president future group marc dunoyer insurance joined glaxo chief executive officer current appointment head rare diseases unit wellcome financial controller andrew appointed chief january chairman gsk japan april leave executive officer may marc appointed chairman cet retires gsk joined glaxo uk gsk japan january end march career february lead company held roles gsks rare diseases business managing director south rd commercialisation africa vice president joined group general manager marketing previously president usa senior vice pharmaceuticals japan president asia pacific january may appointed president deirdre connelly president pharmaceuticals europe president north america pharmaceuticals asia pacific glaxosmithkline january pharmaceuticals japan may abbas hussain deirdre joined gsk february july president emerging markets working eli lilly asia pacific company years abbas joined gsk june held variety positions eli lilly company including sales professional spent years general manager puerto rico overseeing markets throughout executive director human europe africamiddle east resources recently australasia president us operations simon bicknell senior vice president eddie gray governance ethics president assurance pharmaceuticals europe simon appointed eddie became responsible role january groups operations responsible risk europe january management compliance joined beecham internal auditing prior current bill louv formerly svp appointment senior vice simon dingemans senior vice president company secretary president general manager chief financial officer designate core business services corporate compliance officer pharmaceuticals uk simon appointed chief chief information officer simon joined corporate financial officer designate bill appointed chief secretariat th january joined information officer january appointed company secretary gsk goldman sachs addition role glaxosmithkline plc managing director appointed create may combined partner years lead core business services position role experience investment april responsible corporate compliance officer banking including recently information technology april leader goldman sachs across gsk bill joined glaxo current appointment european business vice president head uk medical data sciences prior investment banking current roles bill senior vice president rd information technology gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate executive team cet moncef slaoui patrick vallance chairman research senior vicepresident medicines development discovery development moncef leads groups drug patrick appointed senior discovery development vice president medicines activities well oncology discovery development business next july responsible months assume ensuring flow new david pulman operational responsibility claire thomas medicines rd president global gsk biologicals joined senior vice president pipeline early discovery manufacturing supply group human resources approval david responsible key player building gsks claire leads global human medicine patrick joined gsk global manufacturing vaccines pipeline resources hr function prior supply organisation appointed senior vice previously oversaw hr clinical academic led global procurement joined president worldwide business pharmaceuticals international division medicine glaxo broad development current pharmaceuticals europe university college london experience manufacturing appointment june claire joined company operations previously led appointed primary supply european director human resources manufacturing north american uk pharmaceuticals manufacturing global logistics claire honoured manufacturing strategy outstanding european woman organisations achievement changes cet duncan learmouth senior jean stphenne vice president global chairman president communications left cet biologicals august new jean led gsks global role senior vice president vaccines business since developing countries previously vice president market access phil thomson human vaccines research dan troy appointed senior david redfern development senior vice president vice president global chief strategy officer production joined general counsel communications august david responsible company head dan joined gsk senior vice although proactive exploration new bacterial viral vaccines president general counsel member invited attend business opportunities strategic production jean named september cet meetings required planning dermatology addition current role baron king albert ii partner dan phelan chief staff appointed chairman belgians recognition washington law firm sidley stepped cet board viiv healthcare leading contribution austin llp chief counsel december act ltd effect st april rd industry belgium fda advisor ceo advance began career chaired american eventual retirement gsk corporate bar associations section gsk administrative law development previously adjunct scholar appointed finance director american enterprise europe pharmaceuticals institute washington dc appointed area director central europe northern europe gsk annual report pp noitarenumer dna ecnanrevog corporate governance dear shareholder behalf board pleased present corporate governance report review although operating environment remains challenging believe made significant progress substantially reengineering gsks business restructuring rigorous approach capital allocation effect changes also became increasingly evident delivery diversified underlying sales growth increasing pipeline potential improved cash generation legal settlements becoming balanced synergistic business broad diverse pipeline generating increasing potential board believes generate increased value shareholders deliver even better outcomes patients consumers corporate governance developments seen continuation reviews consultations aimed examining improving corporate governance arrangements predominantly light recent global financial crisis gsk active participant debating issues raised consultations relevant long term interests shareholders also taken opportunity review board practices governance procedures standards contained financial reporting councils frc updated uk corporate governance code updated code published june formerly combined code corporate governance combined code review indicated strong position comply fully provisions report formally gsks compliance updated code next year board role effectiveness chairman role primarily provide leadership board necessary promote success company create value shareholders long term ensuring sound effective corporate governance practices embedded organisation decisionmaking processes number ingredients make effectively functioning board gsks approach set greater detail following report notable example practice exercise audit risk committee oversight powers delegated board decision resolve inherent unpredictability reduce overall litigation exposure core focus committee board audit risk committee holds regular dialogue executive management provide updates progress made resolve outstanding legal matters board acknowledges scale legal provisioning required significant continues believe best long term interests shareholders resolve matters usual conducted rigorous evaluation test board committees effectiveness pleased note frc endorsed updated code approach externally facilitated board evaluations undertaken least every three years approach gsk previously adopted details latest board evaluation actions identified agreed upon drive standards board governance performance found report areas board practice would also like particularly focus business awareness succession planning shareholder engagement key areas made good progress business awareness succession planning year board seeks develop knowledge understanding business gain greater visibility executive talent management succession board made several visits groups sites met key talent senior executives march board visited vaccines site wavre belgium receive update progress main vaccines business continues grow terms contribution group included specific briefings three important vaccine development programmes namely magea synflorix malaria board also pleased meet thank gsk staff site extraordinary efforts made enable group respond hn pandemic july board visited gms rd sites research triangle park zebulon united states visits included briefings several discovery performance units tour pharmaceutical development pilot plant together workshops senior executives board also held reception locally based executives key talent gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance gsk continues target growth emerging markets established important new corporate hub group far east singapore summer abbas hussain president emerging markets asia pacific corporate executive team cet member relocated singapore centrally located region october board held joint strategy review meeting cet members singapore pleased visit gms site tour one gms production facilities pilot plant board also workshop results gsks investment green chemistry continuous manufacture technology singapore contribute groups efforts reduce costs minimise impact environment board also pleased opportunity meet local senior executives key talent addition planned visits nonexecutive directors encouraged attend cet meetings rd related executive meetings provides good perspective management operates gives greater insight key business issues also provides opportunity board members observe skills knowledge integrity behaviour senior management cadre key executive talent whilst enabling employees give direct feedback board members shareholder engagement gsk value open constructive effective interaction shareholders particular ceo cfo maintain ongoing dialogue institutional investors regular programme meetings cover range issues andrew witty attended oneonone meetings investors covering separate funds julian heslop attended nearly oneonone meetings investors covering separate funds addition met multiple additional investors via group meetings broker conferences personally met representative cross section shareholders course year available meet shareholders request along board colleagues also along remuneration committee chairman head human resources company secretary attended meetings institutional investors specifically discuss remuneration policy governance related matters process conduct annually believe level quality engagement key ensuring board senior management understand shareholders views perspectives theme welcome introduction frc stewardship code institutional investors code good practice major shareholders aims strengthen quality engagement process major shareholders companies invest companys agm board directors able attend available usual meet investors meeting discuss issues facetoface basis combined code compliance statement throughout company complied provisions applied main principles section combined code except dr stephanie burns larry culp tom de swaan unable attend companys agm dr stephanie burns larry culp prevented attending due travel disruption caused ash clouds volcano iceland tom de swaan required chair shareholder meeting another public company day resulted partial noncompliance code provision annual reelection directors gsk like number organisations interested parties expressed view consultation period updating combined code frcs proposal mandate annual reelection directors could damaging feared could erode principle unitary board likely increase shorttermism could make even difficult recruit new board members nevertheless change included new provision updated code board agreed board member stand reelection agm monitor effect provision time corporate governance report follows sets gsk complied provisions applied principles combined code year sir christopher gent chairman gsk annual report pp noitarenumer dna ecnanrevog corporate governance governance policy board process section discusses gsks management structures board responsible longterm success company governance procedures together remuneration authority accountable shareholders report pages includes details company ensuring group appropriately managed achieves applies complies principles provisions strategic objectives sets board discharges combined code maintained frc us laws responsibilities annual programme meetings regulations includes approval overall budgetary planning business strategy board reviews groups internal controls risk board corporate executive team management policies approves governance structure directors listed board pages code conduct members cet corporate executive team board appraises approves major financing investment pages licensing decisions excess defined thresholds addition board responsible groups system corporate board evaluates monitors performance group governance ultimately accountable groups activities whole includes strategy risk management financial performance engaging board meetings challenging ceo independence executive directors members cet board considers nonexecutive directors appropriate financial operating performance gsk independent character judgement free external issues material groups prospects business relationship could materially interfere evaluating progress towards achievement groups exercise judgement chairman satisfied financial business objectives annual plans non independence criteria appointment board executive directors scrutinising performance management date publication throughout majority meeting objectives plans board members excluding chairman independent monitoring reports received directly various nonexecutive directors committees significant risks facing group chairman ceo senior independent director board overall responsibility succession planning sir christopher gent chaired company since st january ceo executive nonexecutive directors chairman throughout biographical board given ceo broad authority operate business details found andrew witty ceo group ceo accountable reports biographical details found pages board performance business cet members make chairman leads manages board ceo regular presentations board areas responsibility manages group implements strategy policies board directors meet cet members annual adopted board chairman chairmen board basis discuss develop proposals collectively relation committees communicate regularly ceo cet groups strategy members division responsibilities role board met six times member attending chairman ceo set writing agreed follows board appears full governance section companys website number meetings held whilst board number ceo responsible executive management group member meetings attended assisted cet cet meets least times per year sir christopher gent otherwise necessary andrew witty terms engagement chairman julian heslop nonexecutive director expected devote time dr moncef slaoui necessary proper performance duties professor sir roy anderson dr stephanie burns sir robert wilson appointed senior independent director larry culp sid th may following sir ian prossers retirement sir crispin davis board date responsibilities include annual sir deryck maughan evaluation performance chairman board committees directors collaboration committee james murdoch chairmen years process internally facilitated dr daniel podolsky also available additional point contact board tom de swaan shareholders sir robert wilson sir deryck unable attend two meetings personal reasons gave comments chairman matters discussed advance meetings addition six scheduled meetings board also met quorate basis three occasions gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance directors unable attend board committee board established procedure handling situational meeting communicate comments observations conflicts interest line best practice guidance matters considered via chairman board issued general counsel group accordance relevant board committee chairman raising appropriate companys articles authorised nominations relevant meeting attendance meetings considered committee grant review periodically event part onetoone meetings conducted chairman annually potential actual conflict authorisations directors director counted quorum authorisation actual potential conflicts company secretary minutes business environment personal development consideration conflict authorisations granted recorded ensure board kept uptodate important matters company secretary register conflict authorisations including legal governance regulatory developments noted board next meeting presentations made regular basis external internal advisers ongoing basis directors responsible informing company secretary new actual potential conflicts nonexecutive directors also gain greater insight understanding may arise changes circumstances may business access gsk employees visits affect authorisation previously given even provided group operational facilities attendance various internal authorisation director absolved statutory management meetings including cet research development duty promote success company actual conflict executive product marketing board meetings ad arises post authorisation board choose exclude hoc basis director receipt relevant information participation customised induction process conducted company debate suspend director board last secretary new nonexecutive directors focusing resort require director resign particular experience taking account different nominations committee reviewed register conflict backgrounds primary element process includes meeting authorisations october concluded members cet informally collective individual basis conflicts appropriately authorised process appropriate together senior executives visiting authorisation continues operate effectively particular operational facilities group company secretary addition chairman meets director annually company secretary responsible board available onetoone basis discuss agree individual ongoing individual directors respect board procedures simon training development requirements bicknell company secretary st december independent advice secretary board committees except board recognises may occasions one remuneration committee victoria whyte formerly deputy directors feel necessary take independent legal company secretary appointed company secretary effect andor financial advice companys expense st january secretary remuneration agreed procedure enable explained committee acts secretary board governance section companys website committees since appointment company secretary solicitor fellow institute chartered secretaries indemnification directors administrators qualifying third party indemnity provisions defined section board committees companies act force benefit directors former directors held office board established number committees provides sufficient resources enable undertake directors conflicts interest duties executive directors members audit directors statutory duty avoid situation risk remuneration nominations corporate responsibility direct indirect conflict interest possible committees although may invited attend meetings conflict interest company duty applies particular director member corporate administration exploitation property information opportunity transactions finance committees whether gsk could take advantage companys articles association include general power board authorise conflicts breach duty relevant matter authorised advance gsk annual report pp noitarenumer dna ecnanrevog corporate governance corporate governance framework board chairman executive directors independent nonexecutive directors audit risk committee remuneration committee nominations committee chief executive independent independent nonexecutive independent nonexecutive officer nonexecutive directors directors chairman directors chairman corporate responsibility finance committee corporate administration independent nonexecutive executive nonexecutive transactions committee cet directors chairman directors directors company secretary cet members key board committees management committee executive directors since appointment chief financial officer designate th january executive directors following retirement chief financial officer st march current membership committees shown table corporate audit risk remuneration nominations responsibility sir christopher gent c c professor sir roy anderson dr stephanie burns larry culp sir crispin davis c sir deryck maughan james murdoch dr daniel podolsky tom de swaan c sir robert wilson key c chairman member gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance committee written terms reference approved board reviewed least annually ensure comply latest legal regulatory requirements reflect best practice developments following summary role terms reference committee current full terms reference committee may obtained company secretary governance section companys website meetings committee report committee role terms reference membership comprises per year audit risk reviews financial internal reporting process independent non cid external internal audit processes system executive directors internal controls identification management risks committee also proposes shareholders appointment reappointment removal external auditors directly responsible remuneration oversight work remuneration determines terms service remuneration independent non cid executive directors members executive directors cet assistance external chairman independent advisers evaluates makes recommendations board overall executive remuneration policy assists longterm success group chairman ceo responsible evaluating making recommendations board remuneration nonexecutive directors nominations reviews structure size composition independent non cid board including skills knowledge executive directors independence experience diversity chairman appointment members board cet makes recommendations board appropriate committee monitors planning succession board senior management committee also considers appropriate authorises directors conflicts interest corporate provides boardlevel forum regular review independent non cid responsibility external issues potential serious executive directors impact upon groups business reputation chairman committee also responsible oversight gsks worldwide donations community support finance reviews approves behalf board executive non necessary annual report form f convening executive directors agm together preliminary quarterly statements trading results also approves certain major licensing capital transactions changes groups investment instrument counterparty limits corporate reviews approves matters connection executive non necessary administration administration groups business executive directors transactions certain corporate transactions cet members company secretary gsk annual report pp noitarenumer dna ecnanrevog corporate governance evaluation board board committees directors high level confidence performance board decided undertake externally facilitated ceo strong belief board dynamics facilitated open evaluation process every three years since become honest constructive discussion issues major changes requirement within uk corporate governance code updated boards practices procedures deemed necessary code intervening period review facilitated terms implementation action points previous sid chairman next externally facilitated evaluation year board undertaken end increased focus rd activities successful delivery reminder form board evaluation reviews pipeline pleased progress rd taken together action points agreed set year separately behalf board remuneration committee initiated discussions management shareholders introduction strategically aligned method evaluation actions areas focus performance criteria companys long term incentive plans dr long boardroom utilise board committee result successful conclusion discussions review facilitated time effectively grant lti options made february made two review facilitate contribution additional performance criteria one focuses rd nonexecutive directors new product performance details please refer enhance continuous remuneration report pages education process non sought assistance audit risk committee executive directors fully understand groups key risks work ongoing provide greater visibility board continue consider regular reports executive talent audit risk committee advance management succession boards annual review effectiveness companys risk planning process management next year sir robert wilson increase board time devoted pleased operation nominations committee senior independent strategic discussion enhanced succession planning process resulted director indicators success appointment cfo designate positive progress delivery made recruitment new board members rd pipeline refresh board devote time focused consideration board agreed following actions discussion companys key risks evaluation report ensure continues improve way ongoing basis operates provide board given fundamental strategic challenges facing regular updates insights pharmaceutical industry board seek continue newly enhanced allocate time regular basis focus strategic issues management succession significant challenges facing industry direct planning process aim enhancing returns shareholders board evaluation process enhance information flows providing board accordance established practice sid sir robert members wider variety external perspectives wilson conducted evaluation performance company industry chairman board committees directors rd continue major expense company collaboration committee chairmen board seeking assess extent new board evaluation process included onetoone interview policies implemented recent years added value director topics discussed circulated continue support executive management ethical directors advance included variety aspects associated leadership within group board effectiveness including board committee information flows handling strategic issues collective effectiveness directors led sid also met separately without exploration ways improve way board chairman present discuss chairmans performance operates considered leadership performance overall contribution high standard result high chairman board committees undertook level confidence shared directors sir christophers separate evaluations outcome reported chairmanship board unanimously agreed extend discussed respective committee board appointment chairman period five years effect feedback overall evaluation process provided st january subject reelection shareholders form written report board debated would ensure continuity leadership board findings period several nonexecutive directors would approaching retirement served nine years board board evaluation review concluded board committees operating effectively high level board continued feel receiving high quality information readily understandable format timely basis order fulfil role gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance dialogue shareholders share capital control financial results announced quarterly basis details companys issued share capital number fullyear results included companys annual report shares held treasury st december found company produces annual summary sent note financial statements share capital share shareholders advise availability annual report premium account gsks shares listed london stock notice meeting wwwgskcom exchange also quoted new york stock exchange nyse form american depositary shares ads ads ceo cfo give presentations halfyear full represents two ordinary shares year results facetoface meetings institutional investors analysts media also accessible via webcast holders ordinary shares entitled receive dividends teleconference release first third quarterly declared companys annual report attend results company holds webcast teleconferences institutional speak general meetings company appoint proxies investors analysts media quarterly results also exercise voting rights made available investors section companys website restrictions transfer limitations holding agm takes place london formal notification sent ordinary shares requirements obtain prior approval shareholders least one month advance meeting transfers ordinary shares carry special rights business presentation made shareholders directors able regard control company restrictions attend available formally agm informally voting rights major shareholders voting rights per afterwards questions committee chairmen ordinarily attend share shareholders known arrangements agm respond shareholders questions entire board financial rights held person attendance companys agm may save holder shares known agreements restrictions dr stephanie burns larry culp prevented share transfers voting rights attending due travel disruption caused ash clouds shares acquired gsk share plans rank equally volcano iceland tom de swaan required shares issue special rights trustees chair shareholder meeting another public company companys employee share ownership plan esop trusts day resolutions agm decided poll waived rights dividends shares held esop trusts required companys articles association results poll announced london stock exchange posted change control essential contracts investors section companys website details company contracts arrangements agm set section annual general meeting individually essential businesses party see notice agm published investors significant agreements would take effect alter terminate section companys website upon change control following takeover bid ensure nonexecutive directors aware company agreements director understand views major shareholders company officer would provide compensation loss office board place briefing process managed employment resulting takeover except provisions chairman focusing sectorspecific issues well general companys share plans may cause options awards granted shareholder preferences plans vest takeover details termination provisions companys framework contracts executive groups investor relations department offices london directors given philadelphia acts focal point contact investors throughout year interests voting rights stated far company aware ceo cfo chairman maintain dialogue institutional persons significant direct indirect holdings shareholders performance plans objectives company information provided company pursuant programme regular meetings since appointment ceo financial services authoritys fsa disclosure transparency may andrew witty undertaken extensive ongoing rules dtrs published regulatory information service series meetings gsks institutional shareholders investors section companys website chairman meets regularly institutional investors th february company received notifications hear views discuss issues mutual importance accordance fsas dtrs following notifiable interests communicates views investors board whole voting rights companys issued share capital sid also available shareholders chairman remuneration committee chairman percentage issued shares capital senior vice president human resources company blackrock inc secretary meet annually major shareholders discuss legal general group plc executive remuneration policy governance matters nonexecutive directors including new appointees available percentage ordinary shares issue excluding treasury shares meet major shareholders requested companys website provides access current financial business information group gsk annual report pp noitarenumer dna ecnanrevog corporate governance bank new york mellon depositary companys share buyback programme ads listed nyse ordinary shares representing billion programme share repurchases commenced july companys american depositary receipt program shares costing billion repurchased managed depositary registered name bny programme repurchases made nominees limited details number ordinary shares held company announced publicly rd february depositary found intends commence new longterm share buyback programme expects buyback billion shares company acquired disposed interests period th february th february million shares period review details shares shares purchased cost million programme purchased prior years cancelled held covers purchases company shares cancellation treasury shares disclosed note financial statements held treasury shares accordance authority renewed share capital share premium account shareholders agm may company directors officers authorised purchase maximum million shares interests directors officers connected details shares purchased cancelled held persons issued share capital company given treasury shares disclosed note financial statements remuneration report pages share capital share premium account rules appointment replacement directors exact amount timing future purchases whether contained companys articles association companys shares held treasury shares cancelled articles must approved shareholders accordance determined company dependent market conditions legislation force time time factors articles provide directors may appointed ordinary donations political organisations political expenditure resolution members resolution directors effect st january ensure consistent approach provided latter instance director appointed political contributions across group gsk introduced global way retires first agm following appointment policy stop voluntarily political contributions articles also provide directors normally subject reelection agm intervals three years annually political donations held office continuous period nine years eu political organisations however board agreed directors seek either noneu political organisations election reelection accordance updated code comprising companys members may remove director passing usa ordinary resolution special notice given canada passing special resolution director may automatically cease director notwithstanding introduction policy accordance heshe resigns federal election campaign act company continues heshe offers resign board accept offer support political action committee pac facilitates directors least three number require voluntary political donations eligible gsk employees pac resign controlled gsk decisions amount recipients contributions made participating employees exercising heshe suffering physical mental ill health legal right contribute pool resources make heshe missed directors meetings continuous period political contributions subject strict limitations six months without permission board resolves total donated political heshe shall cease director organisations gsk pac heshe becomes bankrupt compounds hisher agm may shareholders first authorised creditors generally company make donations eu political organisations heshe ceases director virtue articles incur eu political expenditure provisions political companies acts parties elections referendums act heshe prohibited director law year authority since renewed annually companies act requires companies continue articles association obtain shareholder approval make donations powers directors determined uk legislation eu political organisations incur eu political expenditure companys articles association available governance however company make intend section gsks website articles may amended make donations political parties independent election special resolution members directors may exercise candidates make donations eu political companys powers provided articles applicable organisations incur eu political expenditure legislation stipulate powers must exercised members directors authorised issue definitions political donations political expenditure allot ordinary shares current article power political organisations used legislation wide article authority company make purchases particular definition eu political organisations may extend shares subject shareholder authorities bodies concerned policy review law reform sought annual basis agm shares purchased representation business community special interest company may cancelled held treasury shares groups concerned environment company subsidiaries might wish support gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance result definitions may cover legitimate business activities internal control framework ordinary sense considered political donations board recognises responsibility present balanced political expenditure activities designed support understandable assessment groups position prospects political party independent election candidate authority board sought annually precautionary measure board accountability reviewing approving ensure company subsidiaries inadvertently adequacy effectiveness internal controls operated breach legislation group including financial operational compliance controls risk management board delegated responsibility annual general meeting review audit risk committee committee agm held pm thursday th may receives regular reporting aligned gsks assurance programme queen elizabeth ii conference centre broad sanctuary responsibility management cet westminster london swp ee business transacted implement board policies risk control cet responsible meeting include identifying approving monitoring enforcing key policies go heart group conducts business receiving adopting glaxosmithklines annual report internal control framework includes central direction resource allocation risk management key activities research approving remuneration report development manufacturing marketing sales legal human remuneration report pages sets resources information systems financial practice part remuneration policies operated gsk disclosures framework comprehensive planning system directors remuneration including required annual budget approved board results operating companies act large mediumsized units reported monthly compared budget companies groups accounts reports regulations forecasts prepared regularly year resolution proposed approve remuneration report group also place established procedures identify consolidate reporting entities groups control activities include retirement reelection directors policies practices covering appropriate authorisation simon dingemans appointed agm approval transactions application financial reporting standards retire accordance articles eligible reviews significant judgements financial performance offer election agm continuing directors retire rotation agm offer extensive financial regulatory operational controls procedures reelection risk activities reviewed groups internal auditors however responsibility clearly delegated local business units reappointment remuneration auditors supported regional management structure principles resolutions proposed authorise audit risk designed provide environment central leadership coupled committee reappoint pricewaterhousecoopers llp local operating autonomy framework exercise auditors determine remuneration accountability control within group special business group also attaches importance clear principles company seek authority procedures designed achieve appropriate accountability make donations eu political organisations incur control group policy risk management legal compliance eu political expenditure capped mandates business units establish processes managing monitoring risks significant businesses group allot ordinary shares company give directors authority disapply preemption rights internal control framework also relies following allotting new shares connection rights issues mechanisms overseeing reporting risk compliance issues otherwise maximum current issued share capital purchase ordinary shares maximum current issued share capital exempt auditors state name senior statutory auditor company gsks annual report reduce notice required call general meeting less clear days shareholders entitled appoint one proxies attend agm speak vote behalf provided event single shareholder appoints multiple proxies proxy appointed exercise rights attached different share shares held member details appoint appointed corporate representative proxy found notice agm published investors section companys website gsk annual report pp noitarenumer dna ecnanrevog corporate governance risk oversight audit risk compliance committee council internal assurance business unit reporting audit reporting reporting independent external audit emerging business internal review business regulatory incidents risk control audit business unit monitoring agency events management infrastructure activity internal outcome audit activity gsk risk universe management internal assurance audit risk oversight compliance council rocc corporate ethics compliance cec rocc council senior executives authorised board rocc rmcbs assisted cec department assist committee oversee risk management internal responsible supporting development control activities group membership comprises several cet implementation practices facilitate employees compliance members heads departments internal control laws group policy department provides assistance risk management assurance audit compliance responsibilities help employees meet high ethical standards comply applicable laws regulations corporate responsibility rocc meets regular basis review assess significant risks mitigation plans provide oversight internal thrust groups compliance effort due diligence controls ensure compliance applicable laws regulations preventing detecting misconduct noncompliance law internal gsk policies rocc responding group policy regulation promotion ethical behaviour compliance referred provided business units framework laws regulations corporate responsibility levels risk management upward reporting significant risks effective compliance systems mitigation planning identification manager overall gsk employees encouraged seek help report responsibility management given risk requirement concerns suspected cases misconduct without fear risk management compliance boards rmcbs retaliation employees line management rmcbs established major business units via gsks integrity confidential reporting lines managed membership often comprises members senior executive cec concerns allegations fairly independently team respective business unit augmented specialists investigated disciplinary action applicable commensurate appropriate rmcbs oversee management risks issues presented considered important respective business units cec department managed senior vice president including risks designated significant gsk governance ethics assurance reports directly whole thus increasing number risks actively ceo chairs rocc provides summary reports managed across group roccs activities groups significant risks cet business unit corporate function must periodically review committee regular basis direct reporting line significant risks facing businesses review committee provides mechanism bypassing executive include identifying operational risks legal compliance risks risks management need ever arise achievement strategic goals objectives review must occur least annually embedded within aligned annual planning process ensure significant risks identified changes management direction external environment gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance assurance assurance reporting assurance programme implemented assurance reporting committee follows structured enhance governance provide independent assessment programme integrating reporting business units assurance governance risk management control processes internal audit organisation within gsk comprises four main elements business units corporate functions required present internal audit reports annually rocc committee detail gsks internal audit group responsibility independently risk management compliance approach providing balanced assessing adequacy effectiveness management assessment status internal controls key risks significant risk areas reporting outcomes committee highlighting significant compliance issues managers must line agreed assurance plan internal audit group oversee risks considered important respective comprised four principal teams focused following areas business units including risks designated significant group information regarding controls place manage commercial financial risks provided assure committee risks information technology adequately managed within internal control framework anufacturing including environmental health safety addition significant compliance issues internal audit results sustainability escalated rocc committee earliest opportunity research development risk management groups risk management programme extends beyond legal internal audit activity conducted single organisation regulatory issues considers groups overall strategy leadership head audit assurance head changes external environment furthermore risk management audit assurance dual reporting line senior vice principles embedded within management practices part president governance ethics assurance committee business strategy objectives setting process chairman global audit function allows holistic assurance consistency approach independence reporting details risks affecting group see risk factors pages helped eliminate overlaps gaps potential note financial statements legal proceedings auditing effectiveness controls internal audit undertakes continuous process risk assessment internal control framework operation contributes evolution gsks audit strategies whole year review continues operate compilation delivery audit schedule approach date approval report system internal controls allows audit assurance respond expeditiously changes designed manage rather eliminate risk achieving business risk environment ensure audit strategies business objectives provide reasonable fitforpurpose absolute assurance material misstatement loss issues control deficiencies identified committee receives reports areas significant risk audit engagements internal audit recommends processes group related internal controls following consideration improvement gsk managers develop corrective action plans reports received via assurance framework address causes noncompliance gaps internal controls committee reports annually board effectiveness internal audit tracks plans completion reports results controls executive management committee internal audit results areas groups business necessary also compiled reported rocc committee take risks achieve satisfactory return shareholders detailed assurance reporting section investment rd acquiring new products businesses supplement audit programme strategic risk evaluations cases groups objective apply expertise sres performed significant issues facing gsk prudent management rather elimination risk conducted assurance teams partnership business directors review relates company subsidiaries approach designed evaluate risk areas enable extend material associated undertakings development implementation appropriate mitigation plans joint ventures investments two new sres performed covering areas board committee reviewed assessment change management evaluation risks associated risks internal control framework operates gsk existing proposed sales force incentive schemes addition considered effectiveness system internal audit assurance provided implementation support control operation group year covered sres included acquisitions due diligence use report date approval board pseudoephedrine gsk products process followed board reviewing system internal controls accords guidance internal control issued turnbull committee gsk annual report pp noitarenumer dna ecnanrevog corporate governance committee reports attendance board committees report regularly board performance full meetings activities assigned members committee member since audit risk committee report mr tom de swaan chairman st september st january professor sir roy anderson th may sir deryck maughan st january dr daniel podolsky st january sir robert wilson th december dear shareholder structure committees meetings changed committee focused number meetings split two parts part one deals activities associated beyond core financial internal fundamental aspects internal financial control control responsibilities considers standing items receiving reports external auditors audit assurance entire board implementation new assurance model end invited attend part two meetings usually considers involved consolidation audit groups developments external risk environment receives legal new audit assurance function enabled updates new business unit corporate function reports reporting committee streamlined helped reports outcome strategic review evaluations ensure business unit risks internal audit activity topical issues fully aligned addition six scheduled meetings committee also met reflect groups strategy expand quorate basis five occasions emerging markets eastern hemisphere audit hub established focus audit activity asia attendees committee meetings include pacific region ceo response new uk bribery act dedicated anti cfo bribery compliance abac team established chairman part audit assurance details general counsel gsks abac programme found reports head audit assurance publications section companys website company secretary end work commenced assist board chairman research development reviewing cet understanding nature extent risks gsk taking order achieve chief medical officer strategic objectives work ongoing frcs head governance ethics assurance review turnbull guidance continues report external auditors work progresses committees main responsibilities include continued visit groups operations reviewing corporate accounting financial help make committee accessible employees reporting process senior management discuss issues brought committee management meet network monitoring integrity financial statements compliance officers group relies oversee evaluating system internal control identifying drive compliance within gsk managing risks including relation financial reporting process preparation consolidated accounts committee also continues examine improve approach audit assurance overseeing activities groups compliance audit ongoing initiative progress area functions overseeing compliance laws regulations reported next year ethical codes practice committees oversight role requires address regularly relationships management internal external auditors understand monitor reporting relationships tom de swaan tiers accountability audit risk committee chairman gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance committee receives regular reports members cet senior managers covering key risk management scientific expertise compliance activities group including covering rd professor sir roy world renowned medical scientist manufacturing sales marketing corporate functions anderson advanced knowledge infectious disease details reporting framework committee epidemiology set pages internal control framework professor infectious disease epidemiology december committees terms reference faculty medicine imperial college amended reflect role overseeing identification london management risk new assurancebased audit fellow royal society framework referred time foreign associate member institute name audit committee changed audit medicine us national academy risk committee sciences qualifications audit risk committee members foreign associate member french committee members exception professor sir roy academy sciences anderson dr daniel podolsky bring considerable financial former rector imperial college london accounting experience committees work members former chief scientific adviser ministry past employment experience either finance accounting defence uk roles comparable experience corporate activities professor sir roy anderson dr daniel podolskys backgrounds world renowned medical scientists researchers enable bring dr daniel podolsky world renowned researcher scientific expertise committees deliberations advanced knowledge underlying mechanisms disease new therapies gastrointestinal disorders financial accounting experience president university texas mr tom de swaan chief financial officer abn amro southwestern medical center professor st december internal medicine determined board audit member institute medicine us committee financial expert defined national academy sciences sarbanes oxley act sarbanesoxley former mallinckrodt professor medicine nonexecutive director kpmgs public harvard medical school interest committee former chief academic officer partners healthcare sir deryck maughan partner kohlberg kravis roberts co kkr chairman kkr japan former chairman ceo citigroup international vice chairman citigroup inc former chairman cochief executive officer salomon smith barney former chairman chief executive officer salomon brothers inc sir robert wilson economist former nonexecutive chairman economist group chairman bg group plc retired rio tinto held senior management positions culminating appointment executive chairman gsk annual report pp noitarenumer dna ecnanrevog corporate governance committee worked structured programme evaluating effectiveness audit process prior making activities standing items committee required recommendation reappointment external auditors consider meeting together matters focused committee reviews effectiveness performance coincide key events annual financial reporting cycle criteria agrees conjunction management beginning years audit part process committee considers feedback prior years external audit external auditors reported critical accounting gathered survey facilitated auditors client service policies significant judgements review team independent engagement team practices used group alternative undertook audit work survey seeks feedback accounting treatments number sources including certain members board discussed management involved audit process financial management resultant conclusion material written team corporate business unit level communications management restrictions access information agreeing audit fee proposed external auditors committee considers cost comparisons ensure fair cfo reported financial performance appropriate gsk contractual obligations company technical financial restrict committees capacity recommend particular firm accounting matters external auditors group pricewaterhousecoopers llp general counsel reported material litigation remained place auditors since groups inception december performance reviewed annually company secretary reported corporate governance committee since time corporate activities undertaken rocc compliance officer making assessment committee considers papers detail relevant uk legislative regulatory professional heads audit majority heads groups requirements relating external auditors evaluates assurance reported audit scope annual reports external auditors compliance groups compliance coverage audit resources requirements safeguards established audit groups results audits conducted throughout internal quality control procedures consideration year also given committee need include risk company secretary reported matters affected withdrawal external auditors market risk chairman quality timely disclosure financial evaluation planning external auditors required disclosure material information rotate audit engagement partner every five years current committee b oard public markets audit partner commenced engagement st january shareholders enabled audit subject rotation audit gsks financial risk committee review clarity statements concluded completeness disclosures sarbanesoxley act prohibits engagement published annual financial statements external auditors provision certain services legal interim reports quarterly preliminary actuarial internal audit outsourcing financial information systems results announcements formal design external auditors permitted provide non announcements relating financial audit services committee ensures auditor objectivity performance prior approval independence safeguarded policy requiring preapproval board committee services services may include audit auditrelated tax services preapproval detailed committee management internal auditors full particular service categories services subject board work together ensure quality companys specific budget corporate accounting financial reporting committee serves primary link board external guidelines set groups policy engaging internal auditors facilitates necessary independence external auditors provide nonaudit services include management encourages external internal auditors ascertaining skills experience external auditors communicate freely regularly committee make suitable supplier nonaudit services adequate committee met collectively separately safeguards place objectivity independence external auditors head audit assurance group audit threatened compromised fee corporate compliance officer without members management levels relative annual audit fee within limits set present committee external auditors appointment fees external auditors management report regularly committee primary responsibility making committee regarding extent services provided accordance recommendation shareholders appointment preapproval fees services performed appointment removal external auditors annually committee may also preapprove additional services case assessing qualifications expertise resources independence bycase basis expenditure audit nonaudit services set external auditors effectiveness audit process note financial statements operating profit gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance code conduct succession process cfo focused need company also number wellestablished policies gsk operate creativity continued financial discipline including code conduct available website also identify candidate would able bring helpline facility reporting investigation unlawful experience capability support strategy grow conduct waivers code made diversify gsks business organic means bolton acquisitions successful candidate would also responsible nominations committee report delivering cost savings part global restructuring programme implementing additional measures simplify operational model considering potential external internal candidates committee pleased recommend simon dingemans board companys cfo designate simon dingemans managing director partner goldman sachs european business previously head uk investment banking years investment banking built relationships offered strategic advice across sir christopher gent multiple industry sectors including pharmaceuticals consumer nominations committee chairman healthcare worked closely gsk many years helped establish viiv healthcare new worldleading specialist attendance full meetings hiv company members committee member since board approved announced appointment simon sir christopher gent dingemans september joined gsk chairman january st january th december committee also recommended appointment dr patrick larry culp th march vallance cet svp drug discovery medicines sir crispin davis th july development effect st july joined gsk may sir deryck maughan th july head drug discovery since transformed gsks discovery engine focus therapy areas underpinned sir robert wilson th march promising mature science offer fresh insights diseases new role assumed responsibility addition three scheduled meetings committee also medicines development responsible ensuring met quorate basis two occasions gsk maintains flow potential new medicines rd attendees committee meetings pipeline early discovery late stage development ceo recruiting nonexecutive directors committee considers head human resources particular skills knowledge independence diversity experience would benefit board significantly company secretary appointment broad selection criteria used focus relevant appropriate external advisers achieving balance representation european uk nominations committees committee main responsibilities us emerging markets individuals ceo level include proposing appointment board committee experience skills developed various sectors specialities members particular focus continued placed upon committees main focus succession recruiting replacement dr ronaldo schmitz retired process cfo search new nonexecutive directors board agm may committee placed refresh board emphasis candidates current recently retired ceos cfos audit partners significant financial appointing new executive directors cet members expertise preferably individual brings increased diversity committee considers skills knowledge experience boards composition deliberations professional search required particular executive position committee agencies engaged specialise recruitment consider potential external internal candidates high calibre nonexecutive directors dossiers potential recommending board approve new appointment nonexecutive appointees considered committee new directors offer election companys shortlisted interview merit objective criteria next agm appointments announced publicly considering relevant qualifications positive progress made recruitment new nonexecutive directors refresh board gsk annual report pp noitarenumer dna ecnanrevog corporate governance remuneration report gsks cr principles discussed least every two remuneration report found pages years committee also reviews approves corporate responsibility report corporate responsibility committee report work committee cr principles committees area focus access medicines access pricing medicines middle income least developed countries standards ethical conduct embedding ethical values organisation research innovation policy use animals sir christopher gent research development corporate responsibility committee chairman research integrity transparency attendance governance research full meetings conducted external suppliers members committee member since collaborators sir christopher gent rd treatments rare chairman conditions diseases st january th december developing world dr stephanie burns th december potential stem cell science james murdoch th may regenerative medicines employment practices diversity inclusion dr daniel podolsky st july leading developing employees attendees committee meetings employee relations including ceo consultation arrangements general counsel realignment pay head governance ethics assurance performance strategy head global communications management health head corporate responsibility safety risks manufacturing company secretary community investment community partnerships independent external corporate responsibility adviser investment independent external corporate responsibility adviser humanitarian donations augment gsks engagement stakeholder opinion caring environment environmental sustainability march ms sophia tickell appointed independent strategy external adviser corporate responsibility committee management environment committee sophia tickell cofounder director risks manufacturing meteos directs pharma futures series products customers disclosure payments aims align better societal shareholder value also sits healthcare professionals expert review committee access medicines foundation member european healthcare corporate responsibility integrated management innovation leadership network gsks business throughout annual report read sophia tickell attends meetings committee provides advances ensure gsk works efficiently effectively independent advice guidance corporate social possible whilst ensuring always act responsibly responsibility matters chairman ceo interested detail publish comprehensive main responsibilities committee corporate responsibility report available companys website main responsibilities committee set committee rolling agenda receives reports members cet senior managers ensure progress meeting gsks corporate responsibility principles reviewed committee annually reviews progress following five corporate responsibility cr principles access medicines standards ethical conduct research innovation employment practices community investment gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance us law regulation section corporate responsibility financial reports number provisions us law regulation apply gsk sarbanesoxley also introduced requirement ceo companys shares quoted nyse form cfo complete formal certifications confirming ads reviewed annual report form f nyse rules based knowledge contains material misstatements general nyse rules permit company follow uk omissions corporate governance practices instead applied usa provided company explains significant variations based knowledge financial statements explanation contained companys form f filing financial information fairly present material respects accessed securities exchange commissions financial condition results operations cash flows sec edgar database via companys website nyse rules dates periods presented annual report came effect require company file annual form f interim written affirmations concerning audit risk responsible establishing maintaining disclosure committee companys statement significant differences controls procedures ensure material information corporate governance made known evaluated effectiveness sarbanesoxley act controls procedures yearend results following number corporate accounting scandals evaluation contained annual report usa congress passed sarbanesoxley act sarbanes form f oxley wide ranging piece legislation concerned largely responsible establishing maintaining internal financial reporting corporate governance control financial reporting provides reasonable recommended sec gsk established disclosure assurance regarding reliability financial reporting committee committee reports ceo cfo preparation financial statements external purposes audit risk committee chaired company secretary accordance generally accepted accounting principles members consist senior managers finance legal disclosed annual report form f compliance corporate communications investor relations changes internal controls financial reporting external legal counsel external auditors internal experts period covered annual report form f invited attend meetings periodically responsibility materially affected reasonably likely affect materially considering materiality information timely companys internal control financial reporting basis determining disclosure information disclosed based recent evaluation responsibility timely filing reports sec internal control financial reporting external auditors formal review annual report form f audit risk committee significant deficiencies committee met times material weaknesses design operation internal sarbanesoxley requires annual report contains controls financial reporting reasonably likely statement whether member companys audit risk affect adversely companys ability record process committee audit committee financial expert defined summarise report financial information fraud sarbanesoxley summary regarding boards judgement regardless materiality involving persons significant matter refer additional disclosure requirements role companys internal control financial reporting arise section section sarbanesoxley group carried evaluation supervision respect disclosure controls procedures internal control participation groups management including financial reporting ceo cfo effectiveness design operation groups disclosure controls procedures st december inherent limitations effectiveness system disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives ceo cfo expect complete certifications report conclusions effectiveness disclosure controls procedures th march following certificates filed sec part groups form f gsk annual report pp noitarenumer dna ecnanrevog corporate governance section managements annual report internal control financial reporting accordance requirements section sarbanes oxley following report provided management respect companys internal control financial reporting defined rules af df us securities exchange act management responsible establishing maintaining adequate internal control financial reporting group internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance ifrs management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organisations treadway commission changes groups internal control financial reporting materially affected reasonably likely affect materially groups internal control financial reporting management assessed effectiveness internal control financial reporting st december conclusion filed part groups form f pricewaterhousecoopers llp audited consolidated financial statements group year ended st december also assessed effectiveness groups internal control financial reporting auditing standard public company accounting oversight board united states audit report filed groups form f gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report sir crispin davis remuneration committee chairman dear shareholder behalf board pleased present remuneration report seeking approval agm may last years remuneration committee committee implemented number changes including tailored benchmarking versus market simplifying aligning remuneration across corporate executive team throughout consulted shareholders encouraged level support previewed last year priority align closely executive remuneration gsks strategic priorities enhance governance practices report describes progressing objectives strategic alignment longterm incentives board carried thorough review gsks key strategic priorities described annual report board firmly believes achievement priorities deliver strong longterm financial performance shareholder value creation sustainable basis accordingly moved align longterm performance incentives closely groups key strategic priorities help ensure senior management fully focused right priorities incentives deliver longterm incentive awards made february therefore based four equally weighted performance measures directly link groups key strategic priorities overarching goal deliver value shareholders key strategic priorities longterm incentive performance measure grow diversified global business cid business diversification performance deliver products value cid rd new product performance simplify operating model cid adjusted free cash flow deliver value shareholders cid relative total shareholder return tsr targets set committee challenging require significant stretch performance targets adjusted free cash flow relative tsr set however given close linkage performance measures business diversification rd new product performance strategy targets commercially sensitive published date grant though update regularly progress achieved performance period targets outcomes awards disclosed full end performance period believe combination four measures applied performance share plan deferred annual bonus plan ensure balanced framework targets focus strategic objectives year first year executives eligible participate deferred annual bonus plan introduced encourage longterm shareholding drive shareholder returns pleased report takeup positive governance following progress reported last years remuneration report pleased report continuing executive directors contracts severance terms one years base salary similarly andrew witty dr moncef slaoui chairman rd voluntarily agreed remove contractual entitlement bonus severance terms severance terms contract simon dingemans new cfo also based one years base salary order effectively manage risk continue operate clawback mechanism introduced annual bonuses longterm incentive awards problems arise years award made adapted uk pension arrangements light new pension tax legislation continue meet longstanding commitments however company offset additional individual tax costs year review market competitiveness executive directors base salaries packages taking account prevailing economic conditions positioning relativities pay across broader gsk workforce result review ensure appropriate market competitiveness context dr moncef slaouis enhanced role including transition responsibility biologicals receive increase base salary andrew witty simon dingemans receive increase base salary believe changes made recent years support longterm success business best interests shareholders sir crispin davis remuneration committee chairman st march gsk annual report pp noitarenumer dna ecnanrevog remuneration report remuneration committee addition allen powley senior vice president corporate compensation judy lynch senior vice president benefits role committee also invited meetings required role committee set companys remuneration policy executive directors corporate executive team cet exception victoria whyte company secretary members together executives gsk able recruit secretary committee employees company retain motivate executives policy regularly reviewed involved conduct committee meetings ensure consistent companys scale scope committee access external advice required deloitte operations supports business strategy growth plans llp appointed committee provide helps drive creation shareholder value independent advice executive remuneration year setting remuneration policy levels senior deloitte llp provided independent commentary matters executives committee gives consideration remuneration consideration committee provided updates best policy levels wider employee population group practice legislative requirements market practice well ensuring remuneration consistent industry deloitte llp also provided consulting tax assurance broader market norms services gsk year provide advice terms reference executive remuneration matters committee committees full terms reference available towers watson pay governance provided additional market companys website terms reference reviewed data committee annually revised january light best practice corporate governance developments commitment shareholders committee engages regular dialogue shareholders governance holds annual meetings gsks largest investors discuss board considers members committee take feedback remuneration policy governance matters independent nonexecutive directors accordance key developments year particular committee combined code exception sir christopher gent discusses significant changes policy measures chairman company independent appointment used assess performance committee met six times member annual meetings held november attending follows sir crispin davis committee chairman shared progress attendance remuneration matters last months proposals full meetings outlined sir christopher gent chairman updated committee member attendees corporate governance developments members since sir crispin davis chairman th may st july sir robert wilson th march st january larry culp st january sir christopher gent st january james murdoch st october tom de swaan th may larry culp unable attend two meetings personal reasons reviewed papers provided views committee chairman advance meetings tom de swaan also chairman audit risk committee addition six scheduled meetings committee also met quorate basis three occasions principally approve formal grant vesting longterm incentive lti awards accordance gsks remuneration policy andrew witty ceo claire thomas senior vice president human resources invited attend part meetings committee required executives committee attendees involved decision present discussion remuneration gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report diary committees key activities matters addressed set month executives remuneration annual bonus longterm incentive plans governance matters january approve cet set ceo bonus annual committee remuneration including objectives evaluation results salaries ceo cfo chairman rd review bonus plan review remuneration report arrangements chairman rd review remuneration budget review voting policy guidelines remuneration february review approve set psp cash flow target approve remuneration executive directors report cet bonuses approve psp share option plan vesting grant lti awards executive directors cet approve deferred annual bonus award elections march scope review strategic review voting policy alignment lti performance guidelines remuneration measures july agree cfo retirement review progress review strategic alignment review general market appointment packages bonus lti performance measures developments including objectives pensions grant interim lti awards october agree cet salary review cet review strategic alignment annual committee review process bonus process lti performance measures assessment november annual meetings annual meetings investors investors december consider feedback consider new lti performance review tax change annual meetings targets framework implications pension investors remuneration arrangements policy review remuneration benchmarking competitiveness cet level gsk annual report pp noitarenumer dna ecnanrevog remuneration report remuneration policy table outlines key elements remuneration gsks executives remuneration structure cet members including dr moncef slaoui simon dingemans cfo designate harmonised andrew witty result since share options normally longer granted cet members instead cet members receive additional performance share awards also eligible participate gsks deferred annual bonus plan improve alignment executive remuneration arrangements gsks key strategic priorities incentivise management deliver longterm financial performance shareholder value creation sustainable basis two new business specific performance measures introduced longterm incentive awards made executives february ensure balanced framework measures focusing gsks strategic objectives information longterm incentive performance measures outlined pages fixed pay salary salary levels reviewed annually influenced executives role experience benchmarked relevant comparator groups pension uk executives defined contribution plan legacy final salary plans closed new entrants since uk executives participating defined contribution plan benefit company contributions base salary plus matched contribution base salary following changes uk pension tax regime changes made arrangements uk executives continue meet longstanding commitments within new regime see us executives gsk operates us cash balance plan us plan us executives participating us plan benefit contributions salary variable pay annual bonus aximum bonus opportunity majority bonus based achievement financial targets group salary profit interest tax business unit operating profit individual performance predetermined personal objectives rdspecific key performance indicators rd employees clawback committee reviews ongoing financial impact prior year activities executives role may make appropriate adjustments individual bonus awards reflect circumstances deferred individuals may elect defer awards vest end threeyear performance period based four annual bonus earned equally weighted performance measures bonus plan business diversification performance deferred bonuses may matched rd new product performance oneforone subject adjusted free cash flow performance relative tsr performance performance share awards relative tsr calculated twelve month averaging period using share follows comparator group comprising pharmaceutical companies vests plan psp median vesting upper quartile performance salary business diversification rd new product measures adjusted ceo free cash flow vests threshold rising stretching chairman rd performance exceeding set threshold specified margin cfo designate gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report total remuneration benchmarking decided executive director receive base salary committee reviews gsks total remuneration increase year dr moncef slaoui particular comparable companies regular basis ensure committee considered package context enhanced remuneration arrangements structured appropriately deliver role including transition responsibility biologicals value money shareholders longer term table immediately following sets current base salaries competitive relevant comparator groups determined proposed salary increases typically take effect individual executive st april year benchmarking purposes total remuneration incorporates base salary bonus ltis setting pay committee also base effective date base effective date salary salary salary salary change considers pension arrangements andrew witty ceo st april st april uk crossindustry comparator group global pharmaceutical comparator group julian heslop cfo st april angloamerican france sanofiaventis simon dingemans astrazeneca switzerland novartis cfo designate th january barclays roche holdings dr moncef slaoui chairman rd st april st april bg group uk astrazeneca bhp billiton usa abbott laboratories julian heslop retire board st march bp amgen simon dingemans joined board th january british american tobacco bristolmyers squibb variable pay diageo eli lilly hsbc johnson johnson significant proportion gsks total remuneration package reckitt benckiser merck approximately variable particular royal dutch shell pfizer emphasis longterm sharebased incentives order closely rio tinto align executives interests shareholders standard chartered balance fixed base salary variable annual tesco bonus lti elements remuneration varies depending unilever performance charts show anticipated mix vodafone fixed variable pay expected value basis current remuneration policy excluding pensions actual mix amgen included benchmarking since may higher lower depending performance gsk current tsr comparator group individual base salary base salaries set reference relevant comparator group level considered appropriate secure retain ceo talent needed deliver gsks strategic priorities salary levels reviewed annually influenced salary executives role experience pay environment cash bonus deferred bonus including match committee decides individual executive basis whether performance shares primary pay comparator global pharmaceutical sector ukbased large crossindustry multinationals andor comparator groups uk global primary comparator group crossindustry pharmaceutical cfo designate andrew witty ceo cid salary julian heslop cfo cid cash bonus di rm mon nd ci en fg se lm aoa un c c hf ao ir mde ni g rn de cid cid deferred bonus includ ing match performance shares julian heslop retire board st march simon dingemans joined board th january committee considered prevailing economic conditions market competitiveness executive directors chairman rd package positioning relativities pay across broader gsk workforce agreed andrew witty salary salary would held levels cash bonus deferred bonus including match performance shares gsk annual report pp noitarenumer dna ecnanrevog remuneration report safeguards risk management committee would want reward failure views group profit interest important incentive payouts made circumstances tax performance outcome reflects genuine achievement original targets stretching financial addition given nature gsks business annual targets increased focus risk within group committee taken number steps ensure design incentive bonus business unit operating profit arrangements underpins effective risk management chairman audit risk committee member committee provides input audit risk committees review groups performance oversight risk factors relevant remuneration matters considered committee individual objectives annual bonus year committee reviews ongoing financial impact prior year activities role individual executives activities committee may majority annual bonus opportunity based make appropriate adjustments individual bonus awards formal review performance stretching financial reflect circumstances clawback mechanism targets based group profit interest tax business committee ensures continuity unit operating profit targets remainder based executive responsibility initiation adverse event achievements specific individual objectives emergence problem adverse event taken significant weighting towards financial performance account assessing annual bonuses year problem measures committee decided profit remain identified accordingly charges legacy legal matters key financial metric one companys key performance excluded assessment financial performance indicators however committee intends review reflects view committee current management annual bonus plan ensure strategic alignment gsks responsible legal actions shortterm incentives supported seeking resolve matters long term annual bonuses calibrated reflect stretching targets interests shareholders established drive significant changes gsks longterm incentive plans approved shareholders business model bonus threshold target committee may reduce grant vesting levels maximum payable achievement target determines participant engaged conduct bonus threshold reflects stretching nature contrary legitimate expectations company bonus targets employee participants position bonus targets andrew witty set board january also safeguards relating business year setting objectives andrew witty board specific performance measures longterm incentive focuses strategies developed plans outlined detail company set annual report reasons commercial sensitivity specific objectives addition committee decided longterm kept confidential following end financial year board incentive awards good leavers normally vest reviews performance generally set objectives end original vesting period set grant rather vesting committee determines bonus payable year departure ensures continued alignment shareholders interests following cessation employment executives andrew witty sets objectives line company strategy makes recommendations annual bonus committee regarding performance objectives annual bonus designed drive achievement gsks end year recommendations considered annual financial strategic business targets delivery committee determining level bonuses payable personal objectives bonus measures rd employees including dr moncef slaoui ontarget bonus executive directors given linked pipeline robust governance structure table established ensure bonus payable fairly reflects rd ontarget bonus base salary productivity performance well performance profit targets process requires review progress targets andrew witty ceo rd bonus compensation review committee simon dingemans cfo designate includes andrew witty companys two nonexecutive dr moncef slaoui chairman rd directors designated scientific experts professor sir roy anderson dr daniel podolsky committee reviewed maximum bonuses set reference individual ontarget plans operation year decided bonus levels cap bonus payments continue annual bonus rd committee salary cap remains unchanged annual bonus continue keep operation review pensionable gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report longterm incentive plans table shows award levels february awards made executives following executive director line policy longterm incentive plans approved shareholders agm award level award base salary deferred annual bonus plan andrew witty ceo shares simon dingemans b performance share plan cfo designate shares awards share option plan longer dr moncef slaoui granted executives instead cet members receive additional chairman rd ads performance share awards also eligible participate deferred annual bonus plan performance measures following appointment andrew witty board typically awards delivered us resident executives form carried thorough review gsks key strategic priorities ads awards delivered form ordinary shares described annual report board executives resident uk countries awards firmly believes delivery objectives transform made plans incorporate dilution limits consistent gsk organisation deliver longterm financial guidelines provided association british insurers current performance shareholder value creation sustainable estimated dilution existing awards gsk employee basis last years focus committee share plans made last years approximately improve alignment executive remuneration companys issued share capital st december arrangements priorities incentivise management provide closer link shareholder returns payments deliver goals executives notional dividends reinvested paid awards made executives february proportion shares deferred vesting awards value therefore introduced two new businessspecific performance reinvested dividends incorporated benchmarking measures business diversification rd new product award levels performance addition adjusted free cash flow structure performance measures relative tsr measures order ensure deferred annual bonus plan balanced framework measures focusing gsks deferred annual bonus plan encourages longterm strategic objectives outlined diagram shareholding discourages excessive risk taking helps awards vest subject performance end focus gsks key strategic priorities threeyear performance period beginning st january starting bonus year cet members ending st december based four equally eligible participate plan weighted measures business diversification rd new product adjusted free cash flow relative tsr annual bonus earned may deferred three years company match shares oneforone depending strategy remuneration companys performance measures outlined threeyear performance period key strategic lti performance measures b performance shares priorities year performance period award performance share plan ensures focus delivery grow diversified gsks strategic priorities longterm shareholder returns business diversification global business relative pharmaceutical companies deliver performance share plan awards made vest rd new product products value end threeyear performance period subject achievement companys performance measures simplify outlined operating model adjusted free cash flow individual award limit maximum initial value deliver value performance shares may granted individual shareholders relative tsr one year exceptional circumstances maximum face value performance shares may granted individual one year six times base salary details performance measures targets thresholds longterm incentive awards given following table gsk annual report pp noitarenumer dna ecnanrevog remuneration report longterm incentive measures awards award vesting schedule awards business diversification performance due commercial sensitivity targets business incentivises growth global diversified business diversification rd new product measures disclosed along outcomes remuneration designed focus major growth areas vaccines report consumer healthcare emerging markets japan excluding vaccines dermatology businesses proportion threshold proportion award achieved available aggregate revenue target four business divisions threshold threeyear performance period reflects strong growth threshold previous periods market growth maximum rd new product performance target maximum performance expressed recognises importance rd future business growth percentage threshold two measures shown revenue target based new product sales incentivise maximum expressed better rd performance measure threshold new products defined products launched performance business period two preceding years therefore diversification performance period products launched years included measurement rd new product aggregate threeyear revenue target awards new product sales reflects growth historic performance adjusted free cash flow three year adjusted free cash flow targets vesting recognises importance effective working capital threshold cash management threshold billion billion billion maximum billion relative tsr proportion vesting focuses delivery value shareholders relative tsr using comparator group comprising global pharmaceutical companies move four complementary measures relative tsr measured three years line performance period performance measures measure performance stable basis better reflect longterm nature pharmaceutical industry twelvemonth averaging period used relative tsr tsr rank position median performance upper quartile performance gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report board believes current strategic priorities pensions fundamental longterm objectives however recognises pensions provide important tool creating longterm possibility goals may evolve time therefore culture loyalty committee intends review longterm incentive performance executives participate gsk senior executive pension plans measures periodically ensure remain appropriate pension arrangements structured accordance inevitably measures linked directly strategy sensitive plans operated executives country particular committee consider appropriate likely retire details individual arrangements executive disclose targets business diversification rd new directors set product performance grant may result competitive harm new executives gsk eligible either defined however committed fully disclosing targets contribution scheme cash balance pension plan end performance period together details extent existing obligations defined benefit schemes uk performance targets met addition continue honoured committee also commits providing update achievement date targets performance period uk pension arrangements company currently operates defined contribution plan addition setting robust targets committee also legacy final salary plans closed new entrants implemented number safeguards ensure targets newly hired executives uk participate defined met sustainable way performance outcome contribution plan reflects genuine achievement original targets therefore value shareholders uk government announced series changes pensions initially impact pensions approximately business diversification rd new product measures people gsk pension legislation significant light significant event including acquisitions negative consequences effectiveness pensions divestments committee review target payment much reduced pensions continue scale make adjustments considers appropriate important tool creating longterm culture promoting maintain integrity original targets addition employee retention therefore committee decided committee reserves right reduce vesting levels targets existing pension promises honoured pensions achieved manner undermines overall health new limits delivered via gsks existing unfunded scheme business executives participating defined contribution plan receive committee normally include revenue company contribution base salary depending opportunistic events pandemics assessing grade also opportunity receive performance business diversification rd new matched contributions line policy product measures recognised successful response members pension plan event pandemic generate significant value shareholders responses usually require supply capacity andor legacy final salary plans provide twothirds final resource diverted products however salary age employees subject cap benefits including revenue committee must satisfied excess cap currently provided unfunded decision pursue opportunistic revenue clearly arrangements legacy final salary plans actuarial best interests shareholder value creation otherwise reduction factors apply participant leaves employment performance relevant measure sufficiently positive hisher accord age ultimately committee expect management acted employment terminated company cause way enhanced shareholder value way members legacy final business diversification measure market salary plans reduction factors apply growth achieved end performance period b us pension arrangements committee normally reduce vesting levels usa gsk operates us cash balance plan provides part groups strategy increase return rd annual contribution interest sum accumulated investment rd new product revenue target achieved cash balance plan contractual promise provide committee determines insufficient progress specific levels retirement income plan incorporates made measurement period increasing return executive pension credit senior us executives contribution rd investment committee may reduce level vesting rates plan range base salary rd new product measure depending grade current senior us executives eligible adjusted free cash flow measure target may executive pension credit adjusted material factors could distort free cash flow capped employees usa benefits cap performance measure typically include exchange provided unfunded nonqualified plan rate movements may also include legal major taxation settlements special pension contributions could materially distort calculation impact acquisition divestment quantified adjusted event major adjustments calculation disclosed shareholders gsk annual report pp noitarenumer dna ecnanrevog remuneration report share ownership requirements variable pay performance periods ended align interests executives st december shareholders executives required build section provides details performance maintain significant holdings shares gsk time achieved companys annual bonus longterm current share ownership requirements sor set incentive plans performance periods ended table st december annual bonus share ownership requirement majority annual bonus based ceo x base salary achievement financial targets based group profit executive directors x base salary interest tax business unit operating profit cet members x base salary individual performance achievement additional operational efficiency goals also taken account determining executives required continue satisfy shareholding annual bonus levels requirements minimum twelve months following retirement company support longterm nature business objectives set company focused particular shareholdings purpose sor th february continued development launch late stage pipeline assets delivery commercial targets execution restructuring programmes simplify operating model holding holding ordinary shares ordinary shares despite challenging year gsk sor purposes sor purposes increase pharmaceutical industry due effect generic competition shareholding usa rapid loss sales avandia following regulatory andrew witty decisions autumn us healthcare reform significant julian heslop legacy litigation costs management achieved key financial simon dingemans strategic objectives including dr moncef slaoui delivering underlying sales growth excluding pandemic shares sold tax following vesting psp awards products avandia valtrex excluded disclosure simon dingemans date joined board strong sales performance investment areas business th january particularly emerging markets consumer healthcare remuneration elements increasing rd pipeline potential achieving key milestones transformation rd productivity particularly relation executives participate various allemployee share plans late stage rd pipeline products either uk usa simplification gsks business model improved cash sharesave plan sharereward plan uk hm revenue generation legal settlements achievement customs approved plans open uk employees uk operational efficiencies based executive directors terms overall committee took account gsks success sharesave participants may save month achieving objectives well individuals net salary fixed term three years end performance determining bonus awards savings period option buy gsk shares however management fully achieve group discount market price set launch profit interest targets set bonuses plan andrew witty julian heslop sharesave members determined accordingly actual bonus payments executive contribute month plan provides directors shown ranged option buy shares end three base salaries st december year savings period sharereward participants contribute month gross salary purchase gsk shares company annual bonus annual bonus matches number gsk shares bought month change arrangement shares held trust left andrew witty five years removed free uk tax national julian heslop insurance contributions andrew witty julian heslop simon dr moncef slaoui dingemans contribute month buy shares sharereward plan following executive directors elected participate executives also receive benefits including healthcare deferred annual bonus plan respect matching awards medical dental personal financial advice life assurance may vest february subject continued employment cash value benefits received executive directors achievement longterm incentive performance measures shown dr moncef slaoui normally resides outlined report usa seconded uk two year period st november enable closer executive total bonus deferred award matching award gsk biologicals assumes operational responsibility andrew witty shares shares business dr moncef slaoui ads ads gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report longterm incentive plans executive director terms conditions performance share plan vesting awards executive director contracts committee reviewed performance criteria policy set provides framework contracts performance share plan awards granted executive directors executive directors threeyear performance period starting st january ending st december notice period calendar months company ranked median position comparator group termination companies therefore awards vested employing company executive awards made senior executives dependent part relative tsr performance part eps termination payment x annual salary performance eps portion awards vest payable termination vesting schedules awards vesting ltis rules relevant incentive plan shown approved shareholders share options vesting awards pension based existing arrangements share option awards granted executives based terms relevant pension plan eps performance performance conditions awards met result awards lapsed noncompete clause months termination notice date details subsisting options performance conditions attached grant provided audited section ability impose month noncompete period nonsolicitation report restriction executive considered important company order ability protect groups intellectual property staff light historical vesting gsks ltis committee believes would appropriate provide gsks lti performance conditions continue challenging mitigation contracts demonstrated table relative tsr important part lti measures many years measure andrew witty dr moncef slaoui agreed retained current remuneration policy amendment contractual terms remove entitlement bonus part termination package contracts following table shows vesting levels gsks new executives normally include bonus element performance share share option awards executives since termination payment tsr vesting percentage indicates gsks relative tsr performance median comparator group terms new contracts seek balance commercial performance period imperatives best practice company considers important individual work elsewhere performance share share option notice period may make compensatory payment respect plan plan bonus period restraint vesting vesting tsr eps performance period measure measure julian heslop retiring early company st march terms contract entered entitled receive one years notice termination payment include one years annual salary months ontarget bonus simon dingemans joined board th january cfo designate become cfo st april following average annual vesting julian heslops retirement line companys policy going forward simon dingemans contract provides termination award made due change payment based one years base salary award cycle gsk annual report pp noitarenumer dna ecnanrevog remuneration report following table sets details executive directors terms engagement nonexecutive directors service contracts sir christopher gent also set letters appointment nonexecutive directors initial appointment current directors date contract effective date expiry date subsequent reappointment subject election thereafter andrew witty th june nd may st august periodic reelection shareholders julian heslop th march st april st january letters appointment nonexecutive directors simon dingemans th september th january th april contain provision notice periods compensation dr moncef slaoui st december st december st august appointments terminated andrew wittys contract renewed june following appointment following table shows date initial letter ceo amended th february reflect changes appointment nonexecutive director severance terms outlined dr moncef slaouis previous contract dated th may replaced st december reflect changes severance terms outlined nonexecutive director date letter appointment sir christopher gent th may termination payments made respect part professor sir roy anderson th september notice period extending beyond contract expiry date dr stephanie burns th february larry culp th june entitlements sir crispin davis th june addition contractual provisions outlined sir deryck maughan th may event executive directors service agreements terminated james murdoch th february employing company following apply dr daniel podolsky rd july case outstanding awards glaxosmithkline tom de swaan st december annual investment plan closed new deferrals sir robert wilson th june effect first quarter provided agreement terminated cause executive chairman nonexecutive directors fees must exercise bonus investment rights within six months company aims provide chairman nonexecutive termination receive deferred amounts income directors fees competitive paid gains companies equivalent size complexity subject limits contained gsks articles association line policy applicable us senior executives dr moncef slaoui may become eligible future date chairmans fees currently per annum plus receive continuing medical dental insurance retirement allocation shares value per annum following merger participants legacy share option nonexecutive directors fees applying st december schemes elected exchange legacy options options follows gsk shares received additional cash benefit equal grant price original option additional benefit per annum triggered option exercised lapsed qualify standard annual cash retainer fee additional cash benefit participants retain options least second anniversary effective date supplemental fees merger following payments made chairman audit risk committee payments due arrangement senior independent director outside appointments executive directors scientificmedical experts outside appointments considered nominations committee ensure would cause conflict interest chairmen remuneration corporate approved chairman behalf board responsibility committees companys policy remuneration earned nonexecutive director undertaking appointments may kept individual executive director intercontinental travel meetings per meeting chairman nonexecutive directors sir christopher gent current chairman corporate responsibility committee receive additional fee listed terms conditions sir christopher gents letter appointment dated th may agreed would serve company deputy chairman st december st january chairman conclusion agm following third anniversary appointment extended term three years mutual agreement effect reelection director agm held st may extended period five years subject reelection effect st january details provided corporate governance report gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report reflect increased focus within company compliance tsr performance graph risk gsk significantly enlarged remit responsibilities following graph sets performance company audit risk committee commitment required relative ftse index company tom de swaan chairman company agreed constituent pharmaceutical performance comparator time requirement role committee chairman moving group st january st december graph approximately days approximately days per annum prepared accordance regulations defined reflected increase fees payable indication likely vesting awards following independent review supplemental fee granted companys incentive plans chairman audit risk committee increased tsr performance per annum per annum effect st october full details current committees terms reference gsks audit assurance model given pages recent years increase time commitment demands responsibility placed role nonexecutive director generally led increase fees result developments market nonexecutive director fees gsk independently reviewed review highlighted scope increase nonexecutive director fees however light current environment board decided increase fees time continue kept review exchange rate glaxosmithkline total return index fees paid us dollars converted following glaxosmithkline pharma peers return index exchange rates ftse total return index exchange rate date approval period rate applied us th july us th march us rd december us us us given fluctuations sterling us dollar exchange rate agreed effect st october exchange rate would set annually based average daily rate last quarter year prior payment rate would reviewed exchange rates moved significantly year nonexecutive directors share allocation plan enhance link directors shareholders gsk requires nonexecutive directors receive significant part fees form shares least nonexecutive directors total fees excluding chairman paid form shares ads allocated share account non executive directors may also take opportunity invest part balance fees share account shares ads notionally awarded non executive directors allocated interest accounts included within directors interests tables wthe accumulated balance shares ads together notional dividends subsequently reinvested paid nonexecutive directors retirement board upon retirement nonexecutive directors receive either shares ads cash amount equal value shares ads date retirement date payment later gsk annual report pp noitarenumer dna ecnanrevog remuneration report annual remuneration total total fees annual annual fees annual annual salary benefits bonus remuneration salary benefits bonus remuneration footnote executive directors andrew witty abce julian heslop ab dr moncef slaoui cde nonexecutive directors professor sir roy anderson sir crispin davis sir christopher gent james murdoch f tom de swaan sir robert wilson dr stephanie burns larry culp sir deryck maughan dr daniel podolsky former directors dr michle barzach g sir ian prosser h dr ronaldo schmitz h dr jeanpierre garnier b total remuneration analysed executive directors nonexecutive directors former directors total remuneration remuneration directors us payroll reported dollars dollar amounts included totals based conversion sterling average exchange rates year andrew witty julian heslop participate salary sacrifice schemes b following merger order encourage employees convert nonsavings related options held legacy shares ads options glaxosmithkline shares ads employees granted additional cash benefit equal grant price original option additional benefit known exchange offer incentive payable new option exercised lapsed underwater qualify additional cash benefit participants retain options least second anniversary effective date merger year andrew witty received julian heslop received dr jeanpierre garnier received result options granted lapsing payments made c andrew witty dr moncef slaoui elected participate gsks deferred annual bonus plan respect bonuses andrew witty also participated dr moncef slaoui eligible participate year dr moncef slaoui nonexecutive director agency science technology research astar respect received included e benefits andrew witty dr moncef slaoui restated reflect certain elements remuneration longer deemed benefit f james murdoch appointed board effect th may g dr michle barzach received fees cidnil cid gsk france healthcare consultancy provided included within fees salary h sir ian prosser dr ronaldo schmitz retired nonexecutive directors company th may leaving board sir ian prosser dr ronaldo schmitz received accumulated balance shares previously awarded nonexecutive directors share arrangements based share price payment date final payment respect balance sir ian prosser made details set table included within fees salaries none directors received reimbursement expenses year requiring separate disclosure required regulations gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report nonexecutive directors fees total cash sharesads total cash sharesads fees current nonexecutive directors professor sir roy anderson sir crispin davis sir christopher gent james murdoch tom de swaan sir robert wilson dr stephanie burns larry culp sir deryck maughan dr daniel podolsky former nonexecutive directors sir ian prosser dr ronaldo schmitz total remuneration table sets remuneration received nonexecutive directors company nonexecutive directors required take least part total fees form shares allocated share account paid retirement board see details total value shares ads date award together cash payment forms total fees included within annual remuneration table fees salary table sets value fees received form cash shares ads table sets accumulated number shares ads held nonexecutive directors relation fees received board members st december together movements accounts year number shares ads allocated dividends nonexecutive directors share arrangements st december elected reinvested paid st december current nonexecutive directors shares professor sir roy anderson sir crispin davis sir christopher gent james murdoch tom de swaan sir robert wilson ads dr stephanie burns larry culp sir deryck maughan dr daniel podolsky former nonexecutive directors shares sir ian prosser gsk annual report pp noitarenumer dna ecnanrevog remuneration report table sets settlement former nonexecutive directors share arrangements leaving board value value date awards awards payments payments footnote leaving allocation leaving sir ian prosser ab changes value awards allocation leaving subsequent payment attributable dividends reinvested change share price award b awards sir ian prosser nonexecutive directors share arrangements partially settled shares balance shares settled directors interests following interests directors company connected persons shown accordance fsa listing rules shares ads th february st december st january th february st december st january footnote executive directors andrew witty ad simon dingemans b julian heslop ad dr moncef slaoui cd nonexecutive directors professor sir roy anderson e dr stephanie burns e larry culp e sir crispin davis e sir christopher gent e sir deryck maughan e james murdoch e dr daniel podolsky e tom de swaan e sir robert wilson e one glaxosmithkline ads represents two glaxosmithkline shares interests abovementioned directors th february reflect change yearend date includes shares purchased glaxosmithkline sharereward plan andrew witty totalling st december st december shares th february julian heslop totalling st december st december shares th february b simon dingemans joined board th january c includes ads purchased glaxosmithkline stock fund within us retirement savings plan us executive supplemental savings plan performance share plan vesting conditions approved th february detailed however shares vest th february included totals e includes shares ads received part fees described nonexecutive directors share allocation plan dividends received shares ads converted shares ads st december gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report longterm incentive plans share option plan awards options shares granted st december st december footnote date grant exercise period grant price number lapsed andrew witty julian heslop dr moncef slaoui options ads granted st december st december date grant exercise period grant price number lapsed dr moncef slaoui details include change dr slaouis connected person also employee gsk options outstanding st december earliest latest vesting lapse dates options market price glaxosmithkline share yearend given table weighted average vesting date lapse date andrew witty grant price number earliest latest earliest latest options market price yearend vested options market price yearend vested unvested total share options st december weighted average vesting date lapse date julian heslop grant price number earliest latest earliest latest options market price yearend vested options market price yearend vested unvested total share options st december weighted average vesting date lapse date dr moncef slaoui grant price number earliest latest earliest latest options market price yearend vested options market price yearend vested total share options st december options market price yearend vested unvested options market price yearend unvested total ads options st december includes share options held dr moncef slaouis connected person also employee gsk gsk annual report pp noitarenumer dna ecnanrevog remuneration report gsk granted share options executive directors annual basis directors hold options various share option plans referred note financial statements employee share schemes none nonexecutive directors interest option companys shares table sets share options granted performance periods performance targets whether options vested st december performance target vesting status annualised growth percentage grant footnote performance period st december eps award vesting february unvested rpi rpi rpi rpi rpi performance targets share options met result lapsed third anniversary date grant table sets share options granted respect performance period targets performance target vesting status annualised growth percentage grant performance period st december eps award vesting february award unvested rpi february award unvested rpi rpi rpi rpi highest lowest closing prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline ads year ended st december respectively market price glaxosmithkline share st december st december glaxosmithkline ads st december prices th february per glaxosmithkline share per glaxosmithkline ads performance share plan psp awards performance share awards made executive directors annual basis directors hold options various psp plans referred note financial statements andrew witty shares vested unvested market price additional unvested st number price shares st number december granted date market vested dividends december granted performance period grant number price gain lapsed reinvested julian heslop shares vested unvested market additional unvested st number price shares st december granted date market vested dividends december performance period grant number price gain lapsed reinvested gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report dr moncef slaoui ads vested unvested market additional unvested st number price shares st number december granted date market vested dividends december granted performance period grant number price gain lapsed reinvested includes performance shares held dr moncef slaouis connected person also employee gsk lapses performance periods relate change connected person simon dingemans shares vested unvested market additional unvested st number price shares st number december granted date market vested dividends december granted performance period grant number price gain lapsed reinvested terms psp number shares actually vesting determined following end relevant measurement period dependent gsks performance period described pages committee adjusted comparator group removing scheringplough wyeth following delisting revised vesting schedule accordingly outstanding future awards tsr performance measured revised comparator group including gsk set dividends reinvested performance shares awarded executives throughout performance period date final award dividend reinvestment calculated dividend payment date terms psp us participants may defer receipt part vested awards total gain vesting psp awards made executive directors connected persons following vesting schedules apply psp awards made tsr vesting schedule award award performance period tsr rank companies percentage award vesting median median following vesting schedules apply psp awards made tsr vesting schedule award award performance period tsr rank companies percentage award vesting median median adjusted free cash flow vesting schedule cash flow targets award award performance period bn percentage award vesting gsk annual report pp noitarenumer dna ecnanrevog remuneration report deferred annual bonus plan awards deferred annual bonus plan awards made executive directors annually based individuals voluntary bonus deferral election terms deferred annual bonus plan outlined andrew witty shares vested unvested market additional unvested st number price shares st number december granted date market vested dividends december granted performance period grant number price gain lapsed reinvested dr moncef slaoui ads vested unvested market additional unvested st number price shares st number december granted date market vested dividends december granted performance period grant number price gain lapsed reinvested share value plan awards dr moncef slaoui shares ads vested deferred unvested market unvested plan year st price st number december date market december granted grant number price gain executive director dr moncef slaoui eligible receive awards share value plan awards shown reflect holdings dr moncef slaouis connected person employee gsk awards subject threeyear vesting periods vesting contingent continued employment gsk pension benefits accrued annual pension benefits transfer values executive directors office st december retirement set companies act requires disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year fsas listing rules require additional disclosure change accrued benefit net inflation transfer value change pensions executive directors disclosed currency pension payable accrued change benefit accrued change personal transfer transfer accrued transfer value st benefit accrued contributions value value change benefit change december st december benefit made st december st december transfer year net accrued year year value inflation benefit executive directors andrew witty julian heslop dr moncef slaoui dr moncef slaoui cid cid cid cid cid cid cid shown net contributions made individual andrew witty julian heslop participate glaxo wellcome defined benefit plan accrual rate th final pensionable salary per annum benefits accrued glaxo wellcome uk pension arrangements augmented trustees plans reflect distribution surplus augmentation apply element andrew witty julian heslops pension earnings st march gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report transfer values andrew witty julian heslop directors senior management calculated accordance pensions regulation represent information also provided compensation interests present value potential payments pension plan directors senior management group group actuarial assumptions calculation changed since purpose group defined executive st december changes increased nonexecutive directors members cet financial transfer values increase andrew witty year total compensation paid members group increase julian heslop balance periods served capacity increase transfer value result increased valuation aggregate increase accrued pension benefits pension benefit accrued year reduced period net inflation aggregate payment service assumed retirement age defined contribution schemes dr moncef slaoui member us executive cash balance members group granted pension plan plan provides executive pension credit share options ads options share option plan gsk makes annual contributions calculated awarded shares deferred annual bonus percentage executives base salary gsk makes contributions plan shares ads performance base pay fund increases interest rate set share plan nil shares ads share value annually advance based year us treasury bond rate plan notional shares ads granted deferred provide cash sum retirement plan entitlement investment award plan members group spouses pension pension increases awarded reinvestment dividends transfer value cash sum increased shares ads performance share plan shares dr moncef slaoui year result accumulation deferred annual bonus plan notional shares interest contributions paid company deferred investment award plan dr moncef slaoui active participant belgium fortis th february group comprising persons owned plan st may plan defined benefit plan shares ads constituting less lump sum payable normal retirement age issued share capital company group also held plan transfer value cash sum dr moncef slaouis date options purchase shares plan increased cid year result ads shares ads awarded accumulation interest performance share plan including shares ads vested deferred vested deferred ads dr moncef slaoui member us retirement savings plan legacy smithkline beecham midterm incentive plan shares k savings scheme open us employees executive ads awarded share value plan shares supplemental savings plan savings scheme open executives ads deferred annual bonus plan accrue benefits us government limits imposed notional shares awarded deferred investment award retirement savings plan contributions plans invested plan holdings issued various executive share range funds value accumulated funds paid option plans described note financial statements retirement employee share schemes contributions paid basis preparation two schemes gsk respect dr moncef slaoui remuneration report prepared accordance directors interests contracts companies act large mediumsized companies groups accounts reports regulations except described note financial statements related regulations meets relevant requirements fsa party transactions end financial year listing rules accordance regulations following director connected person material interest sections remuneration report contract significance relation groups business subject audit annual remuneration nonexecutive directors group company remuneration incentive plans share options performance share plan awards vesting criteria share value plan awards pension benefits opinion thereon expressed remaining sections subject audit pages referred within audited sections remuneration report approved board directors signed behalf sir crispin davis remuneration committee chairman st march gsk annual report pp stnemetats laicnanif directors statement responsibilities directors statement responsibilities relation business review section contained annual report group financial statements includes fair review development performance business position group together directors responsible preparing annual report description principal risks uncertainties faces remuneration report group financial statements accordance applicable law regulations disclosure information auditors company law requires directors prepare financial statements directors office date report financial year law directors required confirmed prepare group financial statements accordance far aware relevant audit information international financial reporting standards ifrs adopted companys auditors unaware european union preparing group financial statements directors also elected comply ifrs issued taken steps ought international accounting standards board iasb company taken director make aware law directors must approve group financial statements relevant audit information establish companys unless satisfied give true fair view auditors aware information state affairs group profit loss group confirmation given interpreted accordance period provisions section companies act preparing financial statements directors required going concern basis select suitable accounting policies apply consistently business review pages contains information performance group financial position cash flows make judgements accounting estimates reasonable net debt position borrowing facilities information prudent including treasury risk management policies exposures market state group financial statements comply ifrs credit risk hedging activities given note adopted european union ifrs issued iasb financial statements financial instruments related disclosures subject material departures disclosed explained group financial statements making enquiries directors reasonable expectation group adequate resources continue directors responsible keeping adequate accounting operational existence foreseeable future reason records sufficient show explain companys continue adopt going concern basis preparing transactions disclose reasonable accuracy time financial statements financial position group enable ensure group financial statements remuneration report internal control comply companies act article ias board audit risk committee reviewed regulation also responsible safeguarding assets assessment risks internal control framework operates group hence taking reasonable steps prevention gsk considered effectiveness system internal detection fraud irregularities control operation group year covered report group financial statements year ended st december date approval board directors comprising principal statements supporting notes set financial statements pages combined code report board considers glaxosmithkline plc applies main responsibilities auditors relation group financial principles section combined code maintained statements set independent auditors report frc described corporate governance section pages complied provisions except disclosed group financial statements year ended st december included annual report published hard required fsas listing rules auditors considered copy printed form made available companys website directors statement compliance relation points directors responsible maintenance integrity combined code specified review annual report website accordance uk legislation governing preparation dissemination financial annual report statements access website available outside uk annual report year ended st december comparable legislation may different comprising report directors remuneration report current directors whose names functions listed financial statements additional information investors corporate governance section annual report approved board directors signed confirms best knowledge behalf group financial statements prepared accordance ifrs adopted eu ifrs issued sir christopher gent iasb give true fair view assets liabilities financial chairman position profit group st march gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp independent auditors report members glaxosmithkline plc audited group financial statements opinion matter prescribed glaxosmithkline plc year ended st december companies act comprise consolidated income statement consolidated opinion information given directors report statement comprehensive income consolidated balance financial year group financial statements sheet consolidated statement changes equity prepared consistent group financial statements consolidated cash flow statement related notes financial reporting framework applied matters required report preparation applicable law international financial reporting exception standards ifrs adopted european union nothing report respect following respective responsibilities directors companies act required report auditors opinion explained fully directors statement certain disclosures directors remuneration specified law responsibilities set directors responsible made preparation group financial statements satisfied give true fair view responsibility received information explanations audit express opinion group financial statements require audit accordance applicable law international standards listing rules required review auditing uk ireland standards require us comply auditing practices boards ethical standards auditors directors statement set relation going concern report including opinions prepared companys members body accordance chapter part corporate governance statement relating part companies act purpose companys compliance nine provisions june giving opinions accept assume responsibility combined code specified review purpose person report certain elements report shareholders board shown whose hands may come save expressly directors remuneration agreed prior consent writing matters scope audit financial statements reported separately parent company financial audit involves obtaining evidence amounts statements glaxosmithkline plc year ended st disclosures financial statements sufficient give reasonable december information directors assurance financial statements free material remuneration report described audited misstatement whether caused fraud error includes assessment whether accounting policies appropriate company passed resolution accordance section groups circumstances consistently applied companies act senior statutory auditors adequately disclosed reasonableness significant accounting name stated estimates made directors overall presentation financial statements opinion financial statements opinion group financial statements pricewaterhousecoopers llp chartered accountants statutory auditors g ive true fair view state groups affairs london st december profit cash flows year st march ended properly prepared accordance ifrs adopted european union prepared accordance requirements companies act article las regulation separate opinion relation ifrs issued iasb explained note group financial statements group addition complying legal obligation apply ifrs adopted european union also applied ifrs issued international accounting standards board iasb opinion group financial statements comply ifrs issued iasb gsk annual report pp stnemetats laicnanif consolidated income statement year ended st december results major major restructuring restructuring total notes turnover cost sales gross profit selling general administration research development operating income operating profit finance income finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p diluted earnings per share pence p calculation results major restructuring described note presentation financial statements consolidated statement comprehensive income year ended st december profit year exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement fair value movement subsidiary acquisition cash flow hedge reclassified goodwill actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp results results major major major major restructuring restructuring total restructuring restructuring total p p p p gsk annual report pp stnemetats laicnanif consolidated balance sheet st december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity approved board st march sir christopher gent chairman gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp consolidated statement changes equity year ended st december shareholders equity non share share retained controlling total capital premium earnings reserves total interests equity st january profit year comprehensive incomeexpense year distributions noncontrolling interests dividends shareholders ordinary shares issued ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december profit year comprehensive expenseincome year distributions noncontrolling interests changes noncontrolling interests put option noncontrolling interest dividends shareholders ordinary shares issued ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december profit year comprehensive income year distributions noncontrolling interests dividends shareholders ordinary shares issued ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december gsk annual report pp stnemetats laicnanif consolidated cash flow statement year ended st december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments purchase businesses net cash acquired investments associates joint ventures decrease liquid investments interest received dividends associates joint ventures proceeds disposal associates net cash outflow investing activities cash flow financing activities proceeds shares employee share options shares acquired esop trusts issue share capital purchase shares cancellation increase longterm loans increase shortterm loans repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders distributions noncontrolling interests financing cash flows net cash outflow financing activities decreaseincrease cash bank overdrafts exchange adjustments cash bank overdrafts beginning year cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements presentation financial statements estimated total cost approximately billion expanded programme expected deliver annual pretax savings description business approximately billion time substantially complete glaxosmithkline major global healthcare group given extent cost operational excellence engaged creation discovery development manufacture programme management believes material impact marketing pharmaceutical products including vaccines gsks operating results manner gsks overthecounter otc medicines healthrelated consumer business conducted gsk presents restructuring costs products gsks principal pharmaceutical products include incurred solely direct result operational excellence medicines following therapeutic areas respiratory programme separate column income statement titled antivirals including hiv central nervous system cardiovascular major restructuring urogenital metabolic antibacterials oncology emesis vaccines dermatologicals addition restructuring costs operational excellence programme major restructuring column income compliance applicable law ifrs statement includes restructuring costs incurred solely direct financial statements prepared accordance result restructuring programmes follow relate companies act article ias regulation material acquisitions operations acquired business international accounting standards ias international financial overlap extensively gsks existing operations reporting standards ifrs related interpretations adopted restructuring activities follow relate european union acquisitions nature undertaken operational excellence programme also carried financial statements also compliance ifrs issued following detailed formal plan management therefore considers international accounting standards board appropriate present costs restructuring activities composition financial statements manner billion million acquisition consolidated financial statements drawn sterling reliant pharmaceuticals december billion functional currency glaxosmithkline plc accordance billion acquisition stiefel laboratories july ifrs accounting presentation financial statements comprise acquisitions since october meet criteria set acquisitions costs incurred consolidated income statement direct result related restructuring programme consolidated statement comprehensive income included within major restructuring column consolidated balance sheet groups results costs operational excellence consolidated statement changes equity programme acquisitionrelated restructuring programmes consolidated cash flow statement meeting criteria described also presented separate column income statement described notes financial statements results major restructuring presentation accounting convention gsk intends apply consistently future major restructuring financial statements prepared using historical programmes material impact gsks operating results cost convention modified revaluation certain items manner gsks business conducted stated accounting policies adopted show clearly groups results costs restructuring programmes management financial period believes presentation assists investors gaining clearer financial statements cover financial year st january understanding groups financial performance st december comparative figures financial making projections future financial performance results years st january st december include costs virtue size nature limited appropriate st january st december comparative value presentation also consistent way composition group management assesses groups financial performance list subsidiary associated undertakings restructuring costs arise solely direct result opinion directors principally affected amount profit operational excellence programme restructuring net assets group given note principal programmes following relating acquisitions meeting group companies criteria described continue reported operating expenses within results major restructuring presentation restructuring costs october board approved implementation detailed formal plan gsk announced significant new operational excellence restructuring programme second formal plan representing significant expansion operational excellence programme approved board announced february expansion approved board announced february restructuring programme comprising detailed formal plans covers areas gsks business including manufacturing selling rd infrastructure gsk annual report pp stnemetats laicnanif notes financial statements presentation financial statements accounting principles policies continued consolidation accounting principles policies consolidated financial statements include preparation financial statements conformity assets liabilities results cash flows generally accepted accounting principles requires management company subsidiaries including esop trusts make estimates assumptions affect reported amounts groups share results net assets associates assets liabilities disclosure contingent assets joint ventures liabilities date financial statements reported amounts revenues expenses reporting period financial statements entities consolidated made actual results could differ estimates st december year financial statements prepared accordance entities group power govern groups accounting policies approved board financial operating policies accounted subsidiaries described note accounting principles policies group ability exercise joint control information application accounting policies entities accounted joint ventures group including areas estimation judgement given note ability exercise significant influence accounted key accounting judgements estimates appropriate associates results assets liabilities associates comparative figures reclassified ensure consistent joint ventures incorporated consolidated financial presentation current year information statements using equity method accounting implementation new accounting standards interests acquired entities consolidated date effect st january gsk implemented group acquires control interests sold deconsolidated ifrs revised business combinations ias revised date control ceases consolidated separate financial statements minor transactions balances subsidiaries eliminated amendments number accounting standards profit tax taken sales subsidiaries ifrs revised ias revised implemented products sold customers outside group prospectively restatement comparative information relevant proportion profits transactions joint revised accounting policy business combinations set ventures associates also deferred products sold note accounting principles policies acquisitions third parties deferred tax relief unrealised intragroup profit year discussed note acquisitions accounted extent considered recoverable disposals revisions ias impact goodwill capitalised separate item case subsidiaries current period part cost investment case joint ventures parent company financial statements associates goodwill denominated currency financial statements parent company glaxosmithkline operation acquired plc prepared accordance uk gaap uk cost acquisition fair value net accounting presentation company balance sheet presented assets acquired difference recognised directly accounting policies given income statement business combinations business combinations accounted using acquisition accounting method identifiable assets liabilities contingent liabilities acquired measured fair value acquisition date consideration transferred measured fair value includes fair value contingent consideration costs acquisition charged income statement period incurred equity subsidiary acquired non controlling interest recognised either fair value non controlling interests share net assets subsidiary casebycase basis changes groups ownership percentage subsidiaries accounted within equity gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements accounting principles policies continued expenditure expenditure recognised respect goods services received foreign currency translation supplied accordance contractual terms provision foreign currency transactions booked functional currency made obligation exists future liability respect group company exchange rate ruling date past event amount obligation reliably transaction foreign currency monetary assets liabilities estimated manufacturing startup costs validation retranslated functional currency rates exchange ruling achievement normal production expensed incurred balance sheet date exchange differences included advertising promotion expenditure charged income income statement statement incurred shipment costs intercompany transfers consolidation assets liabilities including related goodwill charged cost sales distribution costs sales customers overseas subsidiaries associates joint ventures translated included selling general administrative expenditure sterling rates exchange ruling balance sheet date restructuring costs recognised provided results cash flows overseas subsidiaries associates appropriate respect direct expenditure business joint ventures translated sterling using average rates reorganisation plans sufficiently detailed well exchange advanced appropriate communication affected exchange adjustments arising opening net assets undertaken profits year retained overseas subsidiaries associates research development joint ventures translated sterling less exchange differences research development expenditure charged income arising related foreign currency borrowings hedge statement period incurred development groups net investment operations taken separate expenditure capitalised criteria recognising asset component equity met usually regulatory filing made major translating sterling assets liabilities results market approval considered highly probable property plant cash flows overseas subsidiaries associates joint ventures equipment used research development capitalised reported currencies hyperinflationary economies depreciated accordance groups policy adjustments made material reflect current price levels environmental expenditure loss net monetary assets charged consolidated environmental expenditure related existing conditions resulting income statement past current operations current revenue future benefit discernible charged income statement revenue recognised income statement goods group recognises liability sitebysite basis services supplied made available external customers reliably estimated liability includes groups portion orders received title risk loss passed total costs also portion potentially responsible customer reliable estimates made relevant deductions parties costs probable able satisfy relevant obligations fulfilled respective shares cleanup obligation recoveries earnings process regarded complete reimbursements recorded assets virtually certain turnover represents net invoice value deduction legal disputes discounts allowances given accruals estimated provision made anticipated settlement costs legal future rebates returns methodology assumptions disputes group outflow resources used estimate rebates returns monitored adjusted considered probable reliable estimate made regularly light contractual legal obligations likely outcome addition provision made legal historical trends past experience projected market conditions expenses arising claims received disputes market conditions evaluated using wholesaler respect product liability claims related certain products thirdparty analyses market research data internally generated sufficient history claims made settlements information value added tax sales taxes excluded enable management make reliable estimate provision revenue required cover unasserted claims certain cases incurred reported ibnr actuarial technique used determine group copromotes product third party estimate records sale group records share revenue copromotion income within turnover nature copromotion group may become involved legal proceedings respect activities group records costs sales possible make reliable estimate expected pharmaceutical turnover includes copromotion revenue financial effect could result ultimate resolution million million million proceedings cases appropriate disclosure cases would included provision would made costs royalty income recognised operating income associated claims made group third parties accruals basis accordance terms relevant charged income statement incurred licensing agreements gsk annual report pp stnemetats laicnanif notes financial statements accounting principles policies continued leases leasing agreements transfer group substantially pensions postemployment benefits benefits risks ownership asset treated costs providing pensions defined benefit schemes finance leases asset purchased outright calculated using projected unit credit method spread assets included ppe computer software period benefit expected derived capital elements leasing commitments shown employees services consistent advice qualified obligations finance leases assets held finance leases actuaries pension obligations measured present value depreciated basis consistent similar owned assets estimated future cash flows discounted rates reflecting yields lease term shorter interest element lease rental high quality corporate bonds included income statement leases operating pension scheme assets measured fair value balance leases rental costs charged income statement sheet date actuarial gains losses differences straightline basis lease term expected actual returns assets effect changes goodwill actuarial assumptions recognised statement goodwill stated cost less impairments goodwill deemed comprehensive income year arise indefinite useful life tested impairment annually groups contributions defined contribution plans fair value interest acquired entitys assets charged income statement incurred costs liabilities contingent liabilities exceeds consideration paid postemployment liabilities calculated similar way excess recognised immediately gain income defined benefit pension schemes spread period statement benefit expected derived employees services accordance advice qualified actuaries intangible assets intangible assets stated cost less provisions amortisation employee share plans impairments incentives form shares provided employees share option share award schemes licences patents knowhow marketing rights separately acquired acquired part business combination fair values options awards calculated amortised estimated useful lives generally exceeding grant dates using blackscholes option pricing model charged years using straightline basis time income statement relevant vesting periods available use estimated useful lives determining group provides finance esop trusts purchase company amortisation charge take account patent lives shares open market meet obligation provide shares applicable well value obtained periods non employees exercise options awards costs running exclusivity asset lives reviewed appropriate esop trusts charged income statement shares held adjusted annually contingent milestone payments recognised esop trusts deducted reserves transfer point contingent event becomes certain made reserves retained earnings development costs incurred group associated vesting periods related share options awards reflect acquired licences patents knowhow marketing rights ultimate proceeds receivable employees exercise written income statement incurred unless criteria recognition internally generated intangible asset property plant equipment met usually regulatory filing made major property plant equipment ppe stated cost market approval considered highly probable purchase construction less provisions depreciation impairment financing costs capitalised within cost acquired brands valued independently part fair value qualifying assets construction businesses acquired third parties brand value substantial longterm brands depreciation calculated write cost less residual value either contractual legal nature sold separately ppe excluding freehold land using straightline basis rest businesses acquired brands amortised expected useful life residual values lives reviewed estimated useful lives years except appropriate adjusted annually normal expected useful considered useful economic life indefinite lives major categories ppe costs acquiring developing computer software freehold buildings years internal use internet sites external use capitalised leasehold land intangible fixed assets software site supports buildings lease term years significant business system expenditure leads plant machinery years creation durable asset erp systems software amortised fixtures equipment years seven years computer software three five years disposal ppe cost related accumulated depreciation impairments removed financial statements net amount less proceeds taken income statement gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements accounting principles policies continued trade receivables trade receivables carried original invoice amount less impairment noncurrent assets provisions doubtful debts provisions made carrying values noncurrent assets reviewed evidence risk nonpayment taking account ageing impairment indication assets might previous experience general economic conditions trade impaired additionally goodwill intangible assets indefinite receivable determined uncollectable written firstly useful lives intangible assets yet available use provision available income statement tested impairment annually provision impairment charged income statement year concerned subsequent recoveries amounts previously provided credited income statement longterm receivables impairments goodwill reversed impairment losses discounted effect material noncurrent assets reversed change estimates used determine recoverable amounts trade payables extent revised recoverable amounts trade payables held amortised cost equates exceed carrying values would existed net nominal value longterm payables discounted depreciation amortisation impairments recognised effect material investments associates joint ventures cash cash equivalents investments associates joint ventures carried cash cash equivalents comprise cash hand current balances consolidated balance sheet groups share net assets banks similar institutions highly liquid investments date acquisition postacquisition retained profits generally maturities three months less readily losses together goodwill arising acquisition convertible known amounts cash insignificant risk changes value availableforsale investments liquid investments investments classified available borrowings forsale investments initially recorded fair value plus borrowings initially recorded amount proceeds transaction costs remeasured subsequent reporting received net transaction costs borrowings subsequently dates fair value unrealised gains losses availableforsale carried amortised cost difference investments recognised directly comprehensive income proceeds net transaction costs amount due impairments arising significant prolonged decline fair redemption recognised charge income statement value equity investment reduce carrying amount period relevant borrowing asset directly charged income statement taxation disposal impairment investments gains current tax provided amounts expected paid losses deferred comprehensive income applying tax rates enacted substantively enacted reclassified income statement dividends equity balance sheet date investments recognised income statement deferred tax provided full using liability method groups right receive payment established equity investments temporary differences arising tax bases assets recorded noncurrent assets unless expected liabilities carrying amounts financial statements sold within one year deferred tax assets recognised extent probable purchases sales equity investments accounted future taxable profits available trade date purchases sales availableforsale temporary differences utilised deferred tax provided investments accounted settlement date temporary differences arising investments subsidiaries associates joint ventures except timing inventories reversal temporary difference controlled inventories included financial statements lower probable temporary difference reverse cost including raw materials direct labour direct costs foreseeable future deferred tax provided using rates tax related production overheads net realisable value enacted substantively enacted balance sheet cost generally determined first first basis prelaunch date deferred tax liabilities assets discounted inventory held asset high probability regulatory approval product point provision made carrying value recoverable amount provision reversed point high probability regulatory approval determined gsk annual report pp stnemetats laicnanif notes financial statements accounting principles policies continued key accounting judgements estimates derivative financial instruments hedging preparing financial statements management required derivative financial instruments used manage exposure make estimates assumptions affect amounts market risks principal derivative instruments used gsk assets liabilities revenue expenses reported financial foreign currency swaps interest rate swaps forward foreign statements actual amounts results could differ exchange contracts group hold issue derivative estimates following considered key accounting financial instruments trading speculative purposes judgements estimates made derivative financial instruments classified heldfortrading turnover carried balance sheet fair value derivatives designated revenue recognised title risk loss passed hedging instruments classified inception cash flow customer reliable estimates made relevant deductions hedges net investment hedges fair value hedges relevant obligations fulfilled earnings process regarded complete changes fair value derivatives designated cash flow hedges recognised comprehensive income gross turnover reduced rebates discounts allowances extent hedges effective ineffective portions product returns given expected given vary recognised profit loss immediately amounts deferred product arrangements buying groups arrangements comprehensive income reclassified income statement purchasing organisations dependent upon submission hedged item affects profit loss claims time initial recognition sale accruals made time sale estimated rebates net investment hedges accounted similar way cash discounts allowances payable returns made based flow hedges available market information historical experience changes fair value derivatives designated fair value amounts estimated may fully reflect hedges recorded income statement together final outcome amounts subject change dependent changes fair value hedged asset liability upon amongst things types buying group changes fair value derivative instruments product sales mix qualify hedge accounting recognised immediately level accrual reviewed adjusted regularly light income statement contractual legal obligations historical trends past experience discounting projected market conditions market conditions evaluated time effect money material balances discounted using wholesaler thirdparty analyses market research current values using appropriate rates interest unwinding data internally generated information future events could discounts recorded finance income finance costs cause assumptions accruals based change could affect future results group taxation current tax provided amounts expected paid deferred tax provided temporary differences tax bases assets liabilities carrying amounts rates enacted substantively enacted balance sheet date group open tax issues number revenue authorities gsk continues believe made adequate provision liabilities likely arise open assessments open issues exist ultimate liability matters may vary amounts provided dependent upon outcome negotiations relevant tax authorities necessary litigation proceedings gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements key accounting judgements estimates intangible assets continued intangible assets acquired gsk third parties costs acquisition capitalised licences compounds legal disputes development amortised point gsk provides anticipated settlement costs outflow available use estimated useful lives may resources considered probable reliable estimate may include periods nonexclusivity estimated useful lives made likely outcome dispute legal reviewed annually impairment tests undertaken events expenses arising claims group occur call question carrying values assets brands acquired businesses capitalised independently companys directors taken legal advice separable expected life established provisions taking account relevant one year brands amortised straightline basis facts circumstances matter accordance estimated useful lives exceeding years except accounting requirements respect product liability claims end useful economic life foreseen brands related certain products sufficient history claims made amortised subject annual impairment tests settlements enable management make reliable estimate provision required cover unasserted claims certain initial valuations valuations subsequent impairment cases incurred reported ibnr actuarial technique tests based established market multiples riskadjusted used determine estimate group may become involved future cash flows discounted using appropriate interest rates legal proceedings respect possible make future cash flows based business forecasts reliable estimate expected financial effect could therefore inherently judgemental future events could cause result ultimate resolution proceedings cases assumptions used impairment reviews change appropriate disclosure cases would included consequent adverse effect future results group provision would made st december provisions legal disputes amounted billion pensions postemployment benefits billion costs providing pensions postemployment benefits charged income statement accordance ultimate liability legal claims may vary amounts ias period benefit derived provided dependent upon outcome litigation employees services costs assessed basis proceedings investigations possible settlement negotiations assumptions selected management assumptions position could change time therefore include future earnings pension increases discount rates assurance losses result outcome expected long term rates return assets mortality legal proceedings exceed amount provisions rates disclosed note pensions reported groups financial statements material amount postemployment benefits property plant equipment expected long term rates return bonds determined set note property plant equipment carrying based portfolio mix indexlinked government values property plant equipment tested impairment corporate bonds equity risk premium added indication values assets might equities impaired impairment determined reference higher discount rates derived aa rated corporate bond yields fair value less costs sell value use measured assessing except countries deep market corporate riskadjusted future cash flows discounted using appropriate bonds government bond yields used sensitivity analysis interest rates future cash flows based business provided note pensions postemployment forecasts therefore inherently judgemental future events benefits reduction discount rate would lead could cause assumptions used impairment tests increase net pension deficit approximately change consequent adverse effect future results million increase annual pension cost group approximately million selection different assumptions goodwill could affect future results group goodwill arising business combinations capitalised allocated appropriate cash generating unit deemed indefinite life amortised annual impairment tests relevant cash generating units performed impairment tests based established market multiples riskadjusted future cash flows discounted using appropriate interest rates future cash flows based business forecasts therefore inherently judgemental future events could cause assumptions used impairment tests set note goodwill change consequent adverse effect future results group gsk annual report pp stnemetats laicnanif notes financial statements new accounting requirements exchange rates following new amended accounting standards ifric group uses average exchange rates prevailing interpretations issued iasb likely affect period translate results cash flows overseas future annual reports although current forms none subsidiaries joint ventures associated undertakings expected material impact results financial sterling period end rates translate net assets position group undertakings currencies influence translations relevant exchange rates amendment ias financial instruments presentation classification rights issues issued october implemented gsk st january amendment requires issue rights acquire additional average rates shares existing shareholders recognised equity us regardless currency shares euro yen iasbs annual improvements project published may changes effective st january period end rates project makes minor amendments number standards us areas including consolidation business combinations euro financial instruments yen ias revised related party disclosures issued november implemented gsk st january revised standard clarifies definition related party provides exemptions government related entities ifric extinguishing financial liabilities equity instruments issued november implemented gsk st january interpretation addresses accounting entity issues equity instruments order settle financial liability part full amendment ifric prepayments minimum funding requirement issued november implemented gsk st january amendment permits voluntary prepayment minimum funding requirement recognised asset following new standards interpretations yet endorsed eu ifrs financial instruments first issued november amended october implemented gsk st january standard eventually replace ias covers classification measurement derecognition financial assets financial liabilities iasb intends expand ifrs add new requirements impairment hedge accounting become complete replacement ias end amendment ifrs disclosures transfers financial assets issued october implemented gsk st january amendment requires additional disclosures regarding risk exposures relating transfers financial assets amendment ias deferred tax recovery underlying assets issued december implemented gsk st january amendment requires deferred tax nondepreciable assets measured using revaluation model calculated sale basis gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements segment information gsk revised segmental information disclosures reflect changes internal reporting structures effect st january viiv healthcare shown separate segment stiefel integrated gsk heritage dermatology business reported within relevant geographical pharmaceutical segments trading unallocated pharmaceuticals information combined addition responsibility certain products two small markets moved pharmaceuticals business consumer healthcare comparative information restated onto consistent basis gsks operating segments reported based financial information provided chief executive officer regarded chief operating decision maker codm responsibilities corporate executive team cet individual members cet responsible geographic regions pharmaceuticals business viiv healthcare consumer healthcare business whole respectively major restructuring geographic information regularly provided codm rd investment essential sustainability pharmaceutical businesses however segment reporting usa europe emerging markets asia pacificjapan regional pharmaceutical operating profits exclude allocations globally funded rd well central costs principally corporate functions unallocated manufacturing costs gsks management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis trading unallocated pharmaceuticals segment includes canada puerto rico central vaccine tender sales contract manufacturing sales together costs vaccines rd central dermatology costs central manufacturing costs attributed segments pharmaceuticals rd segment excludes vaccines rd responsibility chairman research development therefore reported separate segment corporate unallocated costs disposal profits include corporate functions costs legal matters fair value movements financial instruments investments unallocated profits asset disposals restated restated turnover segment us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals viiv healthcare trading unallocated pharmaceuticals pharmaceuticals turnover consumer healthcare turnover restated restated pharmaceutical turnover therapeutic area respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis vaccines dermatologicals viiv healthcare hiv consumer healthcare turnover category otc medicines oral healthcare nutritional healthcare gsk annual report pp stnemetats laicnanif notes financial statements segment information continued us pharmaceuticals viiv healthcare made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers segment profit restated restated us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals viiv healthcare pharmaceuticals rd trading unallocated pharmaceuticals costs pharmaceuticals operating profit consumer healthcare operating profit segment profit corporate unallocated costs disposal profits operating profit major restructuring major restructuring total operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation profit taxation year depreciation amortisation segment restated restated us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals viiv healthcare pharmaceuticals rd trading unallocated pharmaceuticals pharmaceuticals depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation depreciation amortisation major restructuring major restructuring total depreciation amortisation gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements segment information continued ppe intangible asset goodwill impairment segment restated restated us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals viiv healthcare pharmaceuticals rd trading unallocated pharmaceuticals pharmaceuticals impairment consumer healthcare impairment segment impairment corporate unallocated impairment impairment major restructuring major restructuring total impairment ppe intangible asset goodwill impairment reversals segment restated restated us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals viiv healthcare pharmaceuticals rd trading unallocated pharmaceuticals pharmaceuticals impairment reversals consumer healthcare impairment reversals segment impairment reversals corporate unallocated impairment reversals impairment reversals major restructuring major restructuring total impairment reversals gsk annual report pp stnemetats laicnanif notes financial statements segment information continued restated net assets segment us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals viiv healthcare pharmaceuticals rd trading unallocated pharmaceuticals pharmaceuticals net operating assets consumer healthcare net operating assets segment net operating assets corporate unallocated operating net assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale net assets trading unallocated pharmaceuticals segment includes assets centrally managed pharmaceutical vaccine manufacturing operations depreciation totalling million million million recovered standard cost product charged businesses geographical information uk regarded groups country domicile restated restated turnover location customer uk usa rest world external turnover turnover location subsidiary uk usa rest world turnover including intersegment turnover uk usa rest world intersegment turnover uk usa rest world external turnover gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements segment information continued operating profit location uk usa rest world total operating profit restated net operating assets location uk usa rest world net operating assets restated noncurrent assets location uk usa rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables major restructuring programme october gsk announced significant new operational excellence programme improve effectiveness productivity operations significant expansion operational excellence programme approved board announced february expansion approved board announced february total approved costs implementation expanded programme increased billion approximately billion period approximately costs incurred st december approximately expected incurred balance total approximately costs expected cash expenditures expected asset writedowns uncertainties exist exact amount timing cash outflows result potential future exchange rate fluctuations many elements restructuring programme subject employee consultation procedures making difficult predict precision procedures completed however majority remaining cash payments expected made programme remains track deliver total annual pretax savings billion savings realised across business total restructuring costs million incurred million incurred operational excellence programme following areas c ost saving projects rd focused primarily simplification streamlining support infrastructure including site rationalisations principally verona italy harlow tonbridge uk adoption customised sales approaches leading staff reductions number sales forces principally usa france italy closure number manufacturing sites including dartford crawley uk giving rise asset writedowns staff reductions projects simplify eliminate processes leading staff reductions administrative support functions remaining costs million incurred year restructuring programme related integration stiefel laboratories inc business usa following acquisition july gsk annual report pp stnemetats laicnanif notes financial statements major restructuring programme continued analysis costs incurred programmes follows asset staff impairment reductions costs total cost sales selling general administration research development effect operating profit net finance expense effect profit taxation effect taxation effect earnings asset staff impairment reductions costs total cost sales selling general administration research development effect operating profit net finance expense effect profit taxation effect taxation effect earnings asset staff impairment reductions costs total cost sales selling general administration research development effect operating profit net finance expense effect profit taxation effect taxation effect earnings asset impairments million million million net costs totalling million million million noncash items principally accelerated depreciation charges settled cash include termination leases site closure costs consultancy project management fees gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements major restructuring programme continued restructuring costs reported major restructuring column income statement income resulting minor restructuring activity initiated prior october amounted million million cost million cost incomecost reported within results major restructuring costs major restructuring programmes arisen follows increase provision major restructuring programmes see note amount provision reversed unused see note impairments losses recognised foreign exchange gainloss recognised liquidation subsidiary noncash charges cash costs net finance expense effect profit taxation noncash charges principally accelerated depreciation arising asset lives shortened result major restructuring programmes cash costs include termination leases site closure costs consultancy project management fees operating income royalty income milestone income impairment equity investments disposal equity investments disposal assets asset rights legal settlements gain recognised creation viiv healthcare fair value movements derivative financial instruments income royalty milestone income principally core recurring income outlicensing intellectual property gsk annual report pp stnemetats laicnanif notes financial statements operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals amortisation intangible assets impairment intangible assets goodwill net reversals net foreign exchange lossesgains inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration fees payable companys auditor associates audit parent company consolidated financial statements audit accounts groups uk overseas subsidiaries pursuant legislation assurance services pursuant legislation including attestation sarbanesoxley act audit assurance services tax services services including regulatory compliance treasury related services st december amount due pricewaterhousecoopers llp associates fees yet invoiced million comprising statutory audit million taxation services million services million addition fees paid respect gsk pension schemes audit services gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities wages salaries decreased cer terms group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans finance income interest income arising cash cash equivalents availableforsale investments derivatives fair value profit loss loans receivables realised gains liquid investments fair value movements derivatives fair value profit loss net investment hedge ineffectiveness unwinding discounts assets derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest income arising derivatives fair value profit loss relates swap interest income gsk annual report pp stnemetats laicnanif notes financial statements finance costs interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value movements derivatives designated hedging instruments fair value adjustments hedged items fair value movements derivatives fair value profit loss reclassification cash flow hedge comprehensive income unwinding discounts provisions net investment hedge ineffectiveness finance expense derivatives fair value profit loss except designated effective hedging instruments classified heldfortrading financial instruments ias associates joint ventures associates share tax profits quest diagnostics inc share tax profits aspen pharmacare holdings limited share tax losses associates share tax lossesprofits joint ventures share turnover joint ventures sales joint ventures associates summarised income statement information respect groups associates set total turnover quest diagnostics inc aspen pharmacare holdings limited others total profit quest diagnostics inc aspen pharmacare holdings limited others results aspen pharmacare holdings limited included summarised income statement information represent estimated earnings aspen group period subsequent yearend gsk sold entire shareholding quest diagnostics inc gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements taxation taxation charge based profits year uk corporation tax uk statutory rate less double taxation relief overseas taxation current taxation deferred taxation reconciliation taxation rate group profits uk statutory rate taxation differences overseas taxation rates benefit special tax status rd credits intercompany stock profit impact share based payments tax profit associates losses benefit recognised permanent differences prior year items restructuring tax rate higher tax rate year ended st december reflects impact relatively low tax relief arising billion legal provisions charged year nondeductibility costs associated certain site closures partly offset settlement certain historical tax matters percentages within reconciliation exacerbated relatively low reported profit group operates countries tax rate differs uk tax rate impact overseas taxes overall rate tax shown profits arising certain operations singapore accorded special status taxed reduced rates compared normal rates tax territory effect reduction taxation charge increased earnings per share p p p group required ifrs create deferred tax asset respect unrealised intercompany profit arising inventory held group yearend applying tax rate country inventory held rather tax rate country profit originally made tax paid practice uk us gaap result difference accounting treatment group tax rate current period intercompany profit ifrs increased increase increase arising changes location workin progress finished goods tax items charged equity statement comprehensive income current taxation share based payments foreign exchange movements deferred taxation share based payments defined benefit plans fair value movements cash flow hedges fair value movements availableforsale investments total chargecredit equity statement comprehensive income items charged statement comprehensive income except tax share based payments gsk annual report pp stnemetats laicnanif notes financial statements taxation continued issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax resolution issues continuing fact life gsk year gsk agreed settled open years major tax authorities including canada federal court appeal overturned judgement tax court canada respect gsks transfer pricing early remanded case back tax court reconsideration parties seeking leave appeal supreme court canada gsk continues believe made adequate provision liabilities likely arise periods open yet agreed tax authorities ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate provision made taxation would arise distribution profits retained overseas subsidiaries grounds group able control timing reversal temporary differences probable reverse foreseeable future aggregate amount unremitted profits balance sheet date approximately billion billion deferred tax unremitted earnings st december estimated million million relates taxes payable repatriation dividend withholding taxes levied overseas tax jurisdictions uk legislation relating company distributions provides exemption tax repatriated profits subject certain exceptions movement deferred tax assets liabilities pensions manu share accelerated intra post legal facturing stock option net offset capital group employment tax restruct valuation award temporary within allowances intangibles profit benefits losses disputes uring adjustments schemes differences countries total deferred tax assets st january deferred tax liabilities st january st january exchange adjustments creditcharge income statement credit equity creditcharge statement comprehensive income acquisitions st december deferred tax assets st december deferred tax liabilities st december deferred tax credit income relating changes tax rates million million million deferred tax movements arise origination reversal temporary differences net temporary differences mainly include accrued expenses tax deduction available paid basis gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements taxation continued tax losses recognised unrecognised trading losses expiring within years years available indefinitely st december deferred tax asset addition group capital losses st december approximately billion billion respect deferred tax asset recognised deferred tax assets recognised probable future taxable profit available utilise losses factors affecting tax charge future years global organisation many factors could affect future effective tax rate group mix profits across different territories transfer pricing disputes tax authorities location research development activity significant impact groups effective tax rate changes tax legislation territories gsk business operations could also impact groups effective tax rate uk government proposed significant changes uk taxation system june uk government announced phased reduction main rate corporation tax years april deferred tax movements reflect reduction uk tax rate substantively enacted november uk government reconfirmed intention introduce patent box regime would apply reduced rate corporation tax income patents effect april following period consultation uk government also continues consult business proposed changes legislation relating controlled foreign companies majority changes expected enacted earnings per share pence pence pence basic earnings per share adjustment major restructuring basic earnings per share major restructuring diluted earnings per share adjustment major restructuring diluted earnings per share major restructuring basic adjusted earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts adjusted earnings per share calculated using results major restructuring earnings calculation results major restructuring described note presentation financial statements diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options diluted gsk annual report pp stnemetats laicnanif notes financial statements dividends first interim second interim third interim fourth interim total total dividend dividend per share pence paidpayable th july th october th january th april total dividend dividend per share pence paid th july th october th january th april total dividend dividend per share pence paid th july th october th january th april ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders property plant equipment plant land equipment assets buildings vehicles construction total cost st january exchange adjustments additions additions business combinations capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost st december exchange adjustments additions additions business combinations capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost st december gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements property plant equipment continued plant land equipment assets buildings vehicles construction total depreciation st january exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation st december exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation st december impairment st january exchange adjustments disposals writeoffs impairment losses reversal impairments impairment st december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment st december total depreciation impairment st december total depreciation impairment st december net book value st january net book value st december net book value st december net book value st december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million included land buildings st december leased assets cost million million accumulated depreciation million million impairment nil nil net book value million million included plant equipment vehicles st december leased assets cost million million accumulated depreciation million million net book value million million lease agreements include renewal purchase options escalation clauses impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs sell value use value use calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate relevant specific risks impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately impairment losses charged cost sales million million rd million million sga million million include million million arising major restructuring programmes reversals impairment arise subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales gsk annual report pp stnemetats laicnanif notes financial statements goodwill cost st january exchange adjustments additions business combinations impairment losses cost st december net book value st january net book value st december impairment losses year arose decision exit pliva research institute site zagreb croatia loss reported consolidated income statement major restructuring programme within selling general administration additions year translated acquisition exchange rates arose primarily acquisition laboratorios phoenix saicyf see note acquisitions disposals details carrying value goodwill translated yearend exchange rates made balances arising acquisition wfollowing businesses cash generating unit stiefel laboratories inc us europe emerging markets asia pacific pharmaceuticals id biomedical corporation us europe emerging markets asia pacific japan pharmaceuticals reliant pharmaceuticals inc us pharmaceuticals sirtris pharmaceuticals inc us europe emerging markets asia pacific japan pharmaceuticals pfizer hiv business viiv healthcare glaxosmithkline kk japan pharmaceuticals domantis limited us europe emerging markets asia pacific japan pharmaceuticals cns inc consumer healthcare polfa poznan sa europe pharmaceuticals certain businesses ucb sa emerging markets asia pacific pharmaceuticals laboratorios phoenix saicyf emerging markets pharmaceuticals novamin technology inc consumer healthcare others gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements goodwill continued goodwill allocated cash generating units tested impairment least annually effect st january gsk revised segmental disclosures reflect changes internal reporting structure viiv healthcare shown separate segment stiefel business integrated gsk legacy dermatology business following changes goodwill arising acquisition stiefel allocated us europe emerging markets asia pacific pharmaceuticals cgus impairment testing purposes benefits acquired business expected arise businesses goodwill arising acquisitions id biomedical sirtris pharmaceuticals domantis split us europe emerging markets asia pacific japan pharmaceutical cgus impairment testing purposes either benefit acquired businesses split among cgus acquired businesses generate independent cash flows allocation polfa poznan sa goodwill changed poland pharmaceuticals europe pharmaceuticals cash generating unit change allocation reflects level gsk internal management monitors polfa poznan sa goodwill valuation us pharmaceuticals cash generating unit goodwill impairment testing purposes prepared fair value less costs sell basis using turnover earnings multiples derived observed market data recoverable amounts cash generating units assessed using either value use fair value less costs sell model value use calculated net present value projected riskadjusted posttax cash flows plus terminal value cash generating unit goodwill allocated initially posttax discount rate applied calculate net present value posttax cash flows posttax discount rate used based group wacc cash generating units integrated operations across large parts group group wacc equivalent pretax discount rate approximately discount rate increased specific country risks sufficiently significant material impact outcome impairment test impairment test indicates recoverable value unit close carrying value test reperformed using pretax discount rate pretax cash flows order determine impairment exists establish magnitude fair value calculated using similar discounted cash flow approach based groups acquisition valuation model posttax discount rate applied projected riskadjusted posttax cash flows terminal value details relating discounted cash flow models used impairment tests significant goodwill balances follows europe emerging markets asia pacific pharmaceuticals cgus viiv healthcare cgu valuation basis value use fair value less costs sell key assumptions sales growth rates sales growth rates profit margins profit margins discount rate discount rate determination assumptions growth rates internal forecasts growth rates internal forecasts based internal based internal external market information external market information margins reflect past experience margins reflect past experience adjusted expected changes adjusted expected changes discount rate based discount rate based group wacc group wacc period specific projected cash flows years years discount rate terminal growth rate europe pa decline pa emerging markets pa asia pacific pa pa gsk annual report pp stnemetats laicnanif notes financial statements goodwill continued japan pharmaceuticals cgu consumer healthcare cgu valuation basis fair value less costs sell fair value less costs sell key assumptions sales growth rates sales growth rates profit margins advertising promotion discount rate investment terminal growth rate discount rate determination assumptions growth rates internal growth rates internal forecasts forecasts based internal based internal external external market information market information margins reflect past experience advertising promotion adjusted expected changes investment based historical levels discount rate based adjusted managements view group wacc support needed innovation expansion terminal growth rate based managements estimate future longterm average growth rates discount rate based group wacc period specific projected cash flows years years discount rate terminal growth rate pa pa terminal growth rates exceed longterm projected growth rates relevant markets terminal growth rates used value use calculations pharmaceuticals cash generating units reflect impact future generic competition take account new product launches consumer healthcare cash generating unit comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion pharmaceutical cash generating units also comprise collection smaller cash generating units including assets indefinite lives carrying value million million details indefinite life brands given note intangible assets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements intangible assets computer licences amortised indefinite life software patents etc brands brands total cost st january exchange adjustments capitalised internal development costs additions business combinations additions disposals asset writeoffs reclassifications cost st december exchange adjustments capitalised internal development costs additions business combinations capitalised borrowing costs additions disposals asset writeoffs reclassifications cost st december amortisation st january exchange adjustments charge year disposals asset writeoffs amortisation st december exchange adjustments charge year disposals asset writeoffs amortisation st december impairment st january exchange adjustments impairment losses disposals asset writeoffs impairment st december exchange adjustments impairment losses disposals asset writeoffs impairment st december total amortisation impairment st december total amortisation impairment st december net book value st january net book value st december net book value st december gsk annual report pp stnemetats laicnanif notes financial statements intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development included impairments million arising major restructuring programmes net book value computer software includes million million internally generated costs licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development net book value includes million million internally generated costs impairment losses million million principally arise assets development longer actively pursued note acquisitions disposals gives details additions business combinations year book values largest individual items follows fluviral lovaza selzentry arzerra duac fraxiparine others amortised brands include otc rights relating alli book value st december million million indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows panadol sensodyne stiefel trade name breathe right physiogel polident corega biotene poligrip solpadeine others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortised brand tested annually impairment applying fair value less costs sell methodology generally using four year posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate countryspecific risks main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment brands gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements investments associates joint ventures joint associated joint associated ventures undertakings total ventures undertakings total st january exchange adjustments additions disposals transfer investments distributions received movements lossprofit tax recognised consolidated income statement st december group held two significant associated undertakings st december quest diagnostics inc us clinical laboratory business listed new york stock exchange investment book value st december million million market value million million st december group owned quest although group held less ownership interest voting control quest group ability exercise significant influence significant shareholding nominated directors active participation quest board directors board subcommittees subsequent yearend gsk sold entire shareholding quest diagnostics inc sale comprised secondary public offering accompanying repurchase shares quest diagnostics together expected generate gross proceeds billion billion tax st december group owned million shares aspen pharmacare holdings limited aspen listed johannesburg stock exchange africas largest pharmaceutical manufacturer major supplier branded generic pharmaceutical healthcare nutritional products southern african selected international markets investment book value st december million million market value million million although group holds less ownership interest voting control aspen group ability exercise significant influence shareholding nominated directors active participation aspen board directors transfer investments relates groups holding jcr pharmaceuticals ltd previously classified within investments summarised balance sheet information respect groups associates set total assets quest diagnostics inc aspen pharmacare holdings limited others total liabilities quest diagnostics inc aspen pharmacare holdings limited others net assets summarised balance sheet information respect aspen pharmacare holdings limited based preliminary results information analysts forecasts available st december investments joint ventures comprise million share gross assets million million share gross liabilities million principally arise interests two joint ventures shionogiviiv healthcare holdings lp developing specified chemical compounds viiv healthcare shire canada primarily comarkets combivir trizivir epivir certain territories part viiv healthcare business investments joint ventures also include interest pharmaceutical insurance limited mutual insurance company covering pharmaceutical business risk interest glaxosmithkline neptunusbio flu vaccine research development manufacturing venture gsk made additional capital contributions million shenzhen glaxosmithkline neptunusbio co ltd million shionogiviiv healthcare holdings lp gsk annual report pp stnemetats laicnanif notes financial statements investments st january exchange adjustments additions net fair value movements impairment losses transfer investments associates joint ventures disposals st december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments discounted cash flows underlying net assets group holds number equity investments entities group entered research collaborations investments include listed investments million million increase primarily arising number additional investments year disposal investments fair value movements reclassified equity income statement based average cost shares acquired different times transfer associates relates groups holding jcr pharmaceuticals increased year impairment losses recorded tables recognised income statement year within operating income together amounts reclassified fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement investments include assets impaired follows original cost impairments recognised income statement subsequent fair value increases carrying value st december noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables inventories raw materials consumables work progress finished goods gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements trade receivables trade receivables prepaid pension contributions prepayments accrued income interest receivable employee loans advances receivables trade receivables include million million due associates joint ventures stated deducting provision bad doubtful debts bad doubtful debt provision st january exchange adjustments charge year subsequent recoveries amounts provided utilised st december cash cash equivalents cash bank hand shortterm deposits assets held sale land buildings plant equipment vehicles gsk annual report pp stnemetats laicnanif notes financial statements trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals accruals customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers principally usa increased year result us healthcare reform amendments accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions accruals based change could affect future results group trade payables include million million due associates joint ventures pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes postemployment costs costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service hybrid defined benefit schemes also include defined contribution sections gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements pensions postemployment benefits continued pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments expected rate return bonds reflects portfolio mix indexlinked government corporate bonds equity risk premium added longer term government bond yields give expected rate return equities projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting pca standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line medium cohort ie improvements recently observed higher levels assumed continue minimum improvements thereafter per year males females usa mortality rates calculated using rp fully generational table projected using scale aa white collar adjustment average life expectancy assumed individual age projected apply individual age follows uk usa male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment following asset liability study group decided adopt strategy reduce gradually allocation investment equities agreed pace reallocation would increased primarily investment deficit reduction contributions bonds target allocation equities property us scheme reduced total uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one usa group applied following financial assumptions assessing defined benefit liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report pp stnemetats laicnanif notes financial statements pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended st december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial gainslosses recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial lossesgains recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial lossesgains recorded statement comprehensive income total actuarial losses recorded statement comprehensive income since st january amount million amounts included within settlements curtailments include million million million augmentation costs arising major restructuring programmes see note provisions gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements pensions postemployment benefits continued fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk usa rest world group average expected rate fair expected rate fair expected rate fair fair st december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets december uk scheme purchased insurance contract guarantee payment specified pensioner liabilities included within assets present value scheme obligations table value million st december uk usa rest world group average expected rate fair expected rate fair expected rate fair fair st december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report pp stnemetats laicnanif notes financial statements pensions postemployment benefits continued uk usa rest world group average expected rate fair expected rate fair expected rate fair fair st december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost restriction surplus recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements pensions postemployment benefits continued postretirement pensions benefits movements defined benefit obligations uk usa rest world group group obligations st january exchange adjustments service cost interest cost settlements curtailments actuarial gains scheme participants contributions benefits paid transfers provisions obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial lossesgains scheme participants contributions benefits paid acquisitions obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial losses scheme participants contributions benefits paid obligations st december unrecognised past service cost recognised balance sheet st december uk defined benefit schemes include defined contribution sections obligations totalling million st december million million liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter us postretirement healthcare scheme amended main change increase cap group costs us pension postretirement healthcare plan amended changes resulted oneoff gain million income statement st december us plan obligation million million million however accordance ias unvested part benefit improvement recognised immediately balance sheet recognised gradually income statement st december unrecognised amount million million million primarily relates effect change us postretirement scheme amounted million million miilion gsk annual report pp stnemetats laicnanif notes financial statements pensions postemployment benefits continued defined benefit pension obligation analysed follows funded unfunded postretirement benefits unfunded postretirement pensions benefits movements fair values assets uk usa rest world group group assets st january exchange adjustments expected return assets settlements curtailments actuarial losses employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets settlements curtailments actuarial gains employer contributions scheme participants contributions benefits paid acquisitions assets st december exchange adjustments expected return assets actuarial gainslosses employer contributions scheme participants contributions benefits paid assets st december uk defined benefit schemes include defined contribution sections account balances totalling million st december million million group made special funding contributions uk pension schemes totalling million million million million million nil us scheme gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified st december actuarial funding valuation additional contributions expected million per year contributions based discount rate inflation assumption next review contribution levels expected st december actuarial valuation employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements pensions postemployment benefits continued postretirement pensions benefits history experience gains losses uk usa rest world group group experience gainslosses scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experience gains scheme assets percentage scheme assets st december experience gainslosses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experience losses scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experience gainslosses scheme assets percentage scheme assets st december experience gainslosses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficitssurpluses schemes experience gains scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficitssurpluses schemes gsk annual report pp stnemetats laicnanif notes financial statements pensions postemployment benefits continued sensitivity analysis effect changes assumptions used annual defined benefit pension postretirement costs benefit obligations decrease discount rate would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation decrease expected rates return assets would following approximate effect increase annual pension cost increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation provisions integration legal major employee restructuring related manufacturing disputes programmes provisions reorganisation provisions total st january exchange adjustments charge year reversed unused unwinding discount utilised transfer pensions obligations reclassifications movements st december settled within one year settled one year st december gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements provisions continued pension augmentations arising staff redundancies million million charged legal disputes year transferred pension obligations provision gsk involved number legal disputes shown note pensions postemployment benefits including notification possible claims set note asset writedowns recognised impairments legal proceedings provisions legal disputes property plant equipment note property plant include amounts relating product liability intellectual property equipment majority amounts provided antitrust government investigations contract terminations expected utilised next two years selfinsurance environmental cleanup property rental employee related provisions charge year primarily relates provisions relation employee related provisions include certain medical benefits investigation us government groups disabled employees spouses usa former manufacturing site cidra puerto rico product liability st december provision benefits amounted antitrust litigation relating paxil investigation million million employee benefits us attorneys office district colorado reflect variety provisions severance costs jubilee awards groups us sales promotional practices product liability longservice benefits cases regarding avandia products discount provisions decreased million million integration manufacturing reorganisation increase calculated using riskadjusted projected cash provisions integration manufacturing reorganisations flows riskfree rates return movement includes reflect costs related ongoing restructuring programmes decrease million million increase arising included within costs disclosed note major change discount rate year restructuring programmes respect product liability claims related certain products provisions sufficient history claims made settlements included provisions contingent consideration respect enable management make reliable estimate provision business acquisitions principally stiefel laboratories inc required cover unasserted claims certain cases ibnr contingent consideration payable upon certain criteria incurred reported actuarial technique used met certain specified dates future aggregate provision determine estimate ultimate liability matters items amounts million st december may vary amounts provided dependent upon million outcome litigation proceedings investigations possible settlement negotiations nature groups business number matters including provided using ibnr actuarial technique may subject negotiation litigation several years st december expected million million provision made legal disputes reimbursed third party insurers amount included within receivables note noncurrent assets note trade receivables discussion legal issues see note legal proceedings major restructuring programmes october gsk announced significant new operational excellence programme improve effectiveness productivity operations see note major restructuring programme significant expansion operational excellence programme approved board announced february expansion approved board announced february provisions staff severance payments made management made formal decision eliminate certain positions communicated groups employees affected provision made staff severance payments made immediately gsk annual report pp stnemetats laicnanif notes financial statements noncurrent liabilities accruals deferred income payables contingent liabilities st december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million st december million million financial assets pledged collateral contingent liabilities discussions tax legal issues refer note taxation note legal proceedings net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings us floating rate note new york stock exchange commercial paper bank loans overdrafts loan stock obligations finance leases longterm borrowings cid european medium term note london stock exchange cid european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note london stock exchange cid european medium term note london stock exchange cid european medium term note london stock exchange us us medium term note new york stock exchange cid european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange bank loans obligations finance leases net debt gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements net debt continued current assets liquid investments classified availableforsale investments st december included us treasury notes government bonds effective interest rate liquid investments st december approximately approximately liquid investment balances st december earning interest floating fixed rates amount million million respectively million million effective interest rate cash cash equivalents st december approximately approximately cash cash equivalents balances st december earning interest floating fixed rates amount million million respectively million million gsks policy regarding credit quality cash cash equivalents referred note financial instruments related disclosures shortterm borrowings gsk us billion billion commercial paper programme none issue st december billion million committed facilities days duration billion billion billion billion renewable annually liquid investments cash cash equivalents shown table weighted average interest rate current bank loans overdrafts st december longterm borrowings yearend gsk longterm borrowings billion billion billion billion falls due five years average effective interest rate notes st december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates range secured liabilities gsk loans secured charges noncurrent current assets year nil group pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations finance lease obligations st december bearing interest floating fixed rates amount million million respectively million million gsk annual report pp stnemetats laicnanif notes financial statements share capital share premium account share ordinary shares p premium number share capital authorised st december st december st december share capital issued fully paid st january issued share option schemes share capital purchased cancelled st december issued share option schemes st december issued share option schemes st december st december st december number shares issuable outstanding options note number unissued shares option st december issued share capital shares held esop trust shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trust disclosed note employee share schemes company purchase shares rd february gsk announced would commence new longterm share buyback programme expected repurchase billion shares depending market conditions factors exact amount timing purchases whether shares held treasury shares cancelled determined company dependent market conditions factors shares purchased period st january rd february period th february th february million shares purchased cost million gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements movements equity retained earnings reserves amounted million st december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity shown following table net translation exchange included non total fair value retained controlling translation reserve earnings interests exchange st january exchange movements overseas net assets reclassification exchange liquidation overseas subsidiary st december exchange movements overseas net assets reclassification exchange liquidation overseas subsidiary st december exchange movements overseas net assets reclassification exchange liquidation disposal overseas subsidiaries st december analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total st january transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts st december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts put option noncontrolling interest st december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts st december reserves include various nondistributable merger premerger reserves amounting million st december million million reserves also include capital redemption reserve created result share buyback programme amounting million st december million million gsk annual report pp stnemetats laicnanif notes financial statements related party transactions gsk held interest quest diagnostics inc st december group quest diagnostics parties longterm contractual relationship quest diagnostics primary provider clinical laboratory testing support groups clinical trials testing requirements worldwide quest diagnostics provided services million million group st december balance payable gsk quest diagnostics million million subsequent yearend gsk sold entire shareholding quest diagnostics inc sale comprised secondary public offering accompanying repurchase shares quest diagnostics together expected generate gross proceeds billion billion tax gsk held interest aspen pharmacare holdings limited st december gsk distributed million million products aspens extensive distribution network st december balance due gsk aspen million million balance payable gsk aspen million million group shionogi co ltd entered transactions us joint venture company support research development activities conducted joint venture company gsk provided services joint venture million million st december balance due gsk joint venture million million st december gsk held interest viiv healthcare shire canada primarily comarkets combivir trizivir epivir certain territories st december balance payable gsk viiv healthcare canada million nil aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance income net finance costs depreciation amortisation intangible assets impairment assets written profit sale intangible assets profit sale investments associates profit sale equity investments changes working capital decreaseincrease inventories decreaseincrease trade receivables decreaseincrease receivables increasedecrease trade payables decreaseincrease payables increasedecrease pension provisions sharebased incentive plans cash generated operations increase pension provisions primarily reflects charge legal costs year billion partly offset legal settlements billion contributions defined benefit pension schemes gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements reconciliation net cash flow movement net debt net debt beginning year decreaseincrease cash bank overdrafts cash inflow liquid investments net increase longterm loans net repayment shortterm loans net repayment obligations finance leases debt subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year analysis changes net debt exchange reclassifications acquisitions cash flow liquid investments cash cash equivalents overdrafts debt due within one year commercial paper eurobonds mediumterm notes debt due one year eurobonds mediumterm notes private financing net debt information significant changes net debt see note net debt acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given acquisitions laboratorios phoenix sacyf th june gsk acquired issued share capital laboratorios phoenix sacyf leading pharmaceutical business focused development marketing sale branded generic overthecounter products latin america cash purchase price million included million net cash million intangible assets million goodwill million net liabilities goodwill arising acquisition business reflects potential business synergies sales growth increase gsks market presence following acquisition established market participant none goodwill recognised expected deductible income tax purposes results phoenix reported part emerging markets operating segment transaction accounted using purchase method accounting proforma results laboratorios phoenix sa cyf full year turnover million loss tax major restructuring million gsk annual report pp stnemetats laicnanif notes financial statements acquisitions disposals continued acquisitions continued laboratorios phoenix sacyf since acquisition gsk recorded turnover million tax losses major restructuring million business transaction costs expensed arising acquisition laboratorios phoenix sacyf amounted million fair value book value adjustments fair value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration acquisitions year gsk completed three smaller subsidiary acquisitions cash total purchase price million included million net cash fair value book value adjustments fair value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill fair value gain recognised conversion associate subsidiary total consideration acquisitions made beginning year estimated group turnover would increased million year subsidiaries fully integrated gsk business practicable separately identify impact acquisitions group profit year goodwill arising acquisitions reflects potential business synergies sales growth increase gsks market presence following acquisition established market participants addition goodwill million recognised respect consideration prior year acquisition none goodwill recognised expected deductible income tax purposes results acquisitions reported primarily part emerging markets reportable operating segment group recognised gain million result measuring fair value associate held prior acquisition date gain reported profit disposal interest associates income statement acquisition costs expensed arising acquisitions totalled million gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements acquisitions disposals continued acquisitions continued investments associates joint ventures gsk made cash noncash contributions million joint venture group share million joint venture group share investment associate million increase groups share investments associates totalling million associates joint cash flows phoenix acquisitions ventures total total cash consideration cash cash equivalents acquired cash consideration net cash acquired net cash consideration paid deferred consideration cash consideration net cash acquired acquisitions certain businesses ucb sa st march group acquired ucb sa marketed product portfolio across certain territories africa middle east asia pacific latin america included several leading pharmaceutical brands number disease areas subsequent date group completed country acquisitions formed part original transaction purchase price million included million net cash million intangible assets million goodwill million net liabilities goodwill arising acquisition business reflects potential product growth throughout regions expected synergies group transaction accounted purchase method accounting transaction included acquisition number legal entities product rights previously marketed outside entities product portfolio acquired integrated gsk business acquisition therefore practicable identify result tax arising result transaction period acquisition prior acquisition estimated product portfolio recorded turnover million since acquisition gsk recorded turnover million products acquired book fair value fair value adjustment value net assets acquired intangible assets property plant equipment cash cash equivalents deferred tax provision liabilities goodwill total consideration gsk annual report pp stnemetats laicnanif notes financial statements acquisitions disposals continued acquisitions continued stiefel laboratories inc nd july group acquired share capital stiefel laboratories inc worlds largest private dermatological company cash consideration million net cash acquired including million debt repaid acquisition purchase price million including contingent cash consideration million payable upon certain criteria met specified dates future included million cash cash equivalents million intangible assets million goodwill representing potential additional growth combination stiefel business gsks existing dermatology portfolio million net liabilities purchase price included potential obligations make additional payments million million depending future performance certain products stiefel laboratories inc turnover million loss tax including restructuring costs million year ended st december million turnover million loss tax including restructuring costs related period since acquisition included group accounts since acquisition stiefel made operating profit million restructuring costs intangible assets amortisation business provide significant opportunities sales cost synergies stiefels products benefit gsks global distribution commercial organisations particularly markets brazil russia india china japan gsks products benefit stiefels speciality sales force relationships experienced management dermatology cost synergies business expected primarily combining manufacturing administrative functions previously reported gsk expects deliver annual pretax cost savings million restructuring costs approximately million excluding restructuring costs stiefel acquisition resulted dilution gsks earnings per share less book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration viiv healthcare limited th october gsk acquired pfizer incs hiv business combined hiv business form viiv healthcare limited subgroup owned gsk pfizer consideration given gsk representing net value gsks hiv business contingent consideration transaction costs valued million represented million intangible assets million deferred tax liability million net assets million increase noncontrolling interests million goodwill representing economies scale gained combination two businesses potential growth partners hiv products within viiv healthcare noncontrolling interest represents pfizers interest viiv healthcare including right preferential dividends based sales performance certain products gsk recognised accounting gain million transaction arising disposal interest gsks hiv business pfizer recorded book value return pfizers hiv business recorded fair value gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements acquisitions disposals continued acquisitions continued acquired pfizer hiv business turnover million loss tax million taking account transition status various territories million turnover million loss tax including restructuring costs recognised group accounts book fair value fair value adjustment value net assets acquired intangible assets assets including cash cash equivalents deferred tax provision noncontrolling interests goodwill total consideration consideration fair value assets contributed gsk fair value contingent equity contributed gsk direct costs total consideration acquisitions investments year included million five subsidiaries million joint venture group share million associate group initial share certain stiefel businesses laboratories cash flows ucb sa inc total cash consideration cash cash equivalents acquired net cash consideration contingent consideration net purchase consideration acquisitions subsidiaries made beginning year estimated group turnover would increased million year acquisitions fully integrated gsk business practicable separately identify impact acquisitions group profit year gsk annual report pp stnemetats laicnanif notes financial statements acquisitions disposals continued acquisitions continued sirtris pharmaceuticals inc th june group acquired issued share capital sirtris pharmaceuticals inc biopharmaceutical company based massachusetts usa cash consideration million company focused discovering developing proprietary orally available small molecule drugs potential treat diseases associated ageing including metabolic diseases type diabetes sirtris drug candidates designed mimic certain beneficial health effects calorie restriction activation sirtuins recently discovered class enzymes sirtris believes control ageing process transaction accounted purchase method accounting goodwill arising acquisition reflects potential enabling gsk enhance metabolic neurology immunoinflammation research efforts establishing worldleading presence sirtuin field aided existence company highly experienced development team encompasses aspects sirtuin biology sirtris pharmaceuticals inc turnover nil loss tax million nil turnover million loss tax related period acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration acquisitions investments year included million subsidiary million deferred million joint venture group share million associate group holding sirtris total cash flows cash consideration cash cash equivalents acquired net cash payment acquisitions subsidiaries acquired beginning combined group turnover year would million combined group profit year would million gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments business combinations pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted number commitments made licensing agreements including arrangements amicus therapeutics amplimmune inc apeiron biologics ag fondazione telethon isis pharmaceuticals inc shionogi co limited new arrangements offset reduced commitments due prior year transactions including actelion pharmaceuticals limited targacept inc neurosearch terminated curtailed year commitments relating business combinations reflect three agreements signed completed balance sheet date gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified st december actuarial funding valuation table shows commitment excludes normal ongoing annual funding requirement approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases post balance sheet events subsequent year end gsk completed acquisition three business combinations referred note commitments since year end gsk sold entire shareholding quest diagnostics inc sale comprised secondary public offering accompanying repurchase shares quest diagnostics together expected generate gross proceeds billion billion tax rd february gsk announced company initiated new longterm share buyback programme intention repurchase billion shares depending market conditions period th february th february million shares purchased cost million gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures borrowings together cash generated operations onlent contributed equity certain subsidiaries used glaxosmithkline plc reports sterling pays dividends pay dividends make acquisitions gsk make share sterling profits role corporate treasury manage repurchases monitor external internal funding requirements financial risks support strategic objectives treasury total capital equity net debt group decreased activities governed policies procedures approved million million decrease board directors recently th october million arises principally result excess dividend distribution year million earnings treasury management group tmg chaired chief financial attributable shareholders million groups positive officer meets monthly basis review treasury activities cash generation sufficient finance groups acquisitions members receive management information relating treasury payment legal costs year net debt continued activities internal auditors review treasury internal control reduce reflecting benefits ongoing restructuring environment regularly programme success working capital initiatives gsk uses variety financial instruments finance operations liquidity risk derivative financial instruments manage risks manage net borrowing requirements portfolio operations derivatives principally comprising forward longterm borrowings including bonds together short foreign currency contracts interest rate currency swaps term finance us billion commercial paper programme used swap borrowings liquid assets currencies required billion committed facilities facilities last group purposes manage exposure funding risks renewed october consider level committed changes foreign exchange rates interest rates facilities adequate given current liquidity requirements gsk hold issue derivatives speculative purposes information facilities please refer note treasury policies specifically prohibit activity financial statements net debt also benefit strong transactions financial instruments undertaken manage positive cash flow operating units risks arising underlying business activities speculation european medium term note programme billion capital management st december billion notes issue manage capital ensure entities group programme also us shelf registration statement able operate going concerns optimise return st december billion billion shareholders appropriate balance debt equity notes issue programme board reviews groups dividend policy funding longterm borrowings mature dates requirements annually longterm debt ratings remained stable since capital structure group consists net debt see february currently rated stable outlook note net debt shareholders equity see consolidated standard poors stable outlook moodys investors statement changes equity service moodys shortterm debt ratings p standard poors moodys respectively commitment use free cash flow support increasing dividends undertake share repurchases returns well committed facilities also substantial cash attractive invest bolton acquisitions investment opportunities cash equivalents liquid investments amounted continue assessed strict financial criteria billion st december also benefit strong positive cash flow operating units tmg monitors gsk operates global basis primarily subsidiary cash flow forecast monthly basis companies established markets trade significant levels patent trademark protection market risk pharmaceutical products compete largely product efficacy interest rate risk management differentiation selling margins sufficient cover normal policy interest rate risk management limits amount operating costs operations cash generative floating interest payments prescribed percentage operating cash flow used fund investment research trading profit development new products also used make routine use series interest rate swaps redenominate one outflows capital expenditure tax dividends repayment external borrowings interest rate coupon required gsk maturing debt extent determined board share duration swap matches duration principal repurchases part new longterm share buyback instrument interest rate derivative instruments accounted programme depending market conditions fair value cash flow hedges relevant assets liabilities factors expect purchase billion shares policy borrow centrally using variety capital market issues borrowing facilities meet anticipated funding requirements gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements financial instruments related disclosures continued foreign exchange risk management foreign currency transaction exposures arising internal external trade flows hedged exposure overseas operating subsidiaries transaction risk minimised matching local currency income local currency costs purpose internal trading transactions matched centrally manage intercompany payment terms reduce foreign currency risk exceptional foreign currency cash flows hedged selectively management corporate treasury manage cash surpluses borrowing requirements subsidiary companies centrally using forward contracts hedge future repayments back originating currency seek denominate borrowings currencies principal assets cash flows primarily denominated us dollars euros sterling certain borrowings swapped currencies required borrowings denominated swapped foreign currencies match investments overseas group assets may treated hedge relevant assets forward contracts also used major currencies reduce exposure investment overseas group assets see net investment hedges section note details tmg reviews ratio borrowings assets major currencies monthly credit risk group considers maximum credit risk million million total groups financial assets exception investments bear credit risk see details groups total financial assets gsks greatest concentration credit risk billion jp morgan chase aaaa rated moodys standard poors respectively comprising billion invested deposits billion derivatives greatest concentration credit risk billion investments us treasury treasury repo money market funds bear credit exposure us government aaaaaa rated moodys standard poors respectively treasuryrelated credit risk gsk continued maintain conservative approach counterparty risk throughout period report relationship banks credit ratings presented annually tmg approval aggregate credit risk respect financial instruments group may one counterparty limited reference longterm credit ratings assigned counterparty moodys standard poors table sets credit ratings counterparties liquid investments cash cash equivalents derivatives gross asset position derivative contract considered purpose table though isda contracts amount risk net position counterparty million invested baabbb rated investments includes bank deposits allied irish bank state bank india indian government bonds counterparties used either local cash management purposes local investment purposes gsk sole shareholder million invested babb rated investments includes greek government bonds issued lieu settlement long outstanding amounts bank deposits hdfc bank domestic bank used india invest funds locally credit rating counterparty aaaaaa aaaa aaaa aa aa baabbb baabbb baabbb babb total bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total credit rating counterparty aaaaaa aaaa aaaa aa aa baabbb baabbb baabbb babb total bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total credit ratings tables assigned moodys standard poors respectively opinion two rating agencies differ gsk assigns lower rating two counterparty local rating agency data source available ratings converted global ratings equivalent moodys investor services standard poors using published conversion tables gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures following methods assumptions used estimate fair values continued cash cash equivalents approximates carrying amount centrally managed cash reserves amounted billion liquid investments based quoted market prices calculated st december available within months excludes based observable inputs case marketable securities billion centrally managed cash held viiv healthcare based principal amounts case nonmarketable owned subsidiary group may invest centrally managed securities short repricing periods liquid assets bank deposits aaaaaa rated us treasuries us treasury repo money market funds short term investments investments traded active market corporate debt instruments minimum shortterm credit determined reference relevant stock exchange quoted rating ap bid price investments determined reference current market value similar instruments reference global counterparty limits assigned gsks banking discounted cash flows underlying net assets investment counterparties based longterm credit ratings shortterm loans overdrafts approximates carrying moodys standard poors corporate treasurys usage amount short maturity instruments limits monitored daily corporate compliance officer cco operates independently corporate treasury longterm loans based quoted market prices case breach limits would reported cfo immediately eurobonds fixed rate borrowings approximates cco also monitors credit rating counterparties carrying amount case floating rate bank loans changes ratings occur notifies corporate treasury loans changes made investment levels authority forward exchange contracts based market data limits appropriate exchange rates balance sheet date wholesale retail credit risk currency swaps based market data balance sheet date usa line pharmaceutical companies interest rate swaps based net present value group sells products small number wholesalers discounted cash flows addition hospitals pharmacies physicians groups receivables payables approximates carrying amount sales three largest wholesalers amount approximately companyowned life insurance policies based cash groups us pharmaceutical sales st december surrender value group trade receivables due three wholesalers totalling million million lease obligations approximates carrying amount group exposed concentration credit risk respect fair value investments gsk shares wholesalers one encounters st december employee share ownership plan financial difficulty could materially adversely affect esop trusts held gsk shares carrying value million groups financial results million fair value million groups credit risk monitoring activities relating million based quoted market price shares wholesalers includes review quarterly financial information represent purchases esop trusts satisfy future exercises standard poors credit ratings development gsk internal options awards employee incentive schemes risk ratings establishment periodic review credit limits carrying value lower cost expected proceeds however group believes credit risk provision shares recognised deduction required excess normal provision bad doubtful reserves st december gsk held treasury shares debts see note trade receivables outside cost million million usa customer accounts trade deducted retained earnings receivables balance committed facilities fair value financial assets liabilities group committed facilities billion billion table presents carrying amounts billion billion days duration renewable fair values groups financial assets liabilities annually st december undrawn st december st december fair values financial assets liabilities included amount instrument could exchanged current transaction willing parties forced liquidation sale gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements financial instruments related disclosures continued carrying fair carrying fair value value value value cash cash equivalents availableforsale investments liquid investments government bonds total liquid investments investments loans receivables trade receivables certain noncurrent assets scope ias financial assets fair value profit loss noncurrent assets heldfortrading financial assets derivatives designated accounting hedges derivatives total financial assets financial liabilities measured amortised cost borrowings bonds designated hedging relationship bonds commercial paper bank loans overdrafts loans private financing obligations finance leases total borrowings trade payables provisions noncurrent liabilities scope ias heldfortrading financial liabilities derivatives designated accounting hedges derivatives total financial liabilities net financial assets financial liabilities gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures continued following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level st december level level level total financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets heldfortrading financial assets derivatives designated accounting hedges derivatives financial liabilities fair value heldfortrading financial liabilities derivatives designated accounting hedges derivatives st december level level level total financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets heldfortrading financial assets derivatives designated accounting hedges derivatives financial liabilities fair value heldfortrading financial liabilities derivatives designated accounting hedges derivatives movements year financial instruments measured using level valuation methods presented st january losses recognised income statement lossesgains recognised comprehensive income additions disposals transfers level exchange st december net losses million million attributable level financial instruments held end year reported operating income transfers level million nil relate equity investments listed stock exchanges year reasonably possible change assumptions unlikely result material change fair value level instruments gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements financial instruments related disclosures continued trade receivables noncurrent assets scope ias following table reconciles financial assets within trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets include companyowned life insurance policies assets include tax receivables pension surplus balances prepayments outside scope ias trade receivables note noncurrent assets note analysed financial assets scope ias assets following table shows age financial assets past due provision bad doubtful debts made past due days past due days past due days past due days past due days amounts past due greater days total million million balance million million relates receivables due state hospital authorities certain european countries given profile customers including large wholesalers government backed agencies credit risk identified trade receivables past due balances allowance made trade payables provisions noncurrent liabilities scope ias following table reconciles financial liabilities within trade payables provisions noncurrent liabilities fall within scope ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities liabilities include payments account tax social security payables provisions constitute contractual obligations deliver cash another financial asset outside scope ias trade payables note provisions note noncurrent liabilities note analysed financial liabilities scope ias liabilities gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures continued debt interest rate repricing table following table sets exposure group interest rates debt effect interest rate swaps maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases effect effect interest interest debt rate swaps total debt rate swaps total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing sensitivity analysis sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations place st december financial instruments affected market risk include borrowings deposits derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes relevant foreign exchange interest rates foreign exchange sensitivity tables show groups sensitivity foreign exchange rates us dollar euro yen financial instruments excluding obligations finance leases certain nonderivative financial instruments net debt present material exposure three currencies major foreign currencies gsks financial instruments denominated gsk considered movements currencies last three years concluded movement rates reasonable benchmark table financial instruments considered sensitive foreign exchange rates functional currency entity holds intercompany loans fully hedged maturity currency swap excluded analysis increase reduction increase reduction nonfunctional currency foreign exchange exposure income equity income equity appreciation us dollar appreciation euro appreciation yen depreciation stated currencies would equal opposite effect movements income statement relate primarily hedging instruments us legal provisions trade payables trade receivables whilst hedging instruments provide economic hedges related provisions financial instruments therefore included table combined sensitivity hedging instruments provisions would insignificant provisions included movements equity relate foreign exchange positions used hedge group assets denominated euro us dollar yen positions closed therefore depreciation currency swap would give rise corresponding appreciation group asset foreign exchange sensitivity group assets financial instruments included gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements financial instruments related disclosures continued table presents groups sensitivity foreign exchange rates based composition net debt adjusting effects foreign exchange derivatives part net debt affect future foreign currency cash flows derivatives relate primarily foreign exchange contracts used hedge groups currency net assets us legal provisions increasedecrease increasedecrease impact foreign exchange movements net debt net debt net debt appreciation us dollar appreciation euro appreciation yen depreciation stated currencies would equal opposite effect interest rate sensitivity table shows groups sensitivity interest rates floating rate sterling us dollar euro financial instruments currencies gsk historically issued debt held investments gsk considered movements interest rates last three years concluded basis points increase reasonable benchmark debt maturity less one year floating rate calculation basis points movement interest rates deemed material effect equity increasedecrease increasedecrease income income basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates interest rates could decreased currently less maximum increasedecrease income would therefore limited million million million sterling us dollar euro interest rates respectively million million million interest rate movements foreign currency derivatives financial instruments net debt present material exposure groups balance sheet based increase decrease interest rates contractual cash flows nonderivative financial liabilities derivative instruments following analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis impact interest rate swaps excluded purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held st december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates st december finance charge trade payables obligations obligations interest finance finance liabilities st december debt debt leases leases net debt total due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance charge trade payables obligations obligations interest finance finance liabilities st december debt debt leases leases net debt total due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures continued following table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options material using undiscounted cash flows cash flows foreign currencies translated using spot rates st december gross cash flows foreign exchange contracts presented purposes table though practice group uses standard settlement arrangements reduce liquidity requirements instruments receivables payables receivables payables less one year one two years two three years three four years four five years greater five years gross contractual cash flows derivative financial instruments hedging programmes following table sets fair values derivatives held gsk fair value fair value assets liabilities assets liabilities fair value hedges interest rate swaps principal amount million million net investment hedges foreign exchange contracts principal amount million million derivatives designated accounting hedges foreign exchange contracts principal amount million million embedded derivatives derivatives designated accounting hedges total derivative instruments analysed current noncurrent total derivative financial instruments principal amount foreign exchange contracts net total outstanding positions balance sheet date majority contracts periods months less st december group held outstanding foreign exchange contracts consisting primarily currency swaps total credit fair value million million credit represent hedges intercompany loans deposits designated accounting hedges changes fair value taken income statement period offset exchange gains losses related intercompany lending borrowing cash flow hedges group entered number foreign exchange forward contracts designated cash flow hedge exchange arising us dollar purchase consideration highly probable business acquisition acquisition occurred october cash flow hedge matured date amount recognised comprehensive income removed upon maturity hedge included initial carrying value goodwill intangibles recorded acquisition entity group also entered number foreign exchange forward contracts designated cash flow hedges exchange exposure arising gbp equivalent interest cost euro loans issued settled july december net fair value movements cash flow hedges disclosed consolidated statement comprehensive income ineffectiveness recorded cash flow hedges gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements fair value hedges group designated series interest rate swaps fair value hedge risk hedged variability fair value bond arising interest rate fluctuations gains losses fair value hedges disclosed note finance costs net investment hedges year certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk principally arising consolidation groups net investment us dollar euro yen foreign operations st december group held net investment hedges respect euro foreign operations addition euro loan capital cid billion issued previous years designated net investment hedge respect foreign currency translation risk principally arising consolidation groups net investment euro operations net investment hedge ineffectiveness disclosed note finance income employee share schemes group operates share option schemes whereby options granted employees acquire shares ads glaxosmithkline plc grant price savingsrelated share option schemes share award schemes addition gsk operates performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period granting restricted share awards replaced granting options certain employees cost scheme readily equates potential gain made employee onwards grants made savingsrelated share option schemes grants share option schemes normally exercisable three ten years date grant grants restricted shares share awards normally exercisable end three year vestingperformance period grants savingsrelated share option schemes normally exercisable three years saving grants share option schemes awards performance share plan normally granted employees acquire shares ads gsk plc circumstances settled cash options share option schemes granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant share options awarded directors effect grant cet subject performance criteria option pricing purposes valuing options awards arrive share based payment charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years years savingsrelated share option share award schemes years years years weighted average share price grants year ordinary shares ads volatility determined based three five year share price history appropriate fair value performance share plan grants take account market conditions expected lives options determined based weighted average historic exercises options gsk annual report pp stnemetats laicnanif notes financial statements employee share schemes continued options outstanding share option share option savingsrelated schemes shares schemes ads share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value st january options granted options exercised options lapsed st december options granted options exercised options lapsed st december options granted options exercised options lapsed st december range exercise prices weighted average market price exercise weighted average remaining contractual life years years years share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes st december weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options normally become exercisable three years date grant may certain circumstances vest earlier set within various scheme rules change effective exercise price outstanding options year share option share option savingsrelated options exercisable schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price st december st december st december gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements employee share schemes continued glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group three year measurement period awards granted directors members cet prior subject single performance condition compares gsks tsr period tsr companies comparator group period awards granted directors members cet award based achievement adjusted free cash flow targets three year measurement period remaining award based relative tsr performance comparator group described pages half tsr element award measured three years half four years awards made eligible employees prior performance conditions consist two parts applies award first part performance condition compares gsks eps growth increase uk retail prices index three year measurement period second part performance condition compares gsks tsr period tsr companies comparator group period awards granted onwards first part performance condition continues based eps second part performance condition based strategic operational business measures three year measurement period specific employees business area shares weighted ads weighted number shares ads issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december share value plan group operates share value plan whereby awards granted form shares certain employees cost awards vest three years performance criteria attached shares weighted ads weighted number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december gsk annual report pp stnemetats laicnanif notes financial statements employee share schemes continued deferred investment award plan group operates deferred investment award plan whereby awards granted form notional shares certain senior executives cost awards typically vest threeyear period commencing fourth anniversary date grant award initially vesting subsequent two years performance criteria attached shares weighted ads weighted number shares ads issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares open market finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves held value proceeds receivable employees exercise deemed permanent diminution value reflected transfer retained earnings trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group st december details given principal country operation location headquarters business sector business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline holdings one limited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline mercury limited ph h brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc phch f brentford smithkline beecham limited phch e h p r brentford wellcome limited phch h brentford glaxo group limited ph h brentford glaxo operations uk limited ph p brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uk limited ph p brentford glaxochem pte ltd ph h brentford setfirst limited phch h brentford wellcome foundation limited ph p cambridge domantis limited ph r brentford viiv healthcare limited ph h brentford viiv healthcare uk limited ph brentford viiv healthcare trading services limited ph e f austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biologicals sa ph e p r czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch marly le roi viiv healthcare sas ph st amand les eaux glaxosmithkline biologicals sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h p r munich glaxosmithkline gmbh co kg ph h greece athens glaxosmithkline aebe phch hungary budapest glaxosmithkline medicine healthcare products limited phch e italy verona glaxosmithkline spa ph h milan glaxosmithkline consumer healthcare spa ch verona glaxosmithkline manufacturing spa ph p gsk annual report pp stnemetats laicnanif notes financial statements principal group companies continued europe location subsidiary sector activity luxembourg mamer glaxosmithkline international luxembourg sarl phch f h netherlands zeist glaxosmithkline bv ph zeist glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk services spz oo ph warsaw glaxosmithkline consumer healthcare spz oo ch e portugal alges glaxosmithklineprodutos farmaceuticos limitada ph republic carrigaline smithkline beecham cork limited ii ph p r ireland cork glaxosmithkline trading services limited ii ph e dublin glaxosmithkline consumer healthcare ireland limited ii ch dublin glaxosmithkline ireland limited ph dungarvan stafford miller ireland limited ii ch p dungarvan glaxosmithkline dungarvan limited ii ch p romania brasov europharm holding sa phch bucharest glaxosmithkline gsk srl ph r russian moscow glaxosmithkline trading zao ph federation moscow glaxosmithkline healthcare zao ch spain madrid glaxosmithkline sa ph madrid glaxosmithkline consumer healthcare sa ch aranda de duero glaxo wellcome sa ph p sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa research triangle park stiefel laboratories inc ph h p marietta corixa corporation ph p philadelphia glaxosmithkline llc phch e h p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h wilmington glaxosmithkline holdings americas inc phch h wilmington glaxosmithkline capital inc ph f cambridge sirtris pharmaceuticals inc ph r research triangle park viiv healthcare company ph americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc ph p r mississauga glaxosmithkline consumer healthcare inc ch laval id biomedical corporation ph h quebec city id biomedical corporation quebec ph p r mexico delegacion tlalpan glaxosmithkline mexico sa de cv phch e p puerto rico guaynabo glaxosmithkline puerto rico inc ph asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china beijing glaxosmithkline china investment co ltd phch h hong kong glaxosmithkline limited phch shanghai glaxosmithkline biologicals shanghai ltd ph p tianjin sinoamerican tianjin smith kline french laboratories ltd ch p r gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements principal group companies continued asia pacific location subsidiary sector activity india mumbai glaxosmithkline pharmaceuticals limited ph p nabha glaxosmithkline consumer healthcare limited iii ch e p r malaysia petaling jaya glaxosmithkline pharmaceutical sdn bhd ph selangor glaxosmithkline consumer healthcare sdn bhd ch new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch p e philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd ph h p r singapore glaxosmithkline pte ltd phch south korea seoul glaxosmithkline korea limited ph ch thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch e p r buenos aires laboratorios phoenix sociedad anonima industrial comercial financiera ph e p brazil rio de janeiro glaxosmithkline brasil limitada phch e p colombia bogota glaxosmithkline colombia sa phch venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithkline sae ph p south africa johannesburg glaxosmithkline south africa pty limited phch e p turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch usa location associate sector activity usa madison quest diagnostics incorporated iv clinical testing middle east africa south africa johannesburg aspen pharmacare holdings limited iv phch p r incorporated singapore ii exempt provisions section companies amendment act ireland iii consolidated subsidiary undertaking accordance section companies act grounds dominant influence iv equity accounted grounds significant influence subsequent yearend gsk sold entire shareholding quest diagnostics inc ee note details directly held wholly owned subsidiary glaxosmithkline plc key business sector ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r research service full details group subsidiary associated undertakings attached companys annual return filed registrar companies glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report pp stnemetats laicnanif notes financial statements legal proceedings revocation action basic patent covering seretide combination ireland filed high court dublin group involved significant legal administrative behalf ivax july high court handed decision proceedings principally product liability intellectual property th june finding patent invalid obviousness tax antitrust governmental investigations well related group filed appeal decision october private litigation group makes provision proceedings trial date set appeal regular basis summarised note accounting principles policies note provisions group may action revocation french seretide combination patent become involved legal proceedings respect filed sandoz tribunal de grande instance paris possible make reliable estimate expected financial effect trial scheduled june basic patent covering could result ultimate resolution proceedings combination product seretide expired september cases appropriate disclosures cases would subject spc extends protection september included provision would made intellectual property january sandoz initiated revocation action claims include challenges validity enforceability groups belgian seretide patent groups patents various products processes well assertions noninfringement patents loss date generic seretide product approved cases could result loss patent protection product major european market despite revocation certain group issue consequences loss could significant patents covering seretide countries decrease sales product could materially affect future argatroban results operations group december encysive pharmaceuticals inc mitsubishi kasei legal expenses incurred provisions related legal claims corporation group filed action united states charged selling general administration costs provisions district court southern district new york barr made taking appropriate legal specialist advice laboratories inc infringement mitsubishis pharmaceutical outflow resources considered probable reliable composition patent covering argatroban pursuant license estimate made likely outcome dispute mitsubishi encysive developed argatroban treatment respect product liability claims related certain products heparininduced thrombocytopenia holds new drug sufficient history claims made settlements enable application approved us fda encysive licensed us management make reliable estimate provision required marketing rights argatroban group mitsubishi patent cover unasserted claims certain cases incurred expires june barr teva pharmaceuticals inc filed reported ibnr estimate using actuarial techniques appropriate abbreviated new drug application anda fda used determine estimate groups exposure certification invalidity unenforceability noninfringement described note provisions st december mitsubishi patent th june group groups aggregate provision legal disputes partners prevailed teva trial judge ruling including tax matters described note taxation mitsubishis patent covering formulation injectable billion ultimate liability legal claims may vary argatroban infringed invalid result courts amounts provided dependent upon outcome litigation decision teva precluded launching generic product proceedings investigations possible settlement negotiations th june expiration date patent teva appealed groups position could change time therefore decision court appeals federal circuit assurance losses result outcome arzerra legal proceedings exceed amount provisions october group filed action united states reported groups financial accounts material amount district court southern district florida declaration happen could material adverse impact us patent socalled cabilly ii patent results operation group reporting period owned jointly genentech inc city hope judgments incurred settlements entered invalid unenforceable infringed groups product significant matters described arzerra ofatumumab arzerra approved fda intellectual property chronic lymphocytic leukaemia orphan indication october february group voluntarily dismissed case advairseretide filed new case united states district court number companies challenged groups patents northern district california suit currently pending covering advairseretide certain european jurisdictions including uk belgium france germany ireland rd march genentech biogen idec filed suit netherlands reported previously groups seretide group united states district court combination patent covering product uk revoked southern district california alleging groups sale rd february actions brought mylan arzerra induces contributes infringement us patent hexal neolab ivax federal court munich revoked patent claims treatment chronic groups german seretide combination patent lack inventive lymphatic leukemia anticd monoclonal antibody step group appealed decision netherlands case early stages action brought sandoz hexal district court hague th january revoked supplementary protection certificate spc extends protection product september group determining whether appeal decision gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements legal proceedings continued combivir patents listed orange book combivir include composition avodart matter tclamivudine combination lamivudine azt january group received notice barr laboratories lamivudine crystal form patents expire filed anda fda allegation invalidity respectively september group received notice three patents listed orange book cover teva pharmaceuticals inc filed anda fda alleging active ingredient avodart use treat benign prostatic combination patent invalid hyperplasia two patents expire one expires february group filed action united november group filed action united states district court district delaware barr states district court district delaware teva infringement patents march group pharmaceuticals usa inc infringement combination barr teva pharmaceuticals inc reached settlement patent april group teva agreed settle litigation th may district court dismissed case suit filed group terms settlement teva pursuant settlement teva obtain license enter obtain license enter us market fourth quarter us market generic dutasteride product fourth quarter earlier certain circumstances light earlier certain circumstances settlement district court dismissed case th may november banner pharmacaps inc sent group notice july group received notice lupin ltd filed filed anda market generic version avodart certification fda alleging combination patent banners notification contained paragraph iv certification invalid infringed product lupin also filed certification alleging two group patents expiring one patent groups patent covering crystal form lamivudine expiring invalid infringed banners proposed invalid infringed august group filed suit generic dutasteride product patents patents lupin united states district court district subject groups settlement teva march delaware infringement combination patent march since teva first file complete anda action lupin stayed mutual consent paragraph iv certification holds day exclusivity pending resolution case teva th may later filers banner enter market expiration groups case teva first anda filer settled forfeiture tevas days exclusivity group sued banner dismissed lupin may choose reactivate case united states district court district delaware group terms stay however lupin january able obtain final approval product expiration forfeiture tevas day exclusivity period december anchen pharmaceuticals inc sent group notices filed andas paragraph iv certifications levitra avodart jalyn alleging group patent expiring group participates marketing levitra pursuant covers dutasteride invalid infringed copromotion agreement bayer healthcare july bayer proposed products jalyn combination dutasteride brought suit teva pharmaceuticals united states tamsulosin covered patents cover district court district delaware infringement avodart anchen launch generic jalyn product patent relating levitra teva filed anda fda expiration nonchallenged patents september certification patent covering active ingredient anchen launch generic avodart product later levitra expires invalid unenforceable september expiration forfeiture tevas day infringed stay fda approval put effect exclusivity group sued anchen united states district filing lawsuit earlier decision case adverse court district delaware january bayer november january trial date matter extended st october th february benlysta teva consented extension stay fda february uk court appeal upheld earlier high approval amount equal extension trial date court decision revoking human genome sciences hgs uk group party suit patent ep claim revocation brought eli lilly patent claims cytokine blys lovaza antibody binds blys benlysta belimumab march group received notice teva group licence patent hgs pharmaceuticals usa inc par pharmaceutical inc apotex party litigation proceedings equivalent european inc filed andas certification two patents covering patent upheld october final appeal lovaza invalid unenforceable infringed patents european patent office following opposition proceeding filed expire group licensee eli lilly uk decision affect european patents pronova biopharma norge owner patents patents arising european patent hgs appealed sued teva par apotex united states district court uk decision july uk supreme court decided district delaware fda approval andas stayed would hear appeal hearing date appeal set earlier may decision favourable one th july decision affect groups hgs generics trial set court th march ability market sell benlysta group party suits three additional patents covering lovaza granted pronova march june pronova sued teva par apotex patents separate trial scheduled rd january additional month stay attached suit patents gsk annual report pp stnemetats laicnanif notes financial statements legal proceedings continued product liability malarone preclinical clinical trials conducted development potential products determine safety efficacy august group filed suit united states district products use humans following approval regulatory court district delaware glenmark generics bodies notwithstanding efforts drugs vaccines inc usa infringement patents related malarone introduced marketplace unanticipated safety issues may group received notification glenmark filed anda become evident group currently defendant number malarone certification alleging groups patents product liability lawsuits related groups pharmaceutical invalid unenforceable infringed patents consumer healthcare products significant expire cover combination atovaquone proguanil matters described hydrochloride use preventing malaria group settled case april terms settlement agreement avandia glenmark received royaltybearing licence enter market group named product liability lawsuits behalf product third quarter earlier certain individuals asserting personal injury claims arising use circumstances case dismissed th may avandia federal cases part multidistrict litigation paxilseroxat proceeding pending united states district court following courtordered mediation second quarter eastern district pennsylvania cases also filed group resolved claims apotex paxil number state courts cases filed state court philadelphia seroxat patent infringement antitrust litigation venued coordinated mass tort program cases state court us district court eastern district pennsylvania well california coordinated los angeles additionally litigation brought apotex group canada purported class actions seeking economic damages behalf litigation dismissed respect parties third party payers consumers asserting claims arising various state federal laws including racketeer influenced treximet corrupt organizations act rico state unfair trade practices october group received letter par andor consumer protection laws pharmaceuticals fda accepted anda treximet rd september fda took action rosiglitazone included certification patents owned pozen inc keeping rosiglitazone products market requiring relating treximet invalid unenforceable infringed additional labeling restrictions use ensure benefits pozens patents licensed group november avandia continue outweigh risks including risk evaluation pozen filed suit par three patents district mitigation strategy rems program ensure safe use court eastern district texas november medicine eu ema announced september group received letter alphapharm designated agent determined suspend marketing authorisation mylan pharmaceuticals fda accepted anda rosigilitazone including avandia products regulatory agencies treximet also included certification pozens patents countries reviewing taken regulatory action relating treximet invalid unenforceable infringed group working implement decisions fda ema pozen filed suit alphapharm mylan january regulatory agencies th february fda infringement patents district court eastern announced change labeling avandia restrict use district texas pozen also sued teva pharmaceuticals patients already taking rosiglitazonecontaining medicine usa inc dr reddys patents new patients unable achieve adequate glycemic court trial held october parties control diabetes medications patients awaiting decision treximet data exclusivity precludes decided take pioglitazone pioglitazone approval generic product april group containing medicines party lawsuits brought pozen group continued receive significant number new vesicare product liability cases regarding avandia usa part group markets vesicare usa license result regulatory action taken fda part based astellas pharma inc september astellas filed suit negative publicity concerning product adjusted teva pharmaceuticals usa inc federal district court provision potential settlements accordingly provision southern district new york infringement patent includes estimate future claims respect product covering active ingredient vesicare astellas received liability cases usa group reached agreements notice teva filed anda certification settle majority claims pending february basic patent expires invalid unenforceable parties settled case dismissed th june one purported class action avandia filed israel terms settlement teva able enter briefing whether certify class action underway eleven market october class actions pending canada early stage th february astellas group announced group cease promoting vesicare usa january gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements legal proceedings continued thimerosal group along number pharmaceutical paxil paxil cr companies named defendant numerous individual group received numerous lawsuits claims alleging personal injury lawsuits state federal district courts use paxil paroxetine caused variety injuries usa alleging thimerosal preservative used many lawsuits claims allege use paxil manufacture vaccines causes neurodevelopmental disorders pregnancy resulted birth child birth defects injuries including autism health issues lawsuits claims allege patients took paxil committed attempted commit suicide acts two cases purported class actions although violence finally third group lawsuits claims allege determination whether cases use paxil caused patients suffer symptoms permitted proceed class action number purported class discontinuing treatment paxil actions jurisdictions withdrawn dismissed plaintiffs seek remedies including compensatory punitive group reached agreements settle vast majority statutory damages well cost fund medical us claims pending february matters monitoring research dismissed without payment lawsuits remain scheduled trial including nine cases scheduled trial philadelphia date report limited number cases mass tort program may june concerning use paxil approached trial dates vaccine manufacturers pregnancy remains purported class action litigation manufacturers thimerosal containing medicinal products canada concerning use paxil pregnancy successful excluding testimony plaintiffs expert witnesses causation specifically grounds plaintiffs california court granted plaintiffs motion certify class failed establish hypothesised link thimerosal consumer fraud lawsuit seeking economic damages focused neurodevelopmental disorders generally accepted reliable discontinuation symptoms within relevant scientific community canada court appeal affirmed quebec courts february office special masters united denial plaintiffs motion certify class patients states court federal claims rejected first three allegedly experienced discontinuation symptoms litigation approximately autism claims filed national concluded vaccine injury compensation program nvicp grounds uk public funding withdrawn claimants failed produce reliable scientific evidence linking hundreds claimants received funding pursue vaccinations medical conditions including autism common issues litigation alleging paroxetine caused group party proceedings findings suffer withdrawal reactions dependency used evidence pending lawsuits legal services commissions decision withdraw funding group three decisions upheld appeal united appealed special cases review panel states court federal claims two three nvicp claimants claimants claimants discontinued claims appealed rulings united states court appeals trial listed commence early high court federal circuit affirmed decisions united london vacated states court federal claims third claimant elected poligrip appeal rejected decision nvicp beginning number product liability lawsuits claims claimant option filing action either filed group state federal courts group andor physician administered vaccine usa including purported class actions alleging zinc question date action commenced poligrip causes copper depletion permanent neurologic remaining approximately nvicp claimants also injury federal cases part denture cream adhesive ultimately option pursuing personal injury lawsuits multidistrict litigation mdl united states district court vaccine manufacturers including group southern district florida established june nd february united states supreme court issued group procter gamble defendants decision bruesewitz v wyeth inc involved issue litigation included mdl purported class actions asserting whether national vaccine injury compensation act nvica economic loss claims state consumer protection laws precludes lawsuits vaccine manufacturers claiming claims medical monitoring three current exceptions two vaccines covered nvicp defectively designed state court cases pennsylvania one new york supreme court affirmed decision united states court state court cases consolidated philadelphia appeal third circuit held nvica preempts mass tort program purported class actions asserting consumer design defect claims vaccine manufacturers brought fraud claims also filed canada group reached plaintiffs seeking compensation injury death caused agreements principle settle vast majority current vaccines side effects cases group voluntarily withdrawn zinccontaining formulations poligrip market date group seen increase number civil lawsuits filed following announcement nvcip decisions since scope bruesewitz ruling impacts ability plaintiffs pursue claims design certain childhood vaccines defective included use thimerosal preservative impact willingness plaintiffs pursue civil lawsuits based legal theories remains unknown date report cases scheduled trial group defendant gsk annual report pp stnemetats laicnanif notes financial statements legal proceedings continued hiv division inquiry th july group received subpoena sales marketing regulation eastern district new yorks us attorneys office regarding sales marketing practices three hiv products well colorado investigation educational programs grants payments physicians february group received subpoena united regarding drug used treat hivinfected adults group states attorneys office colorado regarding groups sales cooperating investigation promotional practices relating nine largest selling products period january investigation average wholesale price later taken united states attorneys office united states department justice number states district massachusetts expanded present putative classes private payers several years respect advair particular government inquired investigating andor bringing civil litigation regarding allegations alleged promotion drugs offlabel uses well numerous pharmaceutical companies including group groupsponsored continuing medical education programmes violated federal state fraud abuse laws result speaker events special issue boards advisory boards speaker way average wholesale price awp wholesale acquisition training programmes clinical studies related grants fees cost wac determined reported various drugs travel entertainment although original subpoena reimbursed medicare medicaid insurance issued us attorneys office colorado scope programmes group reached million civil inquiry nationwide group continues cooperate settlement federal government resolve allegations government investigation relating pricing marketing zofran kytril government also inquiring groups response group also amended existing corporate integrity agreement october letter fdas division drug marketing requirement settlement group received advertising communication requesting information final approval million nationwide private payer class groups alleged promotion wellbutrin sr offlabel use action settlement relating groups price reporting group cooperating investigation providing mdl proceeding united states district court district requested information massachusetts number states respective attorneys general avandiarelated matters counties new york state filed civil group process responding united states lawsuits state federal courts group many department justice subpoena received june seeking drug companies claiming damages restitution due documents relating development marketing awp andor wac price reporting pharmaceutical products avandia group also received civil investigative demands covered states medicaid programmes states seek number state attorneys general offices relating recovery behalf states payers cases development marketing avandia cooperating behalf instate patients consumers offices group separately resolved awp claims state medicaid utah attorney generals office louisiana attorney programmes twothirds states generals office filed suit group asserting doj settlement separate negotiations litigation concerning various statutory common law claims relating groups awp issues continuing six states development marketing avandia suits early days november kentucky state court jury returned compensatory damages verdict group un oil food programme another case filed state kentucky jury found following united nations report alleging bribes group liable violating states consumer protection laws paid iraqi government officials connection un oil liable states medicaid fraud false advertising food programme group received subpoena statutes january judge case awarded state sec february respect groups participation kentucky additional statutory penalties programme united states department justice doj group settled case kentucky judgment also initiated investigation december uk serious vacated group denied liability part settlement fraud office sfo issued formal notice group requiring production documents related groups participation programme th september sfo notified group completed investigation intends take action group received contact sec doj regarding matter gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements legal proceedings continued paxilseroxat following groups settlement lawsuit filed nominal pricing new york state attorney generals office alleging failure disclose group responded two letter requests united states data use paxil children adolescents similar cases senate committee finance dated april february purported class actions filed private documents information relating nominal plaintiffs seeking recover amounts paid paxil purchased price exception best price reporting requirements use patients age following class settlement medicaid drug rebate programme january committee consumers united states district court released findings pharmaceutical manufacturers district minnesota approved million class inappropriately used nominal price exception contrary settlement ensuing lawsuits seeking recovery behalf committees interpretation congressional intent may insurance companies thirdparty payers payments group advised united states department prescriptions paxil children adolescents group justice investigating certain groups nominal denied liability settlements similar purported pricing bundled sales arrangements determine whether class action filed united states district court district arrangements qualify exception best price minnesota behalf federal state local government reporting requirements violate civil statutes laws entities paid prescriptions paxil minors also remains similar purported class action canada seeking march group received broad letter request economic damages behalf individuals third party payers us department justice seeking range documents governmental entities purchased paxil use patients relating groups nominal pricing arrangements since age possible bundled sales group continuing cooperate investigation produce documents cidra puerto rico manufacturing site group also received subpoenas requests april group received subpoena united documents information delaware michigan states attorneys office boston requesting production records related groups nominal price arrangements group regarding manufacturing facilities located cidra puerto rico cooperating investigations producing responsive since ceased operations addition july documents addition governmental investigations group learned united states district court district allegations concerning nominal pricing made massachusetts unsealed complaint brought former b programme litigation group entered employee federal false claims act claiming monetary nominal price arrangements since december damages result alleged failure cidra facility comply fda good manufacturing processes gmps b programme manufacture various products group defending action filed federal court united states district court northern district california th october group finalised agreement county santa clara one county seeks us attorneys office district massachusetts represent putative class hospitals clinics entities us department justice respect investigation california eligible receive discounted ceiling prices groups former manufacturing facility cidra puerto rico pharmaceuticals federal programme known b agreement comprehensive settlement programme plaintiffs allege group numerous pending claims group arising investigation pharmaceutical manufacturers setting ceiling prices group paid total million million civil higher allowed law contract governs criminal penalties sb pharmco puerto rico inc subsidiary programme therefore overcharged entities group pleaded guilty certain charges group california eligible participate b programme process negotiating corporate integrity agreement office inspector general cover manufacturing lawsuit dismissed reinstated august compliance matters following appeal united states supreme court agreed review issue whether b entities standing group received civil investigative demands sue manufacturers manufacturers b contract subpoena several state attorneys general offices relating government trial court stayed proceedings case matters issue federal investigation enquiries supreme courts decision oral argument early stage group cooperating offices supreme court occurred th january supreme secdoj fcpa inquiry court yet issued decision us securities exchange commission sec us department justice doj conducting industrywide investigation whether pharmaceutical companies may engaged violations foreign corrupt practices act relating sale pharmaceuticals including argentina brazil canada china germany italy poland russia saudi arabia group one companies asked respond inquiry cooperating sec doj gsk annual report pp stnemetats laicnanif notes financial statements legal proceedings continued wellbutrin xl actions filed biovail group antitrustcompetition purported classes direct indirect purchasers allege unlawful monopolisation antitrust violations related paxilseroxat enforcement biovails wellbutrin xl patents noted previously group settled patent filing biovail citizen petitions groups motion infringement antitrust litigation apotex regarding paxil dismiss amended complaint indirect purchasers seroxat litigation dismissed parties granted respect claims class representatives many claims asserted indirect eu sector inquiry purchasers case proceeded discovery respect january european commission announced inquiry remaining claims well ones brought purported certain aspects competition pharmaceutical sector class direct purchasers class certification hearing scheduled initiated inspections premises number innovator april generic pharmaceutical companies including group commission published preliminary report november flonase report suggests defensive patenting strategies purported direct indirect purchaser class actions may lead obstacles innovation innovator companies filed united states district court eastern district employ measures hinder generics coming onto market pennsylvania alleging group illegally maintained monopoly final report issued july contradicting power market flonase charged plaintiffs supra preliminary report final report conceded delays competitive prices additionally suit filed roxane generic entry much fault regulatory environment laboratories inc generic competitor seeking lost profits innovator companies defensive strategies report groups alleged actions unlawfully delaying roxanes entry commission stated attack legitimate patenting market predicate allegations filing practices identified areas follow scrutiny group allegedly sham citizen petitions subsequent commission recommended regulatory reform litigation motion direct purchasers certify class improvement granted court group successfully narrowed th january commission requested information claims purported class indirect purchasers group number pharmaceutical companies motions dismiss complaint amended complaints relating patent settlement agreements affecting european union groups motion dismiss roxanes complaint denied european economic area markets request information commercial corporate second monitoring exercise commission patent settlement agreements pharmaceuticals sector group securitieserisa class actions process responding commissions request th july class action suit brought behalf current former employees stiefel laboratories inc filed wellbutrin sr united states district court southern district florida december january february lawsuits complaint alleges stiefel officers directors several purported class actions filed violated us employee retirement income security act erisa united states district court eastern district pennsylvania federal state securities laws inducing stiefel employees group behalf direct indirect purchasers sell shares employee stock plan back stiefel wellbutrin sr complaints allege violations us antitrust greatly undervalued price without disclosing employees laws sham litigation fraud patent office stiefel sold group january group obtaining enforcing patents covering wellbutrin sr defendants motion dismiss granted part denied complaints followed introduction generic competition part specifically court determined erisa claims wellbutrin sr april district appellate court rulings individual stiefel defendants well federal generic manufacturer infringe groups patents securities claims individual defendants stiefel could class direct purchasers certified court recently go forward court dismissed florida securities act entered order granting motion indirect purchaser common law breach fiduciary duty claims holding erisa plaintiffs file renewed motion class certification court preempts state common law well malpractice claim scheduled trial th june regard claims stiefels former accountants trial remaining claims certified class direct purchasers scheduled july secondary wholesaler putative class action suit filed group july rxusa wholesale inc secondary wholesaler th august united states district court filed suit group many pharmaceutical southern district new york complaint alleges manufacturers wholesalers united states district group officers directors certain employees made court eastern district new york complaint alleges misleading public statements avandia defendants engaged conspiracy refuse supply alleged misleading statements exposed pharmaceutical products rxusa violation federal state value groups stock dropped plaintiff brought suit antitrust laws groups motion dismiss complaint behalf participants groups granted united states court appeals second circuit retirement plans claiming group individual affirmed dismissal complaint case concluded defendants breached fiduciary duties plan participants erisa gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements legal proceedings continued environmental matters group notified potential responsibility relating plaintiffs amended complaint add allegations past operations past waste disposal practices certain concerning wellbutrin sr paxil include additional sites primarily usa matters subject group defendants individual members groups litigation including proceedings initiated us federal state benefits committees group filed motion dismiss governments waste disposal site remediation costs tort th february actions brought private parties wage hour claims group advised may responsible party december two purported class actions filed approximately sites appear national group behalf entire groups us priority list created comprehensive environmental response pharmaceutical sales representatives actions compensation liability act superfund proceedings filed transferred united states district court seek require operators hazardous waste facilities central district california initially alleged transporters waste sites generators hazardous representatives exempt employees california law waste disposed sites clean sites reimburse andor us fair labor standards act flsa consequently government cleanup costs instances group entitled overtime pay among things involved alleged generator hazardous waste although superfund provides defendants jointly severally plaintiffs subsequently amended complaints assert class liable cleanup costs proceedings frequently resolved action limited solely pharmaceutical sales representatives basis nature quantity waste disposed working california asserting claims californias generator site groups proportionate liability cleanup wage hour laws costs substantially determined sites suits seek variety compensatory punitive statutory referred damages group moved summary judgment dismissing groups potential liability varies greatly site site claims putative class representatives ground cost investigation study remediation exempt employees court held sites could time substantial group routinely accrues appeals pending united states court appeals amounts related share liability matters ninth circuit cases involving manufacturers virtually factual legal arguments therefore deferred ruling summary judgment motion stayed activity case appellate court rules least one companies pending cases third case filed united states district court district arizona august sought establish nationwide collective action behalf entire groups us pharmaceutical sales representatives ground representatives exempt employees flsa plaintiffs sought double damages overtime allegedly worked groups pharmaceutical sales representatives three year period november court granted groups motion summary judgment dismissed lawsuit ground sales representatives exempt employees outside sales exemption flsa plaintiffs appealed decision united states court appeals ninth circuit th february ninth circuit issued opinion favour group affirming judgment united states district court district arizona finding groups pharmaceutical sales representatives exempt employees outside sales exemption flsa therefore entitled overtime pay november purported class action filed group united states district court northern district new york behalf groups pharmaceutical sales representatives working new york past six years plaintiff alleges sales representatives exempt employees therefore entitled overtime new york wage hour laws closely follow us fair labor standards act january plaintiff filed similar purported class action florida state court alleging groups pharmaceutical sales representatives entitled overtime flsa gsk annual report pp stnemetats laicnanif directors statement responsibilities directors statement responsibilities disclosure information auditors relation companys financial statements directors office date report directors responsible preparing parent company confirmed glaxosmithkline plc financial statements remuneration far aware relevant audit report accordance applicable law regulations information companys auditors unaware company law requires directors prepare financial statements taken steps ought financial year law directors elected taken director make aware prepare parent company financial statements accordance relevant audit information establish companys united kingdom accounting standards applicable law auditors aware information united kingdom generally accepted accounting practice company law directors must approve parent company confirmation given interpreted accordance financial statements unless satisfied give true provisions section companies act fair view state affairs company period going concern basis preparing financial statements directors making enquiries directors reasonable required expectation company adequate resources continue select suitable accounting policies apply operational existence foreseeable future reason consistently continue adopt going concern basis preparing financial statements make judgements accounting estimates reasonable prudent combined code state regard parent company financial statements board considers glaxosmithkline plc applies main applicable uk accounting standards followed principles section combined code mantained subject material departures disclosed explained frc described corporate governance section pages parent company financial statements complied provisions except described directors responsible keeping adequate accounting records sufficient show explain companys required fsas listing rules auditors considered transactions disclose reasonable accuracy time directors statement compliance relation points financial position company enable ensure combined code specified review parent company financial statements remuneration report comply companies act also responsible safeguarding assets company hence taking reasonable steps prevention detection sir christopher gent fraud irregularities chairman st march parent company financial statements year ended st december comprising balance sheet year ended st december supporting notes set pages report responsibilities auditors relation parent company financial statements set independent auditors report financial statements year ended st december included annual report published hard copy printed form made available website directors responsible maintenance integrity annual report companys website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp independent auditors report members glaxosmithkline plc audited parent company financial statements matters required report glaxosmithkline plc year ended st december exception comprise company balance sheet uk gaap nothing report respect following matters related notes ah financial reporting framework companies act requires us report applied preparation applicable law united opinion kingdom accounting standards united kingdom generally accepted accounting practice adequate accounting records kept parent company returns adequate audit respective responsibilities directors received branches visited us auditors parent company financial statements part explained fully directors statement directors remuneration report audited responsibilities set directors responsible agreement accounting records returns preparation parent company financial statements satisfied give true fair view certain disclosures directors remuneration specified law responsibility audit express opinion made parent company financial statements accordance applicable received information explanations law international standards auditing uk ireland require audit standards require us comply auditing practices boards ethical standards auditors matters report including opinions prepared reported separately group financial statements companys members body accordance chapter glaxosmithkline plc year ended st december part companies act purpose company passed resolution accordance section giving opinions accept assume responsibility companies act senior statutory auditors purpose person report name stated shown whose hands may come save expressly agreed prior consent writing scope audit financial statements audit involves obtaining evidence amounts disclosures financial statements sufficient give reasonable assurance financial statements free material misstatement whether caused fraud error includes pricewaterhousecoopers llp assessment whether accounting policies appropriate chartered accountants statutory auditors parent companys circumstances consistently london applied adequately disclosed reasonableness significant st march accounting estimates made directors overall presentation financial statements opinion financial statements opinion parent company financial statements g ive true fair view state companys affairs st december properly prepared accordance united kingdom generally accepted accounting practice prepared accordance requirements companies act opinion matters prescribed companies act opinion part directors remuneration report audited properly prepared accordance companies act information given directors report financial year parent company financial statements prepared consistent parent company financial statements gsk annual report pp stnemetats laicnanif company balance sheet uk gaap st december notes fixed assets investments debtors e cash bank current assets creditors amounts due within one year f net current liabilities net assets capital reserves called share capital g share premium account g reserves h profit loss account h equity shareholders funds approved board st march sir christopher gent chairman glaxosmithkline plc registered number gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes company balance sheet uk gaap presentation financial statements expenditure expenditure recognised respect goods services received description business supplied accordance contractual terms provision glaxosmithkline plc parent company gsk major global made obligation exists future liability respect healthcare group engaged creation discovery past event amount obligation development manufacture marketing pharmaceutical reliably estimated products including vaccines overthecounter otc medicines healthrelated consumer products investments subsidiary companies investments subsidiary companies held cost less preparation financial statements provision impairment financial statements prepared going concern basis drawn accordance uk generally accepted impairment investments accounting principles uk gaap uk accounting carrying value investments reviewed impairment presentation st december comparative figures indication investment might impaired st december appropriate comparative provision resulting impairment review charged figures reclassified ensure consistent presentation income statement year concerned current year information share based payments permitted companies act profit issuance company subsidiaries grant loss account company presented annual report companys options represents additional capital contributions accounting convention standards company subsidiaries additional investment balance sheet prepared using historical cost subsidiaries results corresponding increase shareholders convention complies applicable uk accounting standards equity additional capital contribution based fair value grant issued allocated underlying grants accounting principles policies vesting period preparation balance sheet conformity generally taxation accepted accounting principles requires management make estimates assumptions affect reported amounts current tax provided amounts expected paid assets liabilities disclosure contingent assets applying tax rates enacted substantially enacted liabilities date balance sheet actual amounts could balance sheet date differ estimates company accounts taxation deferred accelerated balance sheet prepared accordance reason timing differences originated companys accounting policies approved board reversed balance sheet date deferred tax assets described note b recognised extent considered recoverable future taxable profits b accounting policies deferred tax measured average tax rates foreign currency transactions expected apply periods timing differences expected reverse deferred tax liabilities assets foreign currency transactions recorded exchange rate discounted ruling date transaction forward rate hedged forward exchange contract foreign currency assets financial guarantees liabilities translated rates exchange ruling balance liabilities relating guarantees issued company behalf sheet date forward rate subsidiaries initially recognised fair value amortised dividends paid received life guarantee dividends paid received included accounts c operating profit period related dividends actually paid received fee relating audit company charged operating profit gsk annual report pp stnemetats laicnanif notes company balance sheet uk gaap fixed assets shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating share based payments e debtors amounts due within one year uk corporation tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings f creditors amounts due within one year bank overdraft amounts owed group undertakings creditors company guaranteed debt issued one subsidiary companies receives annual fee subsidiary aggregate company outstanding guarantees billion debt instruments amount due subsidiary companies relation guarantee fees recovered life bonds disclosed within debtors see note e gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes company balance sheet uk gaap g share capital share premium account share ordinary shares p premium number share capital authorised st december st december share capital issued fully paid st january issued share option schemes st december issued share option schemes st december st december st december number shares issuable outstanding options number unissued shares option st december issued share capital shares held esop trust shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trust disclosed note employee share schemes company purchase shares rd february gsk announced would commence new longterm share buyback programme expected repurchase billion shares depending market conditions exact amount timing purchases whether shares held treasury shares cancelled determined company dependent market conditions factors shares purchased period st january rd february period th february th february million shares purchased cost million h reserves profit reserves loss account total st january profit attributable shareholders dividends shareholders capital contribution relating share based payments st december loss attributable shareholders dividends shareholders capital contribution relating share based payments st december loss glaxosmithkline plc year million profit million dividends million million gave retained loss million profit million profit loss account reserve st december stood million million million unrealised million post balance sheet event rd february company initiated new longterm share buyback programme intention repurchase billion shares depending market conditions period th february th february million shares purchased cost million gsk annual report pp noitamrofni redloherahs financial record quarterly trend unaudited analysis group results pharmaceutical sales therapeutic area provided quarter sterling financial year income statement total months q cer cer turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administration research development operating income operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p diluted earnings per share pence p p income statement results major restructuring total turnover cost sales selling general administration research development operating income operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p diluted earnings per share pence p p calculation results major restructuring described note financial statements presentation financial statements gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial record q q q cer cer cer p p p p p p p p p p p p gsk annual report pp noitamrofni redloherahs financial record quarterly trend pharmaceutical turnover total group q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial record quarterly trend pharmaceutical turnover usa q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report pp noitamrofni redloherahs financial record quarterly trend pharmaceutical turnover europe q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial record quarterly trend pharmaceutical turnover emerging markets q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report pp noitamrofni redloherahs financial record quarterly trend pharmaceutical turnover rest world q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial record quarterly trend consumer healthcare turnover q q q q cer cer cer cer overthecounter medicines oral healthcare nutritional healthcare q q q q cer cer cer cer usa europe rest world gsk annual report pp noitamrofni redloherahs financial record five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board turnover business segment pharmaceutical consumer healthcare pharmaceutical turnover therapeutic area respiratory antivirals hiv central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis vaccines dermatologicals pharmaceutical turnover geographic area usa europe emerging markets asia pacificjapan pharmaceutical turnover includes copromotion income viiv healthcare turnover included geographic area sale made consumer healthcare turnover otc medicines oral healthcare nutritional healthcare gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial record financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share financial results major restructuring turnover operating profit profit taxation profit taxation pence pence pence adjusted earnings per share adjusted diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted return capital employed return capital employed calculated total profit taxation percentage average net assets year balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity gsk annual report pp noitamrofni redloherahs financial record number employees usa europe rest world asia pacific including china japan middle east africa latin america canada rest world manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates day year feb jan dec nov oct sept high low st december federal reserve bank new york ceased publishing noon buying rates bank england pm buying rates used subsequent calculations pm buying rate th february us gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp product development pipeline key inlicense alliance relationship third party bla biological license application month first submission maa marketing authorisation application europe month first regulatory approval maa first eu nda new drug application usa approval letter phase evaluation clinical pharmacology usually conducted volunteers alcr month approvable complete response letter received indicates phase ii determination dose initial evaluation efficacy conducted ultimately approval may given subject resolution small number patients outstanding queries phase iii large comparative study compound versus placebo andor established po month eu positive opinion treatment patients establish clinical benefit safety ta fda tentative approval maa ndabla regulatory milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla biopharmaceuticals beta amyloid monoclonal antibody alzheimers disorders il monoclonal antibody metabolic disease nogoa monoclonal antibody amyotrophic lateral sclerosis multiple sclerosis domain antibody targetted multicomponent malignant melanoma vaccine apn recombinant human angiotensin converting acute respiratory distress syndrome anzyme iboctadekin doxil il immunomodulator topoisomerase ii ovarian cancer inhibitor otelixizumab anticd monoclonal antibody iv graves eye disease otelixizumab anticd monoclonal antibody sc iv rheumatoid arthritis otelixizumab anticd monoclonal antibody sc type diabetes myelinassociated glycoprotein monoclonal stroke ii antibody oncostatin monoclonal antibody rheumatoid arthritis ii parathyroid hormone osteoporosis ii albiglutide glucagonlike peptide glp agonist heart failure ii benlysta antib lymphocyte stimulator monoclonal systemic lupus erythematosus ii antibody sc mepolizumab antiil monoclonal antibody severe asthma nasal polyposis ii ofatumumab anticd human monoclonal antibody sc multiple sclerosis ii ofatumumab anticd human monoclonal antibody sc rheumatoid arthritis ii otelixizumab anticd monoclonal antibody iv myaesthenia gravis ii albiglutide glp agonist type diabetes iii arzerra anticd human monoclonal antibody chronic lymphocytic leukaemia first line therapy use iii relapsed patients arzerra anticd human monoclonal antibody diffuse large b cell lymphoma relapsed patients iii arzerra anticd human monoclonal antibody follicular lymphoma refractory relapsed patients iii otelixizumab anticd monoclonal antibody iv type diabetes iii benlysta antib lymphocyte stimulator monoclonal systemic lupus erythematosus submitted jun jun antibody iv denosumab antireceptor activator nuclear kappa bone metastatic disease submitted na na rank ligand human monoclonal antibody arzerra anticd human monoclonal antibody chronic lymphocytic leukaemia refractory patients approved apr oct prolia antirank ligand human monoclonal antibody hormone ablativechemotherapy bone loss prostate approved na na cancer patients prolia antirank ligand human monoclonal antibody postmenopausal osteoporosis approved may na cardiovascular metabolic sodium dependent glucose transport sglt type diabetes inhibitor sirt activator sarcopaenia also copd psoriasis high affinity nicotinic acid receptor hma metabolic disorders ii agonist oxytocin antagonist premature ejaculation ii prolyl hydroxylase inhibitor anaemia associated chronic renal disease ii prolyl hydroxylase inhibitor peripheral arterial disease ii gprotein coupled receptor grp metabolic disorders ii agonist muopioid receptor inverse agonist compulsive eating disorders ii sirt activator type diabetes also copd psoriasis ii losmapimod p kinase inhibitor cardiovascular disease also copd pain ii retosiban oxytocin antagonist threatened preterm labour ii rilapladib lppla inhibitor atherosclerosis ii darapladib lppla inhibitor atherosclerosis iii arixtra synthetic factor xa inhibitor treatment acute coronary syndrome approved aug al feb sep gsk annual report pp noitamrofni redloherahs product development pipeline achieved regulatory review milestones compound type indication phase maa ndabla infectious diseases leucyl trna synthetase inhibitor oral iv bacterial infections hepatitis c virus inhibitor hepatitis c hepatitis c virus inhibitor hepatitis c polypeptide deformylase inhibitor bacterial infections ii tafenoquine aminoquinoline plasmodium vivax malaria ii relenza neuraminidase inhibitor iv influenza iii neurosciences sphingosinephosphate receptor sp multiple sclerosis agonist histamine h antagonist dementia schizophrenia ii orexin antagonist sleep disorders ii ht antagonist dementia ii firategrast dual alpha integrin antagonist vla multiple sclerosis ii horizant voltagegated calcium channel modulator postherpetic neuralgia ii na losmapimod p kinase inhibitor pain also cardiovascular disease copd ii orvepitant nk antagonist depression anxiety ii ipx dopamine precursor dopa decarboxylase parkinsons disease iii na inhibitor horizant voltagegated calcium channel modulator restless legs syndrome submitted sep jan oct trobaltpotiga neuronal potassium channel opener epilepsy partial seizures submitted po jan cr nov retigabineezogabine oncology akt protein kinase inhibitor cancer pi kinase inhibitor cancer akt protein kinase inhibitor cancer focal adhesion kinase inhibitor cancer vestipitant nk antagonist iv post operative nausea vomiting bkm mitogenactivated protein kinase inhibitor cancer mek pi alpha kinase inhibitor mek inhibitor pancreatic cancer ii mek inhibitor braf protein kinase inhibitor metastatic melanoma ii thrombopoietin receptor agonist thrombocytopaenia ii foretinib mesenchymalepithelial transition factor papillary renal cell carcinoma cancers ii cmet kinase inhibitor revoladepromacta thrombopoietin receptor agonist oncologyrelated thrombocytopaenia ii mek inhibitor metastatic melanoma iii braf protein kinase inhibitor metastatic melanoma iii votrient multikinase angiogenesis inhibitor ovarian cancer maintenance therapy iii revoladepromacta thrombopoietin receptor agonist chronic liver disease induced thrombocytopaenia iii revoladepromacta thrombopoietin receptor agonist hepatitis c induced thrombocytopaenia iii tyverbtykerb egfr dual kinase inhibitor breast cancer adjuvant therapy iii tyverbtykerb egfr dual kinase inhibitor gastric cancer iii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma resectable disease iii votrient multikinase angiogenesis inhibitor renal cell cancer adjuvant therapy iii votrient multikinase angiogenesis inhibitor sarcoma iii votrient tyverbtykerb multikinase angiogenesis inhibitor inflammatory breast cancer iii egfr dual kinase inhibitor avodart alpha reductase inhibitor reduction risk prostate cancer submitted sep cr jan mar duodartjalyn alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fixed dose combination approved mar jun revoladepromacta thrombopoietin receptor agonist idiopathic thrombocytopaenic purpura approved mar nov tyverbtykerb egfr dual kinase inhibitor breast cancer first line therapy approved jun jan votrient multikinase angiogenesis inhibitor renal cell cancer approved jun aoct ophthalmology pazopanib multikinase angiogenesis inhibitor oral agerelated macular degeneration also cancer indications pazopanib multikinase angiogenesis inhibitor eye drops agerelated macular degeneration ii gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp product development pipeline achieved regulatory review milestones compound type indication phase maa ndabla respiratory immunoinflammation p kinase inhibitor inhaled copd transient receptor potential vanilloid trpv pruritis antagonist topical motilin receptor agonist delayed gastric emptying chemokine receptor cxcr antagonist copd urotensin antagonist asthma sirt activator copd also type diabetes sarcopaenia sirt activator psoriasis also type diabetes sarcopaenia ii pde inhibitor inhaled copd ii chemokine receptor cxcr antagonist cystic fibrosis ii glucocorticoid agonist asthma ii p kinase inhibitor iv acute lung injury acute respiratory distress syndrome ii transient receptor potential vanilloid trpv nonallergic rhinitis ii antagonist intranasal novel glucocorticoid agonist inhaled asthma ii novel glucocorticoid agonist topical atopic dermatitis ii muscarinic antagonist beta agonist copd ii motilin receptor agonist delayed gastric emptying ii antiinflammatory macrolide conjugate oral inflammatory bowel disease ii lipoxygenaseactivating protein flap asthma ii inhibitor losmapimod p kinase inhibitor oral copd also cardiovascular disease pain ii muscarinic acetylcholine antagonist copd iii vilanterol muscarinic acetylcholine antagonist copd iii longacting beta agonist vilanterol longacting beta agonist copd iii ccx ccr antagonist crohns disease iii relovair vilanterol longacting beta agonist asthma iii glucocorticoid agonist relovair vilanterol longacting beta agonist copd iii glucocorticoid agonist paediatric vaccines heptavalent combination conjugated neisseria meningitis c haemophilus influenzae type b ii vaccine diphtheria hepatitis b tetanus pertussis poliomyelitis disease prophylaxis mmr live attenuated measles mumps rubella prophylaxis ii usa oct pneumoniae paediatric recombinant conjugated streptococcus pneumoniae disease prophylaxis ii next generation mosquirix recombinant malaria prophylaxis plasmodium falciparum iii na nimenrix menacwytt conjugated neisseria meningitis groups c w disease prophylaxis submitted menhibrix conjugated neisseria meningitis groups c haemophilus influenzae submitted na cr jun hibmencytt type b disease prophylaxis vaccines flu pandemic cellculture based hn vaccine pandemic influenza prophylaxis hiv recombinant hiv disease prophylaxis hiv recombinant hiv disease immunotherapy ii tuberculosis recombinant tuberculosis prophylaxis ii flu vaccine inactivated split quadrivalent seasonal influenza prophylaxis iii zoster recombinant herpes zoster prevention iii flu pre pandemic hn inactivated split monovalent quebec prepandemic pandemic influenza prophylaxis submitted na sjun canada pumarix hn inactivated split monovalent quebec pandemic influenza prophylaxis submitted po nov na gsk annual report pp noitamrofni redloherahs product development pipeline achieved regulatory review milestones compound type indication phase maa ndabla antigen specific cancer immunotherapeutic asci prame recombinant treatment metastatic melanoma prame recombinant treatment resectable nonsmall cell lung cancer nyeso recombinant treatment metastatic melanoma wt recombinant treatment acute myelogenous leukaemia ii magea recombinant treatment melanoma iii magea recombinant treatment nonsmall cell lung cancer iii rare diseases antisense oligonucleotide duchenne muscular dystrophy iii exvivo stem cell gene therapy adenosine deaminase severe combined immune deficiency iii adascid migalastat hcl pharmacological chaperone fabry disease iii stiefel late stage assets tazarotene foam retinoid foam acne vulgaris iii duac low dose clindamycinbenzoyl peroxide gel acne vulgaris submitted nov sorilux vitamin analog mild moderate plaque psoriasis approved oct calcipotriene foam itraconazole tablets oral antifungal onychomycosis approved apr veltin antibioticretinoid gel acne vulgaris approved jul hiv viiv healthcare hiv integrase inhibitor longacting formulation hiv infections nonnucleoside reverse transcriptase inhibitor hiv infections ii pf ccr antagonist hiv infections ii uk nonnucleoside reverse transcriptase inhibitor hiv infections ii hiv integrase inhibitor hiv infections iii abacavir hiv integrase inhibitor reverse transcriptase hiv infections iii sulphate lamivudine inhibitors fixed dose combination optionbased alliances third parties include assets phase later development company disease area phase cancer research uk cancer chemocentryx inflammatory disease ii galapagos autoimmune disease oncomed pharmaceuticals oncology prosensa therapeutics neuroscience ranbaxy laboratories respiratory theravance pain telethon institute gene therapy stem cell gene therapy ii affiris alzheimers disease treatment vaccine ii nabi nicotine vaccine iii two assets gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information ordinary shares company listed london stock dividends per ads exchange new york stock exchange nyse form table sets dividends per ads us dollars american depositary shares ads details listed debt last five years translated us dollars applicable listed refer note net debt exchange rates share price year us st january high year low year st december increasedecrease pence us table sets middle market closing prices companys share price decreased compares increase ftse index year share price th february us uk dividends per share us dividends per ads dividend calendar quarter exdividend date record date payment date q th february th february th april uk share price us adr price us q th may th may th july q rd august th august th october market capitalisation q nd november th november th january market capitalisation based shares issue excluding treasury shares glaxosmithkline st december billion date gsk sixth largest company financial reporting calendar market capitalisation ftse index publication date smithkline beecham plc floating rate results announcements unsecured loan stock quarter april quarter july loan stock listed exchange quarter october redeemed entirety par ie every loan stock preliminaryquarter february held st june annual reportsummary februarymarch dividends gsk pays dividends quarterly continues increase cash returns results announcements shareholders dividend policy dividends remain results announcements issued london stock exchange essential component total shareholder return gsk available news service shortly afterwards committed increasing dividend longterm details issued media made available website sent dividends declared amount payment dates us securities exchange commission nyse given note financial statements dividends financial reports dividends per share gsk publishes annual report shareholder needing table sets dividends per share last five years full detail report summary document available date publication website summary year pence sent shareholders shareholders may elect receive annual report writing registrars alternatively shareholders may elect receive notification email publication financial reports registering wwwshareviewcouk copies previous financial reports available gsks website printed copies obtained registrars uk gsk response center usa gsk annual report pp noitamrofni redloherahs shareholder information corporate responsibility report internet publish corporate responsibilty report information company including details share online st march outline gsks approach price available gsks website wwwgskcom information performance responsibility areas including access made available website constitute part medicines research business ethics environmental annual report sustainability community investment annual general meeting nature trading market queen elizabeth ii conference centre th may following tables set periods indicated high broad sanctuary westminster low middle market closing quotations pence shares london swp ee london stock exchange high low last reported sales prices us dollars ads nyse agm companys principal forum communication pence per share private shareholders addition formal business high low presentation chief executive officer performance group future development quarter ended st march opportunity questions board chairmen february boards committees take questions matters relating january committees december november investors holding shares nominee service october arrange nominee service appointed corporate september representative proxy respect shareholding order quarter ended st december attend vote meeting quarter ended th september adr holders wishing attend meeting must obtain proxy quarter ended th june bank new york mellon enable quarter ended st march attend vote business transacted adr holders may quarter ended st december instruct bank new york mellon way quarter ended th september shares represented adr voted completing quarter ended th june returning voting card provided bank accordance quarter ended st march instructions given year ended st december year ended st december documents display year ended st december articles association company documents referred annual report available us dollars per ads inspection registered office company high low exchange controls limitations quarter ended st march affecting security holders february january currently uk laws decrees regulations restricting december import export capital affecting remittance november dividends payments holders companys shares october nonresidents uk limitations relating september nonresidents uk english law companys quarter ended st december articles association right holder vote respect companys shares quarter ended th september quarter ended th june duplicate publications quarter ended st march quarter ended st december queries relating receipt duplicate copies gsks publications quarter ended th september addressed registrars quarter ended th june investor relations quarter ended st march year ended st december investor relations may contacted follows year ended st december uk year ended st december great west road brentford middlesex tw gs th february tel usa taxation one franklin plaza po box philadelphia pa general information concerning uk us tax effects tel us toll free share ownership set taxation information tel outside usa shareholders gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information cidregistrar glaxo wellcome smithkline beecham companys registrars corporate peps share centre limited equiniti limited oxford house oxford road aylesbury bucks hp sz aspect house spencer road lancing west sussex bn da tel wwwshareviewcouk tel inside uk adr programme administrator tel outside uk adr programme administered lines open pm monday friday bny mellon shareowner services equiniti also provides following services po box pittsburgh pa nominee dealing account individual savings account isa wwwbnymelloncomshareowner g laxosmithkline corporate sponsored nominee tel us toll free tel outside usa hareview service email shrrelationsbnymelloncom share dealing service administrators also provide global buydirect direct ads dividend reinvestment plan purchasesale dividend reinvestment plan adr holders share dealing service gsk response center shareholders may trade shares either held certificates tel us toll free corporate sponsored nominee internet telephone shareview dealing share dealing service provided provision details intended equiniti financial services limited internet deals log invitation inducement engage investment activity wwwshareviewcoukdealing telephone deals call advice share dealing obtained stockbroker inside uk independent financial adviser investment account isa service either wwwshareviewcoukdealing call telephone services available pm monday friday market trading hours pm analysis shareholdings st december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bank new york mellons holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value th february bny nominees limited held ordinary shares representing issued share capital excluding treasury shares date th february number holders shares usa holdings shares number registered holders adr holdings adr certain shares adr held brokers nominees result number holders record registered holders usa representative number beneficial holders residence beneficial holders gsk annual report pp noitamrofni redloherahs taxation information shareholders summary certain uk tax us federal income tax us shareholders consequences certain holders shares adr citizens summary applies shareholder citizen resident uk usa set complete analysis usa domestic corporation person otherwise possible tax consequences purchase ownership subject us federal income tax net income basis respect securities intended general guide holders shares adr holds shares adr capital assets advised consult advisers respect tax consequences resident uk uk tax purposes hold shares purchase ownership shares adr purposes trade profession vocation carried consequences state local tax laws usa uk branch agency summary also implications current ukus income tax convention address tax treatment holders subject special us holders adr generally treated owners tax rules banks taxexempt entities insurance companies underlying shares purposes current usauk double dealers securities currencies persons hold shares adr taxation conventions relating income gains income tax part integrated investment including straddle comprised convention estate gift taxes estate gift tax convention share adr one positions persons purposes us internal revenue code directly indirectly voting stock gsk amended code taxation dividends uk shareholders gross amount dividends received treated foreign source dividend income us tax purposes eligible dividend summary applies uk resident shareholder holds received deduction allowed us corporations dividends adr shares capital assets payable us dollars dividends shares payable sterling taxation dividends dividends paid pounds sterling included income us dollar amount calculated reference exchange rate uk resident individual shareholders generally subject uk day dividends received holder subject certain income tax full amount dividends paid grossed exceptions shortterm hedged positions individual eligible amount one ninth dividend tax credit tax credit may us holder subject us taxation maximum rate set individuals income tax liability respect gross respect qualified dividends received dividend repayable shareholders tax liability less associated tax credit tax year taxation capital gains subsequent tax years additional rate income tax dividends generally us holders subject uk capital gains tax imposed taxpayers whose income subject us tax capital gains realised sale uk resident shareholders corporation taxpayers disposal shares adr gains longterm note dividends generally entitled exemption capital gains subject reduced rates taxation individual corporation tax shareholders doubt holders shares adr held one year position consult professional advisers information reporting backup withholding taxation capital gains dividends payments proceeds sale shares uk shareholders may liable uk tax gains disposal adr paid within usa certain usrelated financial shares adr disposals individuals subject intermediaries subject information reporting may availability exemption relief annual exempt subject backup withholding unless us holder corporation amount taxable capital gain accruing disposal shares exempt recipient provides taxpayer identification adr taxed allowable deductions number certifies loss exemption occurred shareholders taxable income tax year exceeds basic rate nonus holders generally subject information reporting income tax limit cases taxable capital gain accruing backup withholding may required provide certification disposal shares adr may taxed nonus status connection payments received combination rates corporation taxpayers may entitled amounts withheld allowed refund credit indexation allowance applies reduce capital gains holders us federal income tax liability provided required extent gains arise due inflation indexation information furnished irs allowance may reduce chargeable gain create allowable loss estate gift taxes estate gift tax convention us shareholder inheritance tax generally subject uk inheritance tax individual shareholders may liable inheritance tax transfer shares adr tax may charged amount stamp duty value shareholders estate reduced result uk stamp duty sdrt subject certain exemptions transfer way gift disposal less full payable issue transfer shares adr custodian market value depository rate price issued amount consideration provided transferred sale value gift disposal subject uk inheritance transferred consideration tax us estate gift tax estate gift tax convention would generally provide tax paid usa credited sdrt would payable transfer agreement tax payable uk transfer adr uk stamp duty payable transfer adr provided instrument transfer executed stamp duty remains times outside uk stamp duty transfer uk stamp duty stamp duty reserve tax sdrt subject adr would payable rate consideration certain exemptions payable transfer shares rate transfer sale underlying shares would subject certain consideration transfer exceptions result liability uk stamp duty case may sdrt rate gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates combined code guidelines required listing rules financial services authority address principal aspects corporate governance company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid shareholders funds shareholders equity share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity glaxosmithkline holds majority shareholding andor exercises control treasury share treasury stock turnover revenue gsk annual report pp noitamrofni redloherahs index performance overview inventories accounting principles policies investments associates joint ventures acquisitions disposals investor relations adjustments reconciling profit tax operating cash flows key accounting judgements estimates annual general meeting key performance indicators annual remuneration legal proceedings assets held sale major restructuring programme associates joint ventures manufacturing supply board movements equity business review nature trading market cash cash equivalents net debt chairman ceo summary new accounting requirements combined code nonexecutive director terms conditions commitments nonexecutive directors fees committee reports notes financial statements competition operating profit consolidated balance sheet intangible assets consolidated cash flow statement investments consolidated income statement noncurrent assets consolidated statement changes equity noncurrent liabilities consolidated statement comprehensive income operating income consumer healthcare provisions contingent liabilities outlook corporate executive team pensions postemployment benefits corporate governance pharmaceutical turnover critical accounting policies post balance sheet events dialogue shareholders presentation financial statements directors senior management price controls directors interests principal group companies directors interests contracts product development pipeline directors statement responsibilities products dividends property plant equipment donations political organisations quarterly trend political expenditure reconciliation net cash flow movement net debt earnings per share registrar employee costs regulation employee share schemes related party transactions employees remuneration policy exchange rates remuneration report executive director terms conditions research development finance costs responsible business finance income risk factors financial instruments related disclosures segment information financial position resources segment reviews financial review share capital control financial review share capital share premium account financial statements glaxosmithkline plc prepared share options uk gaap share price five year record shareholder information foreign exchange management strategy glossary terms taxation goodwill taxation information shareholders governance policy total equity improving access medicines trade payables incentive plans trade receivables independent auditors report trademarks intellectual property treasury operations interest rate risk management us law regulation internal control framework world market gsk annual report history development company glaxosmithkline plc public limited company incorporated th december english law shares listed london stock exchange new york stock exchange th december company acquired glaxo wellcome plc smithkline beecham plc english public limited companies way scheme arrangement merger two companies gsk subsidiaries associates constitute major global healthcare group engaged creation discovery development manufacture marketing pharmaceutical consumer healthrelated products annual report summary report annual report glaxosmithkline plc year ended st december prepared accordance united kingdom requirements approved board directors st march published nd march summary year intended shareholder needing full detail annual report produced separate document issued shareholders summary constitute set summary financial statements defined section companies act annual report issued shareholders elected receive documents available gsks website report glaxosmithkline group gsk means glaxosmithkline plc subsidiaries company means glaxosmithkline plc glaxosmithkline share means ordinary share glaxosmithkline plc p american depositary shares ads represent two glaxosmithkline shares brand names brand names appearing italics throughout report trademarks either owned andor licensed glaxosmithkline associated companies exception benlysta trademark human genome science bonivabonviva trademark roche botox trademark allergan levitra trademark bayer nicoderm trademark elan johnson johnson merrell novartis sanofiaventis glaxosmithkline potiga trademark valeant prolia trademark amgen vesicare trademark astellas pharmaceuticals many countries yamanouchi pharmaceuticals certain countries volibris trademark gilead used certain countries licence group exchange rates group operates many countries earns revenues incurs costs many currencies results group reported sterling affected movements exchange rates sterling currencies average exchange rates prevailing period used translate results cash flows overseas subsidiaries associates joint ventures sterling period end rates used translate net assets entities currencies influence groups results remain us dollar euro yen sterling details exchange rates used group given note exchange rates average sterling exchange rates stronger euro weaker us dollar yen compared year end sterling exchange rates also stronger euro weaker us dollar yenwe chosen ten andrew witty introduction watch ceo review year outline committed case studies running business responsibly demonstrate progress made strategic priorities stories may viewed online wwwgskcom corporatereporting case studies find downloadable pdfs delivering next generation medicines annual report review form f corporate responsibility review maintaining leadership position respiratory web information link world gsk investing nutritional healthcare link corporate responsibility report conducting sophisticated approach pricing strengthening biopharmaceuticals business extending access developing world growing global vaccines business building leadership position dermatology evolving us business model wwwgskcom head office registered office creating rare diseases unit glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel registered number printed uk paper used production document made post consumer waste pulp bleached using totally chlorine free process